User Image Cart Icon 0 Search Image

PPARα

  1. PPARα and dyslipidemia
  2. The role of PPARα in lipid metabolism and obesity: focusing on the effects of estrogen on PPARα actions
  3. PPARα in atherosclerosis and inflammation
  4. Sorting out the roles of PPARα in energy metabolism and vascular homeostasis
  5. PPARα: energy combustion, hypolipidemia, inflammation and cancer
  6. Comparative analysis of gene regulation by the transcription factor PPARα between mouse and human
  7. The PPARα–leukotriene B4 pathway to inflammation control
  8. PPARα is a key regulator of hepatic FGF21
  9. PPARα governs glycerol metabolism
  10. The cardiac phenotype induced by PPARα overexpression mimics that caused by diabetes mellitus
  11. Identification of a physiologically relevant endogenous ligand for PPARα in liver
  12. PPARα gene variation and physical performance in Russian athletes
  13. PPARα: mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators
  14. The PPARα-humanized mouse: a model to investigate species differences in liver toxicity mediated by PPARα
  15. A critical role for the peroxisome proliferator-activated receptor α (PPARα) in the cellular fasting response: the PPARα-null mouse as a model of fatty acid oxidation …
  16. trans-Activation of PPARα and Induction of PPARα Target Genes by Perfluorooctane-Based Chemicals
  17. Endocrine regulation of the fasting response by PPARα-mediated induction of fibroblast growth factor 21
  18. Activation of PPARα and PPARγ by environmental phthalate monoesters
  19. Molecular scanning of the human PPARα gene: association of the L162V mutation with hyperapobetalipoproteinemia
  20. trans-Activation of PPARα and PPARγ by structurally diverse environmental chemicals
  21. Cannabinoid activation of PPARα; a novel neuroprotective mechanism
  22. Etomoxir-induced PPARα-modulated enzymes protect during acute renal failure
  23. Role of PPARα in hepatic carbohydrate metabolism
  24. Genome-wide analysis of PPARα activation in murine small intestine
  25. PPARα is necessary for the lipopenic action of hyperleptinemia on white adipose and liver tissue
  26. Association between the PPARα-L162V polymorphism and components of the metabolic syndrome
  27. Effect of endurance training on lipid metabolism in women: a potential role for PPARα in the metabolic response to training
  28. Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators
  29. PPARα activator effects on Ang II–induced vascular oxidative stress and inflammation
  30. “New” hepatic fat activates PPARα to maintain glucose, lipid, and cholesterol homeostasis
  31. Conjugated linoleic acid is a potent naturally occurring ligand and activator of PPARα
  32. Gene expression profiling in wild-type and PPARα-null mice exposed to perfluorooctane sulfonate reveals PPARα-independent effects
  33. Peroxisome proliferator-activated receptor α (PPARα) agonist treatment reverses PPARα dysfunction and abnormalities in hepatic lipid metabolism in ethanol …
  34. Characterization of the human PPARα promoter: identification of a functional nuclear receptor response element
  35. Cannabinoids and PPARα signalling
  36. PPARα: an emerging therapeutic target in diabetic microvascular damage
  37. PPARα agonist-induced rodent tumors: modes of action and human relevance
  38. Central role of PPARα-dependent hepatic lipid turnover in dietary steatohepatitis in mice
  39. Role of PPARα in mediating the effects of phthalates and metabolites in the liver
  40. Fibrates and future PPARα agonists in the treatment of cardiovascular disease
  41. PPARα in the pathogenesis of fatty liver disease
  42. Stimulation of PPARα promotes epidermal keratinocyte differentiation in vivo
  43. Oxidized phospholipids activate PPARα in a phospholipase A2-dependent manner
  44. Amelioration of high fructose-induced metabolic derangements by activation of PPARα
  45. Peroxisome proliferator-activated receptor-alpha (PPARα): at the crossroads of obesity, diabetes and cardiovascular disease
  46. PPARα deficiency reduces insulin resistance and atherosclerosis in apoE-null mice
  47. A role for PPARα in the control of SREBP activity and lipid synthesis in the liver
  48. Expression of peroxisome proliferator-activated receptor α (PPARα) in primary cultures of human vascular endothelial cells
  49. Alcoholic liver injury in the rat is associated with reduced expression of peroxisome proliferator-α (PPARα)-regulated genes and is ameliorated by PPARα activation
  50. Chronic activation of PPARα is detrimental to cardiac recovery after ischemia
  51. A critical role for PPARα-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content
  52. Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor α (PPARα)
  53. Role of oxidative stress in cardiac dysfunction of PPARα−/− mice
  54. PPARα activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells
  55. PPARα ligands activate antioxidant enzymes and suppress hepatic fibrosis in rats
  56. Structure of the PPARα and-γ ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family
  57. L-FABP directly interacts with PPARα in cultured primary hepatocytes
  58. Cardiac hypertrophy is enhanced in PPARα−/− mice in response to chronic pressure overload
  59. III. Peroxisomal β-oxidation, PPARα, and steatohepatitis
  60. Variation in the PPARα gene is associated with altered function in vitro and plasma lipid concentrations in Type II diabetic subjects
  61. Identification of a subtype selective human PPARα agonist through parallel-array synthesis
  62. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARα, β/δ, and γ
  63. PPARα agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition
  64. Brain fatty acid synthase activates PPARα to maintain energy homeostasis
  65. PPARα and PPARγ dual agonists for the treatment of type 2 diabetes and the metabolic syndrome
  66. The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARα activation in man
  67. Recent update on the PPARα-null mouse
  68. Anticancer properties of PPARα-effects on cellular metabolism and inflammation
  69. DNA binding-independent induction of IκBα gene transcription by PPARα
  70. Administration of the potent PPARα agonist, Wy‐14,643, reverses nutritional fibrosis and steatohepatitis in mice
  71. Disturbances in the normal regulation of SREBP-sensitive genes in PPARα-deficient mice
  72. Nuclear receptors PPARβ/δ and PPARα direct distinct metabolic regulatory programs in the mouse heart
  73. Statin-induced inhibition of the Rho-signaling pathway activates PPARα and induces HDL apoA-I
  74. PPARα deficiency in inflammatory cells suppresses tumor growth
  75. Keratinocyte differentiation is stimulated by activators of the nuclear hormone receptor PPARα
  76. AMPK activation increases fatty acid oxidation in skeletal muscle by activating PPARα and PGC-1
  77. PPARα activators inhibit tissue factor expression and activity in human monocytes
  78. PPARα downregulates airway inflammation induced by lipopolysaccharide in the mouse
  79. Genistein enhances expression of genes involved in fatty acid catabolism through activation of PPARα
  80. Profiling of promoter occupancy by PPARα in human hepatoma cells via ChIP-chip analysis
  81. PPARα agonist fenofibrate improves diabetic nephropathy in db/db mice
  82. Functional significance of the two ACOX1 isoforms and their crosstalks with PPARα and RXRα
  83. Nuclear receptor peroxisome proliferator-activated receptor α (PPARα) is expressed in resting murine lymphocytes: the PPARα in T and B lymphocytes is both …
  84. Fish oil feeding alters liver gene expressions to defend against PPARα activation and ROS production
  85. Activation of PPARα or γ reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells
  86. PPARα in obesity: sex difference and estrogen involvement
  87. Different ways to regulate the PPARα stability
  88. PPARα agonists inhibit tissue factor expression in human monocytes and macrophages
  89. Central role of PPARα in the mechanism of action of hepatocarcinogenic peroxisome proliferators
  90. Dual action of isoprenols from herbal medicines on both PPARγ and PPARα in 3T3‐L1 adipocytes and HepG2 hepatocytes
  91. The role of the peroxisome proliferator-activated receptor α (PPARα) in the control of cardiac lipid metabolism
  92. Dual activation of PPARα and PPARγ by mono-(2-ethylhexyl) phthalate in rat ovarian granulosa cells
  93. Alterations of PPARα and its coactivator PGC-1 in cisplatin-induced acute renal failure
  94. Activation of PPARα lowers synthesis and concentration of cholesterol by reduction of nuclear SREBP-2
  95. Novel aspects of PPARα‐mediated regulation of lipid and xenobiotic metabolism revealed through a nutrigenomic study
  96. Peroxisome proliferator-activated receptor α (PPARα) influences substrate utilization for hepatic glucose production
  97. The pollutant diethylhexyl phthalate regulates hepatic energy metabolism via species-specific PPARα-dependent mechanisms
  98. Preferential oxidation of triacylglyceride-derived fatty acids in heart is augmented by the nuclear receptor PPARα
  99. PPARα activation is essential for HCV core protein–induced hepatic steatosis and hepatocellular carcinoma in mice
  100. Carvacrol, a component of thyme oil, activates PPARα and γ and suppresses COX-2 expression [S]
  101. A role for peroxisome proliferator-activated receptor α (PPARα) in the control of cardiac malonyl-CoA levels: reduced fatty acid oxidation rates and increased …
  102. Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARα and PPARγ activators
  103. Transcriptional profiling reveals divergent roles of PPARα and PPARβ/δ in regulation of gene expression in mouse liver
  104. Do PPARGC1A and PPARα polymorphisms influence sprint or endurance phenotypes?
  105. PPARα and the regulation of cell division and apoptosis
  106. PPARα/γ ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly
  107. Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPARα, PPARγ, and LXR
  108. PPARα contributes to colonic protection in mice with DSS-induced colitis
  109. Isohumulones modulate blood lipid status through the activation of PPARα
  110. The peroxisome proliferator-activated receptor α (PPARα) regulates bile acid biosynthesis
  111. Gene profiling in the livers of wild-type and PPARα-null mice exposed to perfluorooctanoic acid
  112. Effects of ovariectomy on PPARα, SREBP-1c, and SCD-1 gene expression in the rat liver
  113. Hepatic FGF21 expression is induced at birth via PPARα in response to milk intake and contributes to thermogenic activation of neonatal brown fat
  114. PPARγ-induced cardiolipotoxicity in mice is ameliorated by PPARα deficiency despite increases in fatty acid oxidation
  115. PPARα mediates the hypolipidemic action of fibrates by antagonizing FoxO1
  116. PPARα inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a
  117. Role of PPARα and its agonist in renal diseases
  118. A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPARα agonist with potent lipid-lowering activity
  119. PPARα-and DEHP-induced cancers
  120. Circadian expression of FGF21 is induced by PPARα activation in the mouse liver
  121. PPARα is a potential therapeutic target of drugs to treat circadian rhythm sleep disorders
  122. Sumoylated PPARα mediates sex-specific gene repression and protects the liver from estrogen-induced toxicity in mice
  123. Transcriptional regulation of human and rat hepatic lipid metabolism by the grapefruit flavonoid naringenin: role of PPARα, PPARγ and LXRα
  124. Peroxisome proliferator-activated receptor α (PPARα) turnover by the ubiquitin-proteasome system controls the ligand-induced expression level of its target …
  125. Less extrahepatic induction of fatty acid β-oxidation enzymes by PPARα
  126. Review of the expression of peroxisome proliferator-activated receptors alpha (PPARα), beta (PPARβ), and gamma (PPARγ) in rodent and human development
  127. … activates peroxisome proliferator-activated receptor α (PPARα) and regulates gene expression involved in lipid metabolism in PPARα-expressing HepG2 hepatocytes
  128. Polyenephosphatidylcholine prevents alcoholic liver disease in PPARα-null mice through attenuation of increases in oxidative stress
  129. PPARα activators and fasting induce the expression of adipose differentiation-related protein in liver
  130. Toxicogenomic dissection of the perfluorooctanoic acid transcript profile in mouse liver: evidence for the involvement of nuclear receptors PPARα and CAR
  131. PPARδ, but not PPARα, activates PGC-1α gene transcription in muscle
  132. Citral, a component of lemongrass oil, activates PPARα and γ and suppresses COX-2 expression
  133. Evidence for anti-inflammatory activity of statins and PPARα activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro
  134. Aleglitazar, a new, potent, and balanced dual PPARα/γ agonist for the treatment of type II diabetes
  135. PPARα ligands inhibit radiation-induced microglial inflammatory responses by negatively regulating NF-κB and AP-1 pathways
  136. PPARα activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats
  137. Differential effects of isoflavones, from Astragalus membranaceus and Pueraria thomsonii, on the activation of PPARα, PPARγ, and adipocyte differentiation in …
  138. … (PPAR) α activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARα, PPARγ, and their …
  139. Fenofibrate reduces intestinal cholesterol absorption via PPARα-dependent modulation of NPC1L1 expression in mouse
  140. Human skeletal muscle fibre type variations correlate with PPARα, PPARδ and PGC‐1α mRNA
  141. PPARα agonists reduce 11β-hydroxysteroid dehydrogenase type 1 in the liver
  142. Peroxisome proliferator-activated receptor α (PPARα) signaling in the gene regulatory control of energy metabolism in the normal and diseased heart
  143. Elevated NCOR1 disrupts PPARα/γ signaling in prostate cancer and forms a targetable epigenetic lesion
  144. Fibrate and statin synergistically increase the transcriptional activities of PPARα/RXRα and decrease the transactivation of NFκB
  145. Peroxisome proliferator-activated receptor α (PPARα) and agonist inhibit cholesterol 7α-hydroxylase gene (CYP7A1) transcription
  146. Novel tricyclic-α-alkyloxyphenylpropionic acids: dual PPARα/γ agonists with hypolipidemic and antidiabetic activity
  147. The Epoxygenases CYP2J2 Activates the Nuclear Receptor PPARα In Vitro and In Vivo
  148. PPARα ligand protects during cisplatin-induced acute renal failure by preventing inhibition of renal FAO and PDC activity
  149. Role of peroxisome proliferator-activated receptor-α (PPARα) in bezafibrate-induced hepatocarcinogenesis and cholestasis
  150. Eicosapentaenoic acid improves hepatic steatosis independent of PPARα activation through inhibition of SREBP-1 maturation in mice
  151. The ligands/activators for peroxisome proliferator-activated receptor α (PPARα) and PPARγ increase Cu2+, Zn2+-superoxide dismutase and decrease p22phox …
  152. Statins activate human PPARα promoter and increase PPARα mRNA expression and activation in HepG2 cells
  153. Fasting promotes the expression of SIRT1, an NAD+-dependent protein deacetylase, via activation of PPARα in mice
  154. Sargaquinoic acid and sargahydroquinoic acid from Sargassum yezoense stimulate adipocyte differentiation through PPARα/γ activation in 3T3-L1 cells
  155. Peroxisome proliferator-activated receptor β/δ (PPARβ/δ) but not PPARα serves as a plasma free fatty acid sensor in liver
  156. Modulation of rat liver apolipoprotein gene expression and serum lipid levels by tetradecylthioacetic acid (TTA) via PPARα activation
  157. PPARα blocks glucocorticoid receptor α-mediated transactivation but cooperates with the activated glucocorticoid receptor α for transrepression on NF-κB
  158. Peroxisome-proliferator-activated receptor-α (PPARα) deficiency leads to dysregulation of hepatic lipid and carbohydrate metabolism by fatty acids and insulin
  159. Dietary isoflavone supplementation modulates lipid metabolism via PPARα-dependent and-independent mechanisms
  160. Isoleucine prevents the accumulation of tissue triglycerides and upregulates the expression of PPARα and uncoupling protein in diet-induced obese mice
  161. Differential responses of PPARα, PPARδ, and PPARγ reporter cell lines to selective PPAR synthetic ligands
  162. Cross-talk between statins and PPARα in cardiovascular diseases: clinical evidence and basic mechanisms
  163. Serum metabolomics reveals irreversible inhibition of fatty acid β-oxidation through the suppression of PPARα activation as a contributing mechanism of …
  164. Thermally oxidized dietary fat upregulates the expression of target genes of PPARα in rat liver
  165. Developmental toxicity of perfluorooctane sulfonate (PFOS) is not dependent on expression of peroxisome proliferator activated receptor-alpha (PPARα) in the mouse
  166. PPARα activators inhibit vascular endothelial growth factor receptor-2 expression by repressing Sp1-dependent DNA binding and transactivation
  167. Metabolic profiling of PPARα−/− mice reveals defects in carnitine and amino acid homeostasis that are partially reversed by oral carnitine supplementation
  168. Nrf2-and PPARα-mediated regulation of hepatic Mrp transporters after exposure to perfluorooctanoic acid and perfluorodecanoic acid
  169. Induction of hepatic ABC transporter expression is part of the PPARα–mediated fasting response in the mouse
  170. Apoptosis and proliferation in nongenotoxic carcinogenesis: species differences and role of PPARα
  171. A mitochondrial ketogenic enzyme regulates its gene expression by association with the nuclear hormone receptor PPARα
  172. PPARα and PPARδ activators inhibit cytokine-induced nuclear translocation of NF-κB and expression of VCAM-1 in EAhy926 endothelial cells
  173. Down regulation of hepatic PPARα function by AhR ligand
  174. Metabolism of phytol to phytanic acid in the mouse, and the role of PPARα in its regulation
  175. Inflammatory pathways are activated during cardiomyocyte hypertrophy and attenuated by peroxisome proliferator-activated receptors PPARα and PPARδ∗
  176. PPARα agonists suppress osteopontin expression in macrophages and decrease plasma levels in patients with type 2 diabetes
  177. The peroxisome proliferator-activated receptor α (PPARα): role in hepatocarcinogenesis
  178. PPARα controls the intracellular coenzyme A concentration via regulation of PANK1α gene expression1
  179. PPARα regulates the hepatotoxic biomarker alanine aminotransferase (ALT1) gene expression in human hepatocytes
  180. Analysis of PPARα-dependent and PPARα-independent transcript regulation following fenofibrate treatment of human endothelial cells
  181. Activation of PPARα inhibits IGF‐I‐mediated growth and survival responses in medulloblastoma cell lines
  182. Fenofibrate inhibits adipocyte hypertrophy and insulin resistance by activating adipose PPARα in high fat diet-induced obese mice
  183. PPARα agonists positively and negatively regulate the expression of several nutrient/drug transporters in mouse small intestine
  184. A phytol-enriched diet induces changes in fatty acid metabolism in mice both via PPARα-dependent and-independent pathways
  185. PPARα structure-function relationships derived from species-specific differences in responsiveness to hypolipidemic agents
  186. The PPARα/γ dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats
  187. PPARα activation increases triglyceride mass and adipose differentiation-related protein in hepatocytes
  188. PPARα-activation results in enhanced carnitine biosynthesis and OCTN2-mediated hepatic carnitine accumulation
  189. PPARα ligands as antitumorigenic and antiangiogenic agents
  190. Human urinary metabolomic profile of PPARα induced fatty acid β-oxidation
  191. Long-chain fatty acids regulate liver carnitine palmitoyltransferase I gene (L-CPT I) expression through a peroxisome-proliferator-activated receptor α (PPARα) …
  192. Phytanic acid activates the peroxisome proliferator-activated receptor α (PPARα) in sterol carrier protein 2-/sterol carrier protein x-deficient mice
  193. The liver-enriched transcription factor CREBH is nutritionally regulated and activated by fatty acids and PPARα
  194. Design, synthesis, biological evaluation and docking studies of pterostilbene analogs inside PPARα
  195. Application of the dakin− west reaction for the synthesis of oxazole-containing dual PPARα/γ agonists
  196. Structure-based design of indole propionic acids as novel PPARα/γ co-agonists
  197. Peroxisome proliferator activated receptor α (PPARα) and PPAR gamma coactivator (PGC-1α) induce carnitine palmitoyltransferase IA (CPT-1A) via independent …
  198. WY14, 643, a PPARα ligand, has profound effects on immune responses in vivo
  199. Differential gene regulation in human versus rodent hepatocytes by peroxisome proliferator-activated receptor (PPAR) α: PPARα fails to induce peroxisome …
  200. Farnesol stimulates differentiation in epidermal keratinocytes via PPARα
  201. … -STAT) and peroxisome proliferator-activated receptor-α (PPARα) signaling pathways: Growth hormone inhibition of PPARα transcriptional activity mediated …
  202. Keratinocyte differentiation in hyperproliferative epidermis: topical application of PPARα activators restores tissue homeostasis
  203. The PPARα agonist fenofibrate preserves hippocampal neurogenesis and inhibits microglial activation after whole-brain irradiation
  204. Tumor necrosis factor and interleukin 1 decrease RXRα, PPARα, PPARγ, LXRα, and the coactivators SRC-1, PGC-1α, and PGC-1β in liver cells
  205. The acyl-CoA thioesterase I is regulated by PPARα and HNF4α via a distal response element in the promoter
  206. An afferent vagal nerve pathway links hepatic PPARα activation to glucocorticoid-induced insulin resistance and hypertension
  207. Effects of green tea on insulin sensitivity, lipid profile and expression of PPARα and PPARγ and their target genes in obese dogs
  208. Glucagon and lipid interactions in the regulation of hepatic AMPK signaling and expression of PPARα and FGF21 transcripts in vivo
  209. PPARα protects proximal tubular cells from acute fatty acid toxicity
  210. Beyond lipids, pharmacological PPARα activation has important effects on amino acid metabolism as studied in the rat
  211. Cardiac PPARα expression in patients with dilated cardiomyopathy
  212. ROS accumulation and IGF-IR inhibition contribute to fenofibrate/PPARα-mediated inhibition of glioma cell motility in vitro
  213. PPARα attenuates the proinflammatory response in activated mesangial cells
  214. Inhibition of vascular inflammation by dehydroepiandrosterone sulfate in human aortic endothelial cells: roles of PPARα and NF-κB
  215. Transcription coactivator PBP, the peroxisome proliferator-activated receptor (PPAR)-binding protein, is required for PPARα-regulated gene expression in …
  216. Activation of PPARα and PPARγ reduces triacylglycerol synthesis in rat hepatoma cells by reduction of nuclear SREBP-1
  217. PPARα: its role in the human metabolic syndrome
  218. PPARα activators upregulate eNOS activity and inhibit cytokine-induced NF-κB activation through AMP-activated protein kinase activation
  219. PPARα L162V polymorphism alters the potential of n‐3 fatty acids to increase lipoprotein lipase activity
  220. PPARα and PPARγ attenuate HIV-induced dysregulation of tight junction proteins by modulations of matrix metalloproteinase and proteasome activities
  221. Effect of tesaglitazar, a dual PPARα/γ agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12‐week dose-ranging trial
  222. Lipin 1 is an inducible amplifier of the hepatic PGC-1α/PPARα regulatory pathway
  223. Bezafibrate is a dual ligand for PPARα and PPARβ: studies using null mice
  224. Transcriptomic analysis of PPARα-dependent alterations during cardiac hypertrophy
  225. Induction of overlapping genes by fasting and a peroxisome proliferator in pigs: evidence of functional PPARα in nonproliferating species
  226. Very-long-chain and branched-chain fatty acyl-CoAs are high affinity ligands for the peroxisome proliferator-activated receptor α (PPARα)
  227. Coordinate induction of PPARα and SREBP2 in multifunctional protein 2 deficient mice
  228. Homocysteine-mediated PPARα, γ DNA methylation and its potential pathogenic mechanism in monocytes
  229. Role of the nuclear receptors HNF4α, PPARα, and LXRs in the TNFα-mediated inhibition of human apolipoprotein AI gene expression in HepG2 cells
  230. PPARα suppresses insulin secretion and induces UCP2 in insulinoma cells
  231. PPARα deficiency increases secretion and serum levels of apolipoprotein B-containing lipoproteins
  232. Nonclinical safety evaluation of muraglitazar, a novel PPARα/γ agonist
  233. Peroxisome proliferator-activated receptor α (PPARα) potentiates, whereas PPARγ attenuates, glucose-stimulated insulin secretion in pancreatic β-cells
  234. The PPARα/p16INK4a Pathway Inhibits Vascular Smooth Muscle Cell Proliferation by Repressing Cell Cycle–Dependent Telomerase Activation
  235. Hepatocyte-restricted constitutive activation of PPARα induces hepatoproliferation but not hepatocarcinogenesis
  236. Atorvastatin reverses age‐related reduction in rat hepatic PPARα and HNF‐4
  237. Design and synthesis of α-aryloxyphenylacetic acid derivatives: a novel class of PPARα/γ dual agonists with potent antihyperglycemic and lipid modulating activity
  238. Mouse OCTN2 is directly regulated by peroxisome proliferator-activated receptor α (PPARα) via a PPRE located in the first intron
  239. Design and biological evaluation of novel, balanced dual PPARα/γ agonists
  240. Human peroxisome proliferator-activated receptor α (PPARα) supports the induction of peroxisome proliferation in PPARα-deficient mouse liver
  241. … rats following dietary exposure to ammonium perfluorooctanoate occurs through increased activation of the xenosensor nuclear receptors PPARα and CAR/PXR
  242. Requirement of PPARα in maintaining phospholipid and triacylglycerol homeostasis during energy deprivation
  243. Involvement of PPARα in the growth inhibitory effect of arachidonic acid on breast cancer cells
  244. PPARα and GR differentially down-regulate the expression of nuclear factor-κB-responsive genes in vascular endothelial cells
  245. PPARα agonist fenofibrate protects the kidney from hypertensive injury in spontaneously hypertensive rats via inhibition of oxidative stress and MAPK activity
  246. Fasting upregulates PPARα target genes in brain and influences pituitary hormone expression in a PPARα dependent manner
  247. Unlike PPARγ, PPARα or PPARβ/δ activation does not promote human monocyte differentiation toward alternative macrophages
  248. Urothelial carcinogenesis in the urinary bladder of male rats treated with muraglitazar, a PPARα/γ agonist: evidence for urolithiasis as the inciting event in the mode of …
  249. Genomic and non-genomic interactions of PPARα with xenobiotic-metabolizing enzymes
  250. PPARα agonists up-regulate organic cation transporters in rat liver cells
  251. Growth inhibition and apoptosis in human Philadelphia chromosome-positive lymphoblastic leukemia cell lines by treatment with the dual PPARα/γ ligand TZD18
  252. Fractionation and identification of 9c, 11t, 13t-conjugated linolenic acid as an activator of PPARα in bitter gourd (Momordica charantia L.)
  253. Impaired Ras membrane association and activation in PPARα knockout mice after partial hepatectomy
  254. Involvement of PPARα and PPARγ in apoptosis and proliferation of human hepatocarcinoma HepG2 cells
  255. WY14, 643, a peroxisome proliferator-activated receptor α (PPARα) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in …
  256. Iridoids from Fraxinus excelsior with Adipocyte Differentiation-Inhibitory and PPARα Activation Activity
  257. Alteration of a single amino acid in peroxisome proliferator-activated receptor-α (PPARα) generates a PPARδ phenotype
  258. The PPARα activator fenofibrate slows down the progression of the left ventricular dysfunction in porcine tachycardia-induced cardiomyopathy
  259. Design of potent PPARα agonists
  260. Combination therapy with PPARγ and PPARα agonists increases glucose-stimulated insulin secretion in db/dbmice
  261. Multiple roles of PPARα in brown adipose tissue under constitutive and cold conditions
  262. Identification of novel peroxisome proliferator-activated receptor α (PPARα) target genes in mouse liver using cDNA microarray analysis
  263. Beneficial effect of berberine on hepatic insulin resistance in diabetic hamsters possibly involves in SREBPs, LXRα and PPARα transcriptional programs
  264. Fenofibrate increases homocystinemia through a PPARα-mediated mechanism
  265. Ragaglitazar: a novel PPARα & PPARγ agonist with potent lipid‐lowering and insulin‐sensitizing efficacy in animal models
  266. Molecular basis of non-responsiveness to peroxisome proliferators: the guinea-pig PPARα is functional and mediates peroxisome proliferator-induced hypolipidaemia
  267. Modulation of peroxisome proliferator-activated receptors (PPARs) by PPARα-and PPARγ-specific ligands and by 17β-estradiol in isolated zebrafish hepatocytes
  268. Activation of the rat scavenger receptor class B type I gene by PPARα
  269. Fibrate induction of the adrenoleukodystrophy‐related gene (ABCD2) Promoter analysis and role of the peroxisome proliferator‐activated receptor PPARα
  270. … subjected to short-term exposure to perfluorooctanesulfonate are high-dose phenomena mediated in part by peroxisome proliferator-activated receptor-alpha (PPARα …
  271. Characterization of Peroxisome Proliferator–Activated Receptor α—Independent Effects of PPARα Activators in the Rodent Liver: Di-(2-ethylhexyl) phthalate also …
  272. Vaticanol C, a resveratrol tetramer, activates PPARα and PPARβ/δ in vitro and in vivo
  273. Dietary saponins of sea cucumber alleviate orotic acid-induced fatty liver in rats via PPARα and SREBP-1c signaling
  274. Microgram-order ammonium perfluorooctanoate may activate mouse peroxisome proliferator-activated receptor α, but not human PPARα
  275. Reduced hepatic fatty acid oxidation in fasting PPARα null mice is due to impaired mitochondrial hydroxymethylglutaryl-CoA synthase gene expression
  276. Palmitoylation of ketogenic enzyme HMGCS2 enhances its interaction with PPARα and transcription at the Hmgcs2 PPRE
  277. PPARα Inhibits TGF-β–Induced β5 Integrin Transcription in Vascular Smooth Muscle Cells by Interacting With Smad4
  278. Oxidized omega-3 fatty acids inhibit NF-κB activation via a PPARα-dependent pathway
  279. Inhibition of cholesterol absorption associated with a PPARα-dependent increase in ABC binding cassette transporter A1 in mice
  280. Dual PPARα/γ activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats
  281. Suppression of mouse hepatocyte apoptosis by peroxisome proliferators: role of PPARα and TNFα
  282. Peroxisome proliferator-activated receptor (PPAR)-γ positively controls and PPARα negatively controls cyclooxygenase-2 expression in rat brain astrocytes through a …
  283. Novel approach to treat insulin resistance, type 2 diabetes, and the metabolic syndrome: simultaneous activation of PPARα, PPARγ, and PPARδ
  284. … -activated receptor-alpha (PPARα) cDNA cloned from guinea-pig liver encodes a protein with similar properties to the mouse PPARα: implications for species …
  285. Inflammation, dyslipidaemia, diabetes and PPars: pharmacological interest of dual PPARα and PPARγ agonists
  286. A nuclear complex containing PPARα/RXRα is markedly downregulated in the hypertrophied rat left ventricular myocardium with normal systolic function
  287. Effects of PPARγ and PPARα agonists on serum leptin levels in diet-induced obese rats
  288. High-density lipoprotein hydrolysis by endothelial lipase activates PPARα: a candidate mechanism for high-density lipoprotein-mediated repression of leukocyte …
  289. Effect of PPARα activation of macrophages on the secretion of inflammatory cytokines in cultured adipocytes
  290. Synthesis and dual PPARα/δ agonist effects of 1, 4-disubstituted 1, 2, 3-triazole analogues of GW 501516
  291. Epidermal lipoxygenase products of the hepoxilin pathway selectively activate the nuclear receptor PPARα
  292. PPARα, but not PPARγ, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia
  293. The transcriptional coactivator peroxisome proliferator–activated receptor (PPAR) γ coactivator-1α and the nuclear receptor PPARα control the expression of glycerol …
  294. The human myeloperoxidase gene is regulated by LXR and PPARα ligands
  295. PPARα and PPARγ effectively protect against HIV‐induced inflammatory responses in brain endothelial cells
  296. Hop bitter acids efficiently block inflammation independent of GRα, PPARα, or PPARγ
  297. Dietary oxidized fat prevents ethanol-induced triacylglycerol accumulation and increases expression of PPARα target genes in rat liver
  298. Relationships between the functional PPARα Leu162Val polymorphism and obesity, type 2 diabetes, dyslipidaemia, and related quantitative traits in studies of 5799 …
  299. Feeding oxidized fat during pregnancy up-regulates expression of PPARα-responsive genes in the liver of rat fetuses
  300. Impairment of hepatic Stat‐3 activation and reduction of PPARα activity in fructose‐fed rats
  301. PPARα and PPARγ activators suppress the monocyte-macrophage apoB-48 receptor1
  302. PPARα L162V underlies variation in serum triglycerides and subcutaneous fat volume in young males
  303. RXR agonists activate PPARα-inducible genes, lower triglycerides, and raise HDL levels in vivo
  304. The Korean traditional medicine Gyeongshingangjeehwan inhibits obesity through the regulation of leptin and PPARα action in OLETF rats
  305. Suppression of expression of muscle-associated proteins by PPARα in brown adipose tissue
  306. Novel 2, 3-dihydrobenzofuran-2-carboxylic acids: highly potent and subtype-selective PPARα agonists with potent hypolipidemic activity
  307. Fenofibrate, a ligand for PPARα, inhibits aromatase cytochrome P450 expression in the ovary of mouse
  308. Differential response to trichloroethylene-induced hepatosteatosis in wild-type and PPARα-humanized mice
  309. PPARα mediates transcriptional upregulation of novel organic cation transporters-2 and-3 and enzymes involved in hepatic carnitine synthesis
  310. Cloning and characterization of murine 1-acyl-sn-glycerol 3-phosphate acyltransferases and their regulation by PPARα in murine heart
  311. Discovery of azetidinone acids as conformationally-constrained dual PPARα/γ agonists
  312. PPARα is essential for microparticle-induced differentiation of mouse bone marrow-derived endothelial progenitor cells and angiogenesis
  313. Lack of hypotriglyceridemic effect of gemfibrozil as a consequence of age-related changes in rat liver PPARα
  314. Bioassay‐guided purification and identification of PPARα/γ agonists from Chlorella sorokiniana
  315. Oxidized low density lipoprotein activates peroxisome proliferator-activated receptor-α (PPARα) and PPARγ through MAPK-dependent COX-2 expression in …
  316. Auraptene, a citrus fruit compound, regulates gene expression as a PPARα agonist in HepG2 hepatocytes
  317. Relationship between PPARα activation and NO on proximal tubular Na+ transport in the rat
  318. PPARα agonists inhibit nitric oxide production by enhancing iNOS degradation in LPS‐treated macrophages
  319. The dual PPARα/γ agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats
  320. Statins and PPARα agonists induce myotoxicity in differentiated rat skeletal muscle cultures but do not exhibit synergy with co-treatment
  321. Fatty acid regulation of liver X receptors (LXR) and peroxisome proliferator-activated receptor α (PPARα) in HEK293 cells
  322. Synthesis, biological evaluation, and molecular modeling investigation of new chiral fibrates with PPARα and PPARγ agonist activity
  323. Osthol regulates hepatic PPARα-mediated lipogenic gene expression in alcoholic fatty liver murine
  324. Association of PPARα gene polymorphisms and lipid serum levels in a Brazilian elderly population
  325. Design and synthesis of novel PPARα/γ/δ triple activators using a known PPARα/γ dual activator as structural template
  326. PPARα is involved in photoentrainment of the circadian clock
  327. PPARα activation potentiates AhR-induced CYP1A1 expression
  328. Additivity of molecular fields: CoMFA study on dual activators of PPARα and PPARγ
  329. Fatty acids induce L-CPT I gene expression through a PPARα-independent mechanism in rat hepatoma cells
  330. Isoform specific changes in PPARα and β in colon and breast cancer with differentiation
  331. Energy balance: A new role for PPARα
  332. A Val227Ala polymorphism in the peroxisome proliferator activated receptor α (PPARα) gene is associated with variations in serum lipid levels
  333. Role of the peroxisome proliferator-activated receptor α (PPARα) in responses to trichloroethylene and metabolites, trichloroacetate and dichloroacetate in mouse liver
  334. Reduced fat mass in rats fed a high oleic acid–rich safflower oil diet is associated with changes in expression of hepatic PPARα and adipose SREBP-1c …
  335. Differential effects of PPARα activators on induction of ectopic expression of tissue-specific fatty acid binding protein genes in the mouse liver
  336. PPARα activators may be good candidates as antiaging agents
  337. A Chemical Switch Regulates Fibrate Specificity for Peroxisome Proliferator-activated Receptor α (PPARα) VersusLiver X Receptor
  338. Molecular mechanism of allosteric communication in the human PPARα‐RXRα heterodimer
  339. Feeding of a deep-fried fat causes PPARα activation in the liver of pigs as a non-proliferating species
  340. Decreased longevity and enhancement of age-dependent lesions in mice lacking the nuclear receptor peroxisome proliferator-activated receptor α (PPARα)
  341. PPARα/γ expression and activity in mouse and human melanocytes and melanoma cells
  342. C333H, a novel PPARα/γ dual agonist, has beneficial effects on insulin resistance and lipid metabolism
  343. Intestine-specific regulation of PPARα gene transcription by liver X receptors
  344. Administration of a PPARα agonist increases serum apolipoprotein AV levels and the apolipoprotein AV/apolipoprotein C-III ratio
  345. “Hypothesis of seven balances”: molecular mechanisms behind alcoholic liver diseases and association with PPARα
  346. Thyroid hormone regulates hepatic expression of fibroblast growth factor 21 in a PPARα-dependent manner
  347. Antihypertensive effect of ragaglitazar: A novel PPARα and γ dual activator
  348. Dual PPARα/γ agonist tesaglitazar reduces atherosclerosis in insulin-resistant and hypercholesterolemic ApoE* 3Leiden mice
  349. … Receptor (PPAR) Activation Induces Tissue-Specific Effects on Fatty Acid Uptake and Metabolism in Vivo—A Study Using the Novel PPARα/γ Agonist Tesaglitazar
  350. Icariin promotes expression of PGC‐1α, PPARα, and NRF‐1 during cardiomyocyte differentiation of murine embryonic stem cells in vitro1
  351. Effects and mechanisms of PPARα activator fenofibrate on myocardial remodelling in hypertension
  352. … of the critical structural determinant (s) of species-selective peroxisome proliferator-activated receptor alpha (PPARα)-activation by phenylpropanoic acid-type PPARα …
  353. Changes in liver PPARα mRNA expression in response to two levels of high-safflower-oil diets correlate with changes in adiposity and serum leptin in rats and mice
  354. Relationship between insulin resistance and low urinary pH in patients with gout, and effects of PPARα agonists on urine pH
  355. Bezafibrate stimulates canalicular localization of NBD-labeled PC in HepG2 cells by PPARα-mediated redistribution of ABCB4
  356. Relationship between peroxisome proliferator‐activated receptors (PPARα and PPARγ) and endothelium‐dependent relaxation in streptozotocin‐induced diabetic …
  357. Human skeletal muscle PPARα expression correlates with fat metabolism gene expression but not BMI or insulin sensitivity
  358. PPARα ligands reduce PCB-induced endothelial activation: possible interactions in inflammation and atherosclerosis
  359. PPARα-dependent induction of the energy homeostasis-regulating nuclear receptor NR1i3 (CAR) in rat hepatocytes: potential role in starvation adaptation
  360. Association between the PPARα L162V polymorphism, plasma lipoprotein levels, and atherosclerotic disease in patients with diabetes mellitus type 2 and in …
  361. Potential utility of PPARα activation in the prevention of ischemic and drug-induced acute renal damage
  362. PPARα-dependent modulation of hepatic CYP1A by clofibric acid in rats
  363. A practical synthesis of the PPARα agonist,(R)-K-13675, starting from (S)-2-hydroxybutyrolactone
  364. Synthesis and biological evaluation of new clofibrate analogues as potential PPARα agonists
  365. PPARα and PP2A are involved in the proapoptotic effect of conjugated linoleic acid on human hepatoma cell line SK‐HEP‐1
  366. Hepatic lipid metabolism response to dietary fatty acids is differently modulated by PPARα in male and female mice
  367. Effects of PPARα, γ and δ haplotypes on plasma levels of lipids, severity and progression of coronary atherosclerosis and response to statin therapy in the lipoprotein …
  368. L-FABP is exclusively expressed in alveolar macrophages within the myeloid lineage: evidence for a PPARα-independent expression
  369. Involvement of PPARγ co-activator-1, nuclear respiratory factors 1 and 2, and PPARα in the adaptive response to endurance exercise
  370. Regulation of phase I and phase II steroid metabolism enzymes by PPARα activators
  371. Alterations in skin and stratified epithelia by constitutively activated PPARα
  372. … levels for interleukin-1β, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor α (PPARα) in primary endothelial …
  373. Susceptibility of pancreatic beta cells to fatty acids is regulated by LXR/PPARα-dependent stearoyl-coenzyme a desaturase
  374. Design, synthesis and evaluation of carbazole derivatives as PPARα/γ dual agonists and antioxidants
  375. The effect of peroxisome proliferator-activated receptors α (PPARα) agonist, fenofibrate, on lipid peroxidation, total antioxidant capacity, and plasma …
  376. Mechanistic evaluation of PPARα-mediated hepatocarcinogenesis: Are we there yet?
  377. PPARα signaling mediates the synergistic cytotoxicity of clioquinol and docosahexaenoic acid in human cancer cells
  378. Effects of high dietary fat and cholesterol on expression of PPARα, LXRα, and their responsive genes in the liver of apoE and LDLR double deficient mice
  379. PPARα activation elevates blood pressure and does not correct glucocorticoid-induced insulin resistance in humans
  380. PPARα stimulation exerts a blood pressure lowering effect through different mechanisms in a time-dependent manner
  381. Evaluation of the therapeutic potential of PPARα agonists for X-linked adrenoleukodystrophy
  382. Thyroid hormone interacts with PPARα and PGC-1 during mitochondrial maturation in sheep heart
  383. Association of V227A PPARα polymorphism with altered serum biochemistry and alcohol drinking in Japanese men
  384. The dual PPARα/γ agonist tesaglitazar blocks progression of pre‐existing atherosclerosis in APOE*3Leiden.CETP transgenic mice
  385. Hepatic fibroblast growth factor 21 is regulated by PPARα and is a key mediator of hepatic lipid metabolism in ketotic states
  386. PPARα transcriptionally induces AhR expression in Caco-2, but represses AhR pro-inflammatory effects
  387. The role of new technologies in defining a manufacturing process for PPARα agonist LY518674
  388. … of the heat shock response in mouse liver reveals transcriptional dependence on the nuclear receptor peroxisome proliferator-activated receptor α (PPARα)
  389. Evaluation of the role of peroxisome proliferator-activated receptor α (PPARα in mouse liver tumor induction by trichloroethylene and metabolites
  390. Influences of the PPARα-L162V polymorphism on plasma HDL2-cholesterol response of abdominally obese men treated with gemfibrozil
  391. Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPARα and γ agonist in healthy subjects and patients with type 2 diabetes
  392. Hepatic PGC-1β overexpression induces combined hyperlipidemia and modulates the response to PPARα activation
  393. Stimulation of cardiac cardiolipin biosynthesis by PPARα activation
  394. Farnesol decreases serum triglycerides in rats: identification of mechanisms including up-regulation of PPARα and down-regulation of fatty acid synthase in …
  395. … (PFOS) toxicity in domestic chicken (Gallus gallus domesticus) embryos in the absence of effects on peroxisome proliferator activated receptor alpha (PPARα) …
  396. Evidence of differing genotypic effects of PPARα in women and men
  397. Selectivity of fatty acid ligands for PPARα which correlates both with binding to cis-element and DNA binding-independent transactivity in Caco-2 cells
  398. A novel PPARα agonist ameliorates insulin resistance in dogs fed a high-fat diet
  399. Peroxisome proliferator activated receptor δ (PPARδ) agonist but not PPARα corrects carnitine palmitoyl transferase 2 deficiency in human muscle cells
  400. Synthesis, biological evaluation, and molecular modeling investigation of chiral phenoxyacetic acid analogues with PPARα and PPARγ agonist activity
  401. Fibrates upregulate TRB3 in lymphocytes independent of PPARα by augmenting CCAAT/enhancer-binding proteinβ (C/EBPβ) expression
  402. PPARα-mediated remodeling of repolarizing voltage-gated K+ (Kv) channels in a mouse model of metabolic cardiomyopathy
  403. Polyunsaturated fatty acids stimulate hepatic UCP-2 expression via a PPARα-mediated pathway
  404. Down-regulated expression of PPARα target genes, reduced fatty acid oxidation and altered fatty acid composition in the liver of mice transgenic for hTNFα
  405. PPARα-dependent activation of cell cycle control and DNA repair genes in hepatic nonparenchymal cells
  406. PPARα activation upregulates nephrin expression in human embryonic kidney epithelial cells and podocytes by a dual mechanism
  407. Alterations in carbohydrate metabolism and its regulation in PPARα null mouse hearts
  408. Modulation of PPARα expression and inflammatory interleukin-6 production by chronic glucose increases monocyte/endothelial adhesion
  409. PPARα activator fenofibrate modulates angiotensin II-induced inflammatory responses in vascular smooth muscle cells via the TLR4-dependent signaling pathway
  410. Tesaglitazar, a dual PPARα/γ agonist, ameliorates glucose and lipid intolerance in obese Zucker rats
  411. Evidence for peroxisome proliferator-activated receptor (PPAR) α-independent peroxisome proliferation: effects of PPARγ/δ-specific agonists in PPARα-null mice
  412. The dietary antioxidant resveratrol affects redox changes of PPARα activity
  413. … for transcription coactivator peroxisome proliferator-activated receptor (PPAR)-binding protein/TRAP220 in liver regeneration and PPARα ligand-induced liver …
  414. Liver PPARα and UCP2 are involved in the regulation of obesity and lipid metabolism by swim training in genetically obese db/db mice
  415. Design and synthesis of indane-ureido-thioisobutyric acids: A novel class of PPARα agonists
  416. Peroxisome proliferator-activated receptor α (PPARα) protects against oleate-induced INS-1E beta cell dysfunction by preserving carbohydrate metabolism
  417. Increase in weight induced by muraglitazar, a dual PPARα/γ agonist, in db/db mice: adipogenesis/or oedema?
  418. PPARγ but not PPARα ligands are potent repressors of major histocompatibility complex class II induction in atheroma-associated cells
  419. Reduction of all-trans-Retinal in the Mouse Liver Peroxisome Fraction by the Short-Chain Dehydrogenase/Reductase RRD:  Induction by the PPARα Ligand …
  420. Evidence against the peroxisome proliferator-activated receptor α (PPARα) as the mediator for polyunsaturated fatty acid suppression of hepatic L-pyruvate …
  421. Cholesteryl ester hydroperoxides increase macrophage CD36 gene expression via PPARα
  422. Identification of a series of oxadiazole-substituted α-isopropoxy phenylpropanoic acids with activity on PPARα, PPARγ, and PPARδ
  423. Time-course comparison of xenobiotic activators of CAR and PPARα in mouse liver
  424. Food entrainment of circadian gene expression altered in PPARα−/− brown fat and heart
  425. Irbesartan treatment up‐regulates hepatic expression of PPARα and its target genes in obese Koletsky (fak/fak) rats: a link to amelioration of hypertriglyceridaemia
  426. Dual regulation of mouse Δ5-and Δ6-desaturase gene expression by SREBP-1 and PPARα
  427. Synthesis and evaluation of novel α-heteroaryl-phenylpropanoic acid derivatives as PPARα/γ dual agonists
  428. RXR activators molecular signalling: involvement of a PPARα‐dependent pathway in the liver and kidney, evidence for an alternative pathway in the heart
  429. Regulated expression by PPARα and unique localization of 17β‐hydroxysteroid dehydrogenase type 11 protein in mouse intestine and liver
  430. Peroxisome proliferator-activated receptor α (PPARα) down-regulation in cystic fibrosis lymphocytes
  431. Sex-dependent regulation of hepatic peroxisome proliferation in mice by trichloroethylene via peroxisome proliferator-activated receptor α (PPARα)
  432. (2R)-2-Ethylchromane-2-carboxylic Acids:  Discovery of Novel PPARα/γ Dual Agonists as Antihyperglycemic and Hypolipidemic Agents
  433. Differential regulation of cytosolic and peroxisomal bile acid amidation by PPARα activation favors the formation of unconjugated bile acids
  434. Molecular cloning and characterization of two mouse peroxisome proliferator-activated receptor α (PPARα)-regulated peroxisomal acyl-CoA thioesterases
  435. Nonalcoholic steatohepatitic (NASH) mice are protected from higher hepatotoxicity of acetaminophen upon induction of PPARα with clofibrate
  436. Fatty acid oxidation inhibition with PPARα activation (FOXIB/PPARα) for normalizing gene expression in heart failure?
  437. PPARα mediates the effects of the pesticide methyl thiophanate on liver of the lizard Podarcis sicula
  438. Combined therapy with PPARα agonist and l-carnitine rescues lipotoxic cardiomyopathy due to systemic carnitine deficiency
  439. … ameliorates diabetic and dyslipidemic profiles in KKAy mice partly via down-regulation of 11β-HSD1, PEPCK and DGAT2.: Comparison of PPARα, PPARγ, and liver x …
  440. Differential regulation of the cynomolgus, human, and rat acyl-CoA oxidase promoters by PPARα
  441. Synergistic vascular protective effects of combined low doses of PPARα and PPARγ activators in angiotensin II‐induced hypertension in rats
  442. Effects of modifications of the linker in a series of phenylpropanoic acid derivatives: Synthesis, evaluation as PPARα/γ dual agonists, and X-ray crystallographic …
  443. Oxidized omega-3 fatty acids in fish oil inhibit leukocyte-endothelial interactions through activation of PPARα
  444. Transcriptional activation of PPARα by phenobarbital in the absence of CAR and PXR
  445. Peroxisome proliferator-activated receptor alpha (PPARα) agonists induce constitutive androstane receptor (CAR) and cytochrome P450 2B in rat primary hepatocytes
  446. Effects of combined PPARγ and PPARα agonist therapy on reverse cholesterol transport in the Zucker diabetic fatty rat
  447. Novel sulfamide analogs of oleoylethanolamide showing in vivo satiety inducing actions and PPARα activation
  448. The Effects of a PPARα agonist on myocardial damage in obese diabetic mice with heart failure
  449. … in enoyl-CoA hydratase/L-3-hydroxyacyl-CoA dehydrogenase-deficient mouse liver: Further support for the role of fatty acyl CoA oxidase in PPARα ligand …
  450. Pseudomonas aeruginosa and sPLA2 IB stimulate ABCA1-mediated phospholipid efflux via ERK-activation of PPARα–RXR
  451. Ligand-and species-dependent activation of PPARα
  452. Mouse carnitine–acylcarnitine translocase (CACT) is transcriptionally regulated by PPARα and PPARδ in liver cells
  453. Lack of NF-κB1 (p105/p50) attenuates unloading-induced downregulation of PPARα and PPARα-regulated gene expression in rodent heart
  454. … , synthesis and evaluation of substituted phenylpropanoic acid derivatives as peroxisome proliferator-activated receptor (PPAR) activators: novel human PPARα …
  455. PPARα and PPARγ are co‐expressed, functional and show positive interactions in the rat urinary bladder urothelium
  456. Pancreatic islet response to hyperglycemia is dependent on peroxisome proliferator-activated receptor alpha (PPARα)
  457. Effect of BM 17.0744, a PPARα ligand, on the metabolism of perfused hearts from control and diabetic mice
  458. The role of NF-κB in PPARα-mediated hepatocarcinogenesis
  459. Evidence for cross talk between PPARα and p38 MAP kinase
  460. … cooperatively with peroxisome proliferator-activated receptor gamma (PPARγ) coactivator 1α to coactivate nuclear receptors estrogen-related receptor α and PPARα
  461. Design and synthesis of potent and subtype-selective PPARα agonists
  462. The dominant negative thyroid hormone receptor β-mutant Δ337T alters PPARα signaling in heart
  463. Prostacyclin protects renal tubular cells from gentamicin-induced apoptosis via a PPARα-dependent pathway
  464. Overexpression of peroxisome proliferator-activated receptor-α (PPARα)-regulated genes in liver in the absence of peroxisome proliferation in mice deficient …
  465. Fatty acid synthesis and PPARα hand in hand
  466. Altered mRNA expression of hepatic lipogenic enzyme and PPARα in rats fed dietary levan from Zymomonas mobilis
  467. Effects of fatty acids and growth hormone on liver fatty acid binding protein and PPARα in rat liver
  468. … domains from the human oestrogen receptor α (hERα) crystal structure, and the human peroxisome proliferator activated receptor α (PPARα) ligand binding domain …
  469. Substituted 2-[(4-aminomethyl) phenoxy]-2-methylpropionic acid PPARα agonists. 1. Discovery of a novel series of potent HDLc raising agents
  470. The role of PPARα as a “lipostat” transcription factor
  471. Tesaglitazar, a PPARα/γ agonist, induces interstitial mesenchymal cell DNA synthesis and fibrosarcomas in subcutaneous tissues in rats
  472. Discovery of tertiary aminoacids as dual PPARα/γ agonists-I
  473. Butyrate inhibits cytokine-induced VCAM-1 and ICAM-1 expression in cultured endothelial cells: the role of NF-κB and PPARα
  474. Induction of peroxisome proliferator-activated receptor alpha (PPARα)-related enzymes by di (2-ethylhexyl) phthalate (DEHP) treatment in mice and rats, but not …
  475. Different sensitivity of PPARα gene expression to nutritional changes in liver of suckling and adult rats
  476. Regulatory role for phosphatidylcholine transfer protein/StarD2 in the metabolic response to peroxisome proliferator activated receptor alpha (PPARα)
  477. PPARα mediates peroxisome proliferator-induced transcriptional repression of nonperoxisomal gene expression in mouse
  478. PPARα gene expression is up-regulated by LXR and PXR activators in the small intestine
  479. Maturation of peroxisomes in differentiating human hepatoblastoma cells (HepG2): possible involvement of the peroxisome proliferator-activated receptor α (PPARα)
  480. Discovery of a peroxisome proliferator activated receptor γ (PPARγ) modulator with balanced PPARα activity for the treatment of type 2 diabetes and dyslipidemia
  481. Hepatic expression of PPARα, a molecular target of fibrates, is regulated during inflammation in a gender‐specific manner
  482. Influence of pharmacological PPARα activators on carnitine homeostasis in proliferating and non-proliferating species
  483. PPARα and PPARγ regulation of liver and adipose proteins in obese and dyslipidemic rodents
  484. The Interleukin-1 receptor antagonist is a direct target gene of PPARα in liver
  485. Evidence for an association between the Leu162Val polymorphism of the PPARα gene and decreased fasting serum triglyceride levels in glucose tolerant subjects
  486. Highly sensitive upregulation of apolipoprotein A-IV by peroxisome proliferator-activated receptor α (PPARα) agonist in human hepatoma cells
  487. PRIC295, a nuclear receptor coactivator, identified from PPARα-interacting cofactor complex
  488. Mouse hepatocyte response to peroxisome proliferators: dependency on hepatic nonparenchymal cells and peroxisome proliferator activated receptor α (PPARα)
  489. Novel pirinixic acids as PPARα preferential dual PPARα/γ agonists
  490. Troglitazone reduces the expression of PPARγ while stimulating that of PPARα in mononuclear cells in obese subjects
  491. Oxidized frying oil up-regulates hepatic acyl-CoA oxidase and cytochrome P450 4 A1 genes in rats and activates PPARα
  492. DNA binding preferences of PPARα/RXRα heterodimers
  493. Enantioselective synthesis of the PPARα agonist (R)-K-13675 via (S)-2-hydroxybutyrolactone
  494. Differential action of 13-HPODE on PPARα downstream genes in rat Fao and human HepG2 hepatoma cell lines
  495. The peroxisome proliferator-activated receptor α (PPARα) regulates the plasma thiobarbituric acid-reactive substance (TBARS) level
  496. PPARα/γ-independent effects of PPARα/γ ligands on cysteinyl leukotriene production in mast cells
  497. Expression of the mRNA encoding truncated PPARα does not correlate with hepatic insensitivity to peroxisome proliferators
  498. Increased entropy production in diaphragm muscle of PPARα knockout mice
  499. PPARα does not suppress muscle-associated gene expression in brown adipocytes but does influence expression of factors that fingerprint the brown adipocyte
  500. Transcriptional regulation of macrophage cholesterol trafficking by PPARα and LXR
  501. PPARα deficiency augments a ketogenic diet-induced circadian PAI-1 expression possibly through PPARγ activation in the liver
  502. Time course investigation of PPARα-and Kupffer cell-dependent effects of WY-14,643 in mouse liver using microarray gene expression
  503. Aleglitazar, a dual PPARα and PPARγ agonist for the potential oral treatment of type 2 diabetes mellitus.
  504. Synthesis and evaluation of azaindole-α-alkyloxyphenylpropionic acid analogues as PPARα/γ agonists
  505. PPARα ligands and clinical trials: cardiovascular risk reduction with fibrates
  506. Minor structural modifications convert a selective PPARα agonist into a potent, highly selective PPARδ agonist
  507. AZ 242, a novel PPARα/γ agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats
  508. … alterations in splenic iNOS regulation: influence of constitutively expressed IFN-γ and correction following supplementation with PPARα activators or vitamin E
  509. 7-Hydroxy-benzopyran-4-one derivatives: A novel pharmacophore of peroxisome proliferator-activated receptor α and-γ (PPARα and γ) dual agonists
  510. Reversal of high dietary fructose-induced PPARα suppression by oral administration of lipoxygenase/cyclooxygenase inhibitors
  511. Double gene deletion reveals the lack of cooperation between PPARα and PPARβ in skeletal muscle
  512. Synthesis, in vitro and in silico evaluation of l-tyrosine containing PPARα/γ dual agonists
  513. A PPARα promoter variant impairs ERR-dependent transactivation and decreases mortality after acute coronary ischemia in patients with diabetes
  514. Prevention of diet-induced obesity by safflower oil: insights at the levels of PPARα, Orexin, and Ghrelin gene expression of adipocytes in mice
  515. Modulación del PPARα por agentes farmacológicos y naturales y sus implicaciones metabólicas
  516. The characterization of PPARα ligand drug action in an in vivo model by comprehensive differential gene expression profiling
  517. Design, synthesis, and structure–activity relationship of carbamate-tethered aryl propanoic acids as novel PPARα/γ dual agonists
  518. Heat shock protein-90 (Hsp90) acts as a repressor of peroxisome proliferator-activated receptor-α (PPARα) and PPARβ activity
  519. Expression of peroxisome proliferator-activated receptor α, and PPARα regulated genes in spontaneously developed hepatocellular carcinomas in fatty acyl-CoA …
  520. Campest-5-en-3-one, an oxidized derivative of campesterol, activates PPARα, promotes energy consumption and reduces visceral fat deposition in rats
  521. The Korean traditional medicine Gyeongshingangjeehwan inhibits adipocyte hypertrophy and visceral adipose tissue accumulation by activating PPARα actions in rat …
  522. A dual‐response partial least squares regression QSAR model and its application in design of dual activators of PPARα and PPARγ
  523. Pharmacological characterization of a human-specific peroxisome proliferater-activated receptor α (PPARα) agonist in dogs
  524. Effects of phthalate ester derivatives including oxidized metabolites on coactivator recruiting by PPARα and PPARγ
  525. Adiponectin-mediated heme oxygenase-1 induction protects against iron-induced liver injury via a PPARα-dependent mechanism
  526. Fenofibrate induces a selective increase of protein-bound homocysteine in rodents: a PPARα-mediated effect
  527. Regulation of blood pressure, natriuresis and renal thiazide/amiloride sensitivity in PPARα null mice
  528. PPARα and AP-2α regulate bombesin receptor subtype 3 expression in ozone-stressed bronchial epithelial cells
  529. Importance of PPARα for the effects of growth hormone on hepatic lipid and lipoprotein metabolism
  530. The PPARα ligand fenofibrate: meeting multiple targets in diabetic nephropathy
  531. PPARα activators down-regulate CYP2C7, a retinoic acid and testosterone hydroxylase
  532. PPARα agonists stimulate progastrin production in human colorectal carcinoma cells
  533. The adjuvant effect of di-(2-ethylhexyl) phthalate is mediated through a PPARα-independent mechanism
  534. Induction of plasminogen activator inhibitor 1 by the PPARα ligand, Wy-14,643, is dependent on ERK1/2 signaling pathway
  535. Involvement of ZIP/p62 in the regulation of PPARα transcriptional activity by p38-MAPK
  536. … , homogeneous, fluorescence polarization binding assay for peroxisome proliferator-activated receptors alpha and gamma using a fluorescein-tagged dual PPARα/γ …
  537. PPARα ligands cause lymphocyte depletion and cell cycle block and this is associated with augmented TRB3 and reduced Cyclin B1 expression
  538. Osthole regulates enzyme protein expression of CYP7A1 and DGAT2 via activation of PPARα/γ in fat milk-induced fatty liver rats
  539. A potent activator of PPARα and γ reduces the vascular cell recruitment and inhibits the intimal thickning in hypercholesterolemic rabbits
  540. HMG-CoA reductase inhibitors (statins) activate expression of PPARα/PPARγ and ABCA1 in cultured gallbladder epithelial cells
  541. Synthesis of long-chain polyunsaturated fatty acids in lactating mammary gland: role of Δ5 and Δ6 desaturases, SREBP-1, PPARα, and PGC-1
  542. Discovery of a novel class of 2-mercaptohexanoic acid derivatives as highly active PPARα agonists
  543. PPARα gene expression in the developing rat kidney: Role of glucocorticoids
  544. Combined effects of PPARγ2 P12A and PPARα L162V polymorphisms on glucose and insulin homeostasis: the Québec Family Study
  545. The effect of PPARα and PPARγ ligands on inflammation and ABCA1 expression in cultured gallbladder epithelial cells
  546. Peroxisome proliferator-activated receptorα (PPARα) agonists down-regulate α2-macroglobulin expression by a PPARα-dependent mechanism
  547. The PPARγ agonist pioglitazone represses inflammation in a PPARα-dependent manner in vitro and in vivo in mice
  548. Species-specific kinetics and zonation of hepatic DNA synthesis induced by ligands of PPARα
  549. Apoptosis of Endothelial Cells may be Mediated by Genes of Peroxisome Proliferator-activated Receptor γ1 (PPAR γ1) and PPARα Genes
  550. Effect of prenatal peroxisome proliferator-activated receptor α (PPARα) agonism on postnatal development
  551. PPARα activation reverses adverse effects induced by high-saturated-fat feeding on pancreatic β-cell function in late pregnancy
  552. Tesaglitazar, a dual peroxisome proliferator-activated receptor agonist (PPARα/γ), improves metabolic abnormalities and reduces renal injury in obese Zucker rats
  553. Antagonism of COUP-TF and PPARα-RXRα on the Activation of the Malic Enzyme Gene Promoter: Modulation by 9-cis-RA
  554. HMG-CoA reductase and PPARα are involved in clofibrate-induced apoptosis in human keratinocytes
  555. Molecular Mechanism of Age-Specific Hepatic Lipid Accumulation in PPARα (+/−): LDLR (+/−) Mice, an Obese Mouse Model
  556. In vivo involvement of cytochrome P450 4A family in the oxidative metabolism of the lipid peroxidation product trans-4-hydroxy-2-nonenal, using PPARα …
  557. Design and synthesis of 2-methyl-2-{4-[2-(5-methyl-2-aryloxazol-4-yl) ethoxy] phenoxy} propionic acids: a new class of dual PPARα/γ agonists
  558. Design, synthesis, and evaluation of a new class of noncyclic 1, 3-dicarbonyl compounds as PPARα selective activators
  559. Effects of PPARα on cardiac glucose metabolism: a transcriptional equivalent of the glucose-fatty acid cycle?
  560. Selective CETP inhibition and PPARα agonism increase HDL cholesterol and reduce LDL cholesterol in human ApoB100/Human CETP transgenic mice
  561. The clinical significance of PPARα and γ agonism
  562. PPARα activation and increased dietary lipid oppose thyroid hormone signaling and rescue impaired glucose-stimulated insulin secretion in hyperthyroidism
  563. Downregulation of lactoferrin by PPARα ligands: Role in perturbation of hepatocyte proliferation and apoptosis
  564. Phosphatidylcholine and PPARα: A relevant connection in liver disease?
  565. Activation of PPARα by bezafibrate negatively affects de novo synthesis of sphingolipids in regenerating rat liver
  566. PPARα activation by Wy 14643 induces transactivation of the rat UCP-1 promoter without increasing UCP-1 mRNA levels and attenuates PPARγ-mediated increases …
  567. Molecular modelling of the peroxisome proliferator-activated receptor α (PPARα) from human, rat and mouse, based on homology with the human PPARγ crystal …
  568. Analysis of tissue-specific and PPARα-dependent induction of FABP gene expression in the mouse liver by an in vivo DNA electroporation method
  569. Differential transcriptional expression of PPARα, PPARγ1, and PPARγ2 in the peritoneal macrophages and T-cell subsets of non-obese diabetic mice
  570. PPARα activation abolishes LDL-stimulated IL-8 production via AP-1 deactivation in human aortic smooth muscle cells
  571. Differences in the formation of PPARα-RXR/acoPPRE complexes between responsive and nonresponsive species upon fibrate administration
  572. Monocarboxylate transporter (MCT)-1 is up-regulated by PPARα
  573. … , biological evaluation, and molecular modeling investigation of chiral 2-(4-chloro-phenoxy)-3-phenyl-propanoic acid derivatives with PPARα and PPARγ agonist …
  574. … isoform 4 (PDK4) protein expression in oxidative skeletal muscle does not require the obligatory participation of peroxisome-proliferator-activated receptor α (PPARα)
  575. Deficiency of PPARα disturbs the response of lipogenic flux and of lipogenic and cholesterogenic gene expression to dietary cholesterol in mouse white adipose …
  576. A pan-PPAR ligand induces hepatic fatty acid oxidation in PPARα−/− mice possibly through PGC-1 mediated PPARδ coactivation
  577. The peroxisome proliferator-activated receptor α (PPARα) agonist ciprofibrate inhibits apolipoprotein B mRNA editing in low density lipoprotein receptor …
  578. PPARα: Tempting fate with fat
  579. α-Lipoic Acid is a Weak Dual PPARα/γ Agonist: An Ester Derivative with Increased PPARα/γ Efficacy and Antioxidant Activity.
  580. PPARα-dependent alteration of GRP94 expression in mouse hepatocytes
  581. Four weeks one-leg training and high fat diet does not alter PPARα protein or mRNA expression in human skeletal muscle
  582. Uncoupling protein-2 up-regulation and enhanced cyanide toxicity are mediated by PPARα activation and oxidative stress
  583. Pleural mesothelial cells express both BLT2 and PPARα and mount an integrated response to pleural leukotriene B4
  584. Structure‐based drug design of a novel family of chalcones as PPARα agonists: virtual screening, synthesis, and biological activities in vitro1
  585. PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORα (PPARα) AGONIST, WY-14,643, INCREASED TRANSCRIPTION OF MYOSIN LIGHT CHAIN-2 IN …
  586. Aspirin inhibits MMP-2 and MMP-9 expressions and activities through upregulation of PPARα/γ and TIMP gene expressions in ox-LDL-stimulated macrophages …
  587. Influence of peroxisome proliferator-activated receptor-alpha (PPARα) activity on adverse effects associated with amiodarone exposure in mice
  588. 4, 4-Dimethyl-1, 2, 3, 4-tetrahydroquinoline-based PPARα/γ agonists. Part I: Synthesis and pharmacological evaluation
  589. Thioredoxin-1 and its natural inhibitor, vitamin D3 up-regulated protein 1, are differentially regulated by PPARα in human macrophages
  590. The pesticide adjuvant, Toximul™, alters hepatic metabolism through effects on downstream targets of PPARα
  591. PPARα stimulates the rat gastrin-producing cell
  592. PPARα-mediated upregulation of uncoupling protein-2 switches cyanide-induced apoptosis to necrosis in primary cortical cells
  593. Conversion of human-selective PPARα agonists to human/mouse dual agonists: a molecular modeling analysis
  594. Aspirin inhibits MMP-2 and MMP-9 expression and activity through PPARα/γ and TIMP-1-mediated mechanisms in cultured mouse celiac macrophages
  595. Cell cross-talk mediates PPARα null hepatocyte proliferation after peroxisome proliferator exposure
  596. Novel phospholipid analogues of pan-PPAR activator tetradecylthioacetic acid are more PPARα selective
  597. WY-14 643, a selective PPARα agonist, induces proinflammatory and proangiogenic responses in human ocular cells
  598. PPARα Contributes to Tubular Protection
  599. PPARα ligand WY14643 reduced acute rejection after rat lung transplantation with the upregulation of IL-4, IL-10 and TGFβ mRNA expression
  600. PPARα agonists clofibrate and gemfibrozil inhibit cell growth, down-regulate hCG and up-regulate progesterone secretions in immortalized human trophoblast cells
  601. Possible role of fatty acids in milk as the regulator of the expression of cytosolic binding proteins for fatty acids and vitamin A through PPARα in developing rats
  602. … ) phthalate induces both pro-and anti-inflammatory responses in rat alveolar macrophages through crosstalk between p38, the lipoxygenase pathway and PPARα
  603. PPARα and PPARδ transactivity and p300 binding activity induced by arachidonic acid in colorectal cancer cell line Caco-2
  604. Structure-based design and synthesis of fluorescent PPARα/δ co-agonist and its application as a probe for fluorescent polarization assay of PPARδ ligands
  605. Inhibition of PPARα/RXRα‐mediated direct hyperplasia pathways during griseofulvin‐induced hepatocarcinogenesis
  606. Transcriptional modulations by RXR agonists are only partially subordinated to PPARα signaling and attest additional, organ-specific, molecular cross-talks
  607. Differential modulation of PPARα and γ target gene expression in the liver and kidney of rats treated with aspirin
  608. Interaction models of a series of oxadiazole-substituted α-isopropoxy phenylpropanoic acids against PPARα and PPARγ: molecular modeling and comparative …
  609. Proteomics analysis of cardiac muscle from rats with peroxisomal proliferator-activated receptor α (PPARα) stimulation
  610. The discovery of equipotent PPARα/γ dual activators
  611. Mode of action analysis and human relevance of liver tumors induced by PPARα activation
  612. PPARα-dependent induction of liver microsomal esterification of estradiol and testosterone by a prototypical peroxisome proliferator
  613. Expression of PPARα modifies fatty acid effects on insulin secretion in uncoupling protein-2 knockout mice
  614. Design, synthesis, and evaluation of novel aryl-tetrahydropyridine PPARα/γ dual agonists
  615. Synthesis and evaluation of N-acetyl-l-tyrosine based compounds as PPARα selective activators
  616. 4, 4-Dimethyl-1, 2, 3, 4-tetrahydroquinoline-based PPARα/γ agonists. Part. II: Synthesis and pharmacological evaluation of oxime and acidic head group structural …
  617. Δ5 desaturase mRNA levels are increased by simvastatin via SREBP-1 at early stages, not via PPARα, in THP-1 cells
  618. Cardiovascular actions of the peroxisome proliferator‐activated receptor‐alpha (PPARα) agonist Wy14, 643
  619. Dehydroepiandrosterone up-regulates the Adrenoleukodystrophy-related gene (ABCD2) independently of PPARα in rodents
  620. PPARα: Savior or savage?
  621. Omega-3 fatty acids regulate gene expression levels differently in subjects carrying the PPARα L162V polymorphism
  622. Major role of soybean oil in preventing decrease in CYP4A1 mRNA content relative to PPARα mRNA down-regulation in infant rats
  623. PAR-5359, a well-balanced PPARα/γ dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo
  624. P450 CYP2C epoxygenase and CYP4A ω-hydroxylase mediate ciprofibrate-induced PPARα-dependent peroxisomal proliferation
  625. PPARα activation during pregnancy severely impairs mammary lobuloalveolar development in mice
  626. Association between the FABP2 Ala54Thr, PPARα Leu162/Val, and PPARα intron7 polymorphisms and blood lipids ApoB and ApoCIII in hypertriglyceridemic subjects …
  627. Effects of cevoglitazar, a dual PPARα/γ agonist, on ectopic fat deposition in fatty Zucker rats
  628. Improvement of postprandial lipid handling and glucose tolerance in a non-diabetic population by the dual PPARα/γ agonist, tesaglitazar
  629. Molecular mechanics and molecular orbital simulations on specific interactions between peroxisome proliferator-activated receptor PPARα and plasticizer
  630. … coactivator PRIP, the peroxisome proliferator-activated receptor (PPAR)-interacting protein, is redundant for the function of nuclear receptors PPARα and CAR, the …
  631. Circumventing glucocorticoid-mediated hyperinsulinemia via the activation of PPARα
  632. Identification of novel PPARα ligands by the structural modification of a PPARγ ligand
  633. Structure–activity studies on 1, 3-dioxane-2-carboxylic acid derivatives, a novel class of subtype-selective peroxisome proliferator-activated receptor α (PPARα) …
  634. Design and synthesis of novel bis-oximinoalkanoic acids as potent PPARα agonists
  635. … response element (PPRE) present at positions− 681/− 669 in the rat liver 3-ketoacyl-CoA thiolase B gene functionally interacts differently with PPARα and HNF-4
  636. MK-0767, a novel dual PPARα/γ agonist, displays robust antihyperglycemic and hypolipidemic activities
  637. Peroxisome Proliferator-Activated Receptor α (PPARα) activators, bezafibrate and Wy-14,643, increase uncoupling protein-3 mRNA levels without modifying the …
  638. Molecular modeling study of species-selective peroxisome proliferator-activated receptor (PPAR) α agonist; possible mechanism (s) of human PPARα selectivity of an …
  639. A convergent kilogram-scale synthesis of the PPARα agonist LY518674: Discovery of a novel acid-mediated triazolone synthesis
  640. Combating atherosclerosis with LXRα and PPARα agonists: is rational multitargeted polypharmacy the future of therapeutics in complex diseases?
  641. Induction of the expression of the peroxisome proliferator‐activated receptor alpha (PPARα) by clofibrate in jerboa tissues
  642. The induction of atherogenic dyslipidaemia in poloxamer 407‐treated mice is not mediated through PPARα
  643. Influence of DMBA-induced mammary cancer on the liver CPT I, mit HMG-CoA synthase and PPARα mRNA expression in rats fed a low or high corn oil diet
  644. Glycine amides as PPARα agonists
  645. Relationship between signal transduction and PPARα-regulated genes of lipid metabolism in rat hepatic-derived Fao cells
  646. Peroxisome proliferator-activated receptor α (PPARα) activators induce hepatic farnesyl diphosphate synthase gene expression in rodents
  647. The possible therapeutic actions of peroxisome proliferator-activated receptor α (PPARα) agonists, PPARγ agonists, 3-hydroxy-3-methylglutaryl coenzyme A (HMG …
  648. Design, synthesis, and structure–activity relationships of piperidine and dehydropiperidine carboxylic acids as novel, potent dual PPARα/γ agonists
  649. PPARα and PPARβ are differentially affected by ethanol and the ethanol metabolite acetaldehyde in the MCF-7 breast cancer cell line
  650. Hepatic nuclear receptor PPARα in the koala (Phascolarctos cinereus): Cloning and molecular characterisation
  651. Activation of PPARα attenuates IFNγ and IL-1β-induced cell proliferation in astrocytes: involvement of IL-6 independent pathway
  652. PPARα and Effects of TCE
  653. Down-regulation of α-amino-β-carboxymuconate-ε-semialdehyde decarboxylase by polyunsaturated fatty acids in hepatocytes is not mediated by PPARα
  654. PPARα: essential component to prevent myocardial oxidative stress?
  655. PPARα and PPARγ coactivation rapidly induces Egr-1 in the nuclei of the dorsal and ventral urinary bladder and kidney pelvis urothelium of rats
  656. PPARα siRNA–Treated Expression Profiles Uncover the Causal Sufficiency Network for Compound-Induced Liver Hypertrophy
  657. Aspirin inhibits MMP-9 mRNA expression and release via the PPARα/γ and COX-2/mPGES-1-mediated pathways in macrophages derived from THP-1 cells
  658. Docosahexaenoic acid modulates the expression of T-bet and GATA-3 transcription factors, independently of PPARα, through suppression of MAP kinase activation
  659. Synergistic activation of UCP-3 expression in cultured fetal rat brown adipocytes by PPARα and PPARγ ligands
  660. Baker’s yeast-mediated reduction of ethyl 2-(4-chlorophenoxy)-3-oxoalkanoates intermediates for potential PPARα ligands
  661. Effects of peroxisome proliferator-activated receptor α (PPARα) agonists on leucine-induced phosphorylation of translational targets in C2C12 cells
  662. … of 2-aryl-4-oxazolylmethoxy benzylglycines and 2-aryl-4-thiazolylmethoxy benzylglycines as novel, potent PPARα selective activators-PPARα and PPARγ selectivity …
  663. Activation of PPARα and PPARγ induce expression of the hepatic LDL receptor
  664. … terpenes on hepatic cytochrome P450 CYP4A, peroxisomal Acyl CoA oxidase (AOX) and peroxisome proliferator activated receptor alpha (PPARα) in the common …
  665. Synergistic effect of the human GLP‐1 analogue liraglutide and a dual PPARα/γ agonist on glycaemic control in Zucker diabetic fatty rats
  666. Pyridine-2-propanoic acids: Discovery of dual PPARα/γ agonists as antidiabetic agents
  667. Haploinsufficiency in the PPARα and LDL receptor genes leads to gender-and age-specific obesity and hyperinsulinemia
  668. Ampk enhances the expression of pancreatic duodenal homeobox-1 via PPARα, but not PPARγ, in rat insulinoma cell line INS-1
  669. Liver PPARα and UCP2 are involved in the regulation of ovariectomy-induced adiposity and steatosis by swim training
  670. Cytochrome P450 eicosanoids regulate fatty acid metabolism via PPARα
  671. Antral G cells in rats during dosing with a PPARα agonist: a morphometric and immunocytochemical study
  672. Increased Proximal tubule PPARα in KAP2-PPARα Tg mice confers protection during acute kidney injury
  673. Species differences in induction of hepatic enzymes by BM 17.0744, an activator of peroxisome proliferator-activated receptor alpha (PPARα)
  674. Administration of ciprofibrate to lactating mothers induces PPARα-signaling pathway in the liver and kidney of suckling rats
  675. The conserved residue Phe273 (282) of PPARα (γ), beyond the ligand-binding site, functions in binding affinity through solvation effect
  676. Liquid chromatography-tandem mass spectrometry of a new PPARα/γ dual agonist PAR-5359 in rat plasma
  677. [14C] and [3H]‐labelling of Ragaglitazar: A dual acting PPARα and PPARγ agonist with hypolipidemic and anti‐diabetic activity
  678. The Peroxisomal 3-keto-acyl-CoA thiolase B Gene Expression Is under the Dual Control of PPARα and HNF4α in the Liver
  679. Preventing type 2 diabetes and cardiovascular disease in metabolic syndrome: the role of PPARα
  680. TNF and IL-1 decrease RXRα, PPARα, PPARγ, LXRα, and the coactivators SRC-1, PGC-1α, and PGC-1β in liver cells
  681. Effects of 12 weeks of exercise on hepatic TNF-α and PPARα in an animal model of high-fat diet-induced nonalcoholic steatohepatitis
  682. The Peroxisome Proliferator-Activated Receptor α (PPARα) Ligand WY 14,643 Does Not Interfere with Leukotriene B4 Induced Adhesion of Neutrophils to Endothelial …
  683. PPARα deficiency does not modify age dependency but prevents high fat diet increase in plasma PAI-1 as well as insulin resistance
  684. PPARα, A key regulator of hepatic energy homeostasis in health and disease
  685. Differential antiatherogenic effects of PPARα versus PPARγ agonists: should we be surprised?
  686. (2R)-2-Methylchromane-2-carboxylic acids: Discovery of selective PPARα agonists as hypolipidemic agents
  687. Supramolecular Behavior of the Amphiphilic Drug (2R)-2-Ethylchromane-2-Carboxylic Acid Arginine Salt (a Novel PPARα/γ Dual Agonist)
  688. A selective PPARα agonist, CP-900691, improves plasma lipids, lipoproteins, and glycemic control in diabetic monkeys
  689. Synthesis of a 5-((Aryloxy) methyl)-3-(4-(trifluoromethyl) phenyl)[1, 2, 4] thiadiazole Derivative: A Promising PPARα, δ Agonist
  690. PPARβ/δ but not PPARα serves as plasma free fatty acid sensor in liver
  691. Reciprocal regulation of BMAL1 and PPARα defines a novel positive feedback loop in the rodent liver circadian clock
  692. Exploring the activation and function of PPARα and PPARβ/δ using genomics
  693. The PPARα activator fenofibrate fails to alter myocardial metabolism in healthy individuals despite marked peripheral effects
  694. Pyridine-3-propanoic acids: Discovery of dual PPARα/γ agonists as antidiabetic agents
  695. WY14, 643, a PPARα ligand, attenuates expression of anti-glomerular basement membrane disease
  696. Partial resistance to PPARα agonists in Zucker diabetic fatty (ZDF) rats is associated with defective hepatic mitochondrial metabolism
  697. Fenugreek extract rich in 4-hydroxyisoleucine and trigonelline activates PPARα and inhibits LDL oxidation: Key mechanisms in controlling the metabolic syndrome
  698. Leukotriene B4: agonist for the fat regulator PPARα
  699. PPARα agonist fenofibrate inhibits IGF-I-mediated growth and DNA repair responses and sensitizes human glioblastoma cells to cisplatin
  700. Effects of Tribu Saponin from Tribulus terrestris on Gene Expression of ICAM-1, VCAM-1, PPARα and PPARγ in Artery Vessels of Atherosclerotic Rats.
  701. CoMFA, ADVANCE CoMFA AND CoMSIA STUDIES ON THE OXADIAZOLE SUBSTITUTED α-ISOPROPOXY PHENYLPROPIONIC ACIDS FOR PPARα AGONISTIC …
  702. PPARα activation and its consequences in humans
  703. Expression of the human UGT1 locus in transgenic mice by WY-14643 and implications on drug metabolism through PPARα activation
  704. PPARα activation: a drink from the fountain of youth?
  705. Regulation of arginine metabolism by dietary fatty acids: involvement of PPARα
  706. Rescue of cardiomyopathy in PPARα transgenic mice by deletion of lipoprotein lipase identifies sources of cardiac lipids and PPARα activators
  707. Synthesis of urea acetates as potential PPARα/γ dual agonists
  708. Ab initio fragment molecular orbital calculations on the specific interactions between human, mouse and rat PPARα and GW409544
  709. The effect of soy isoflavones on the PPARα and PPARγ
  710. PPARα, Lipoprotein Metabolism, Metabolic Diseases, and Atherosclerosis
  711. Synthesis of tritium and carbon‐14 labelled NNC 61‐4655: a potent dual‐acting PPARα and PPARγ agonist
  712. Quantitative Structure Activity Analysis of 2-Alkoxydihydrocinnamates as PPARα/γ Dual Agonist
  713. Synthesis of 2-methoxy-2-methyl-3-{6-[2-(5-methyl-2-phenyl-1, 3-oxazol-4-yl) ethoxy] pyridin-3-yl} propanoic acid, a dual PPARα/γ agonist
  714. Peroxisome Proliferator-Activated Receptor Alpha (PPARα): The Association with Pathogenesis of Fatty Liver Disease
  715. Beneficial effect of berberine on hepatic insulin resistance in diabetic hamsters possibly involves in SREBPs, LXRα and PPARα transcriptional programs
  716. Effect of aerobic exercise on the expression of PPARα, ABCA1 and ApoAI mRNA in high-fat diet rats muscles.
  717. Muscle ring finger‐1 (MuRF1) regulates cardiac fatty acid and glucose metabolism via its interaction with PPARα
  718. Polymorphisms of peroxisome proliferator-activated receptor a (PPARα)-exon 5 and its relationship with carcass and meat quality traits in cattle.
  719. Reduced LPA expression after peroxisome proliferator-activated receptor alpha (PPARα) activation in LPA-YAC transgenic mice
  720. Sustained formation of POBN radical adducts in mouse liver by peroxisome proliferators is dependent upon PPARα, but not NADPH oxidase
  721. Exploring the Activation and Function of PPARα and PPARß/δ Using Genomics
  722. Accelerated triacylglyceride dynamics induced by cardiac PPARα overexpression are potentiated by adrenergic stress to reveal increased reliance on endogenous …
  723. Tissue-specific Expression of Two Peroxisomal 3-ketoacyl-CoA Thiolase Genes in Wild and PPARα-null Mice and Induction by Fenofibrate
  724. The Effect of Rivoglitazone (Rivo) on Expression of Genes Targeted by PPARα and Those Implicated in Cardiac Function.
  725. (S)-3-(4-(2-(5-Methyl-2-phenyloxazol-4-yl) ethoxy) phenyl)-2-(piperazin-1-yl) propanoic acid compounds: Synthesis and biological evaluation of dual PPARα/γ …
  726. Muscle ring finger‐1 (MuRF1) inhibits spontaneous cardiac hypertrophy induced by the PPARα agonist fenofibrate in vivo
  727. Design and Synthesis of Novel 1, 3-Dioxane-2-carboxylic Acid Derivatives as PPARα/γ Dual Agonists
  728. PPARα and Atherosclerosis
  729. The Role of PPARα in Fatty Acid Metabolism and Hepatocarcinogenesis: Studies with PPARα-Null Mice
  730. A non-TZD PPARα/γ dual agonist CG301360 alleviates insulin resistance and lipid dysregulation in db/db mice
  731. Cardiac Lipoprotein Lipase Deficiency Rescues Lipotoxic Cardiomyopathy and Identifies a Distinct Cellular PPARα Signaling Pathway
  732. Effect of PPARα ligand on TNFα-dependent expression of EGF receptor in human glioma cell line
  733. Transcriptional Regulation of Nutrient Metabolism by PPARα, γ and LXRα.
  734. Impaired Ras membrane-association and activation in PPARα knockout mice following partial hepatectomy
  735. Studies on the attenuation effects of intestinal PPARα
  736. PPARα and GR Differentially Down-Regulate the
  737. Statin reduces triglyceride level via activating PPARα and upregulating apolipoprotein A5 in hypertriglyceridemic rats
  738. Differential hepatic effects of perfluorobutyrate (PFBA) mediated by mouse and human PPARα
  739. KRP-101: A Potent PPARα Agonist Ameliolates Fat-Induced Insulin Resistance with Suppression of Adiposity in Dogs.
  740. PPARα-Regulated growth responses and their importance to hepatocarcinogenesis
  741. Role of Oxidative Stress in Cardiac Dysfunction of PPARα-/-Mice
  742. Identification of new PPARα target genes support its anti-inflammatory function in liver
  743. Regulation of Peroxisome Proliferator-Activated Receptor-Alpha (PPARα)
  744. RAGE dependent regulation of PPARα in bone metabolism
  745. PPARα controlling HDL metabolism and atherosclerosis
  746. Transcriptomic analysis of PPARα-dependent alterations during cardiac hypertrophy
  747. Research Article Fasting Upregulates PPARα Target Genes in Brain and Influences Pituitary Hormone Expression in a PPARα Dependent Manner
  748. PPARα regulates the expression of the amino acid degrading enzyme histidase
  749. Research Article Gene Expression Profiling in Wild-Type and PPARα-Null Mice Exposed to Perfluorooctane Sulfonate Reveals PPARα-Independent Effects
  750. Probing the role of peroxisome proliferator-activated receptor alpha (PPARα) in the small intestine
  751. Poor match between genome wide in silico screening of PPARα targets and actual gene regulation in the mouse
  752. Perfluorohexanesulfonate and perfluorooctanesulfonate decrease plasma cholesterol and triglycerides in APOE* 3Leiden transgenic mice. Indication for a PPARα …
  753. Transcription coactivator PRIP is not essential for the function of nuclear receptors CAR and PPARα in liver
  754. Mannose binding lectin is a circulating mediator of hepatic PPARα activity in human
  755. Gly395Arg polymorphism of PPARα gene was not detected in japanese population of 729 individuals
  756. Peroxisome Proliferator-Activated Receptor (PPARα) Targeted Mutation Mouse Model
  757. The Krüppel like factors KLF11 and KLF10 are putative novel PPARα target genes in liver with a potential metabolic role
  758. Modulation of PPARα and PPARβ by ethanol in human breast cancer cell lines
  759. Fatty acid-dependent gene regulation of transporters and phase I/II metabolic enzymes by PPARα in murine small intestine
  760. PPARα is Essential for Cardiac Metabolic Adaptation to Chronic Hypoxia
  761. THE ANTI-INFLAMMATORY AND PRO-NEUROGENIC ROLE OF PPARα IN MODULATING RADIATION-INDUCED BRAIN INJURY
  762. α-Lipoic Acid is a Weak Dual PPARα/γ Agonist
  763. The Dual PPARα/γ Agonist Tesaglitazar Reduces Atherosclerosis Development Beyond its Plasma Cholesterol-Lowering Effects in APOE* 3Leiden Transgenic …
  764. HEPATIC EXPRESSION OF PEROXISOME PROLIFERATORS ACTIVATED RECEPTORα (PPARα) IN PRIMARY BILIARY CIRRHOSIS: 1195
  765. Research Article Differences in Transcriptional Activation by the Two Allelic (L162V Polymorphic) Variants of PPARα after Omega-3 Fatty Acids Treatment
  766. Differences in transcriptional activation by the two allelic (L162V polymorphic) variants of PPARα after omega-3 fatty acids treatment
  767. Research Article PRIC295, a Nuclear Receptor Coactivator, Identified from PPARα-Interacting Cofactor Complex
  768. PPARα activation is essential for severe hepatic steatosis and hepatocellular carcinoma induced by HCV core protein
  769. The Role of Chronic PPARα Activation During Ischemia and Reperfusion Injury in the Female Rat Heart
  770. Treatment of obesity and type 2 diabetes with PPARα agonists–effects on myocardial metabolism, gene expression and ventricular function
  771. Possible role of fatty acids in milk as the regulator of the expression of cytosolic binding proteins for fatty acids and vitamin A through PPARα in developing rats
  772. Human skeletal muscle PPARα expression correlates with expression of fat metabolism genes but not with BMI or insulin sensitivity
  773. Dietary saponins of sea cucumber alleviate orotic acid-induced fatty liver in rats via PPARα and SREBP-1c signaling.
  774. Identification of a novel PPARα‐interacting protein
  775. PPARα and TCE: Keshava et al. Respond
  776. An epitope-tagging system for studying regulation of the peroxisome proliferator activated receptor alpha (PPARα)
  777. PPARα is a Key regulator of Hepatic FGF21 PPAR is a Key regulator of Hepatic FGF21
  778. Effect of maternal dietary restriction during pregnancy in rats on PPARα-regulated genes in the heart of the male offspring
  779. Effect of oleic acid on triglycerides (TG) accumulation and mRNA level of TNFα and PPARα in goose primary hepatocytes.
  780. In vivo PPARα activation attenuates cerebrovascular endothelial dysfunction via impeding NADPH oxidase-derived superoxide and augmenting …
  781. Repression of CYP4F1 gene by peroxisome proliferators is mediated by HNF4α and PPARα competition for PPRE sites in the CYP4F1 promoter
  782. PPARα Activation Reduced Remodelling And Improved Left Ventricular Function In Chronic Pressure/volume Overload Induced Heart Failure
  783. Thioredoxin-mediated negative autoregulation of peroxisome proliferator activated receptor α (PPARα) transcriptional activity
  784. Highly Sensitive and Potent Upregulation of Apolipoprotein A-IV/V by Novel PPARα Agonist, KRP-101, as Major PPARα-Regulated Genes in Human Hepatocytes.
  785. Acyl‐CoA Ligands of HNF‐4α and HNF‐4α/PPARα Interplay
  786. Partial resistance to PPARα agonists in Zucker diabetic fatty (ZDF) rats is associated with defective hepatic mitochondrial metabolism
  787. Glucagon Stimulates Fatty Acid Oxidation and Inhibits Triglyceride Synthesis in a PPARα-, p38 MAPK-and AMPK-Dependent Manner.
  788. Involvement of AMPK, p38 MAPK and PPARα in the regulation of avian uncoupling protein expression: regulation by isoproterenol and fatty acids in chick myoblasts
  789. Role of PPARα in control of torpor through FGF21-NPY pathway: From circadian clock genes to seasonal change and cardiovascular disease
  790. Activators of Nuclear Hormone Receptors, PPARα and FXR, Accelerate Maturation of the Epidermal Permeability Barrier In Utero• 321
  791. Statin induction of Liver Fatty Acid-Binding Protein (L-FABP) gene expression is PPARα-dependent.
  792. Protective Effect of KRP-101, Novel PPARα Agonist, on Fatty Liver Disease Through Induction of Lipid Oxidation & Suppression of Lipogenesis in Hamsters.
  793. The human multidrug resistance 3 (MDR3) transporter is a peroxisome proliferator-activated receptor α (PPARα) target gene
  794. PPARα AGONIST THERAPY AUGMENTS PARENCHYMAL REJECTION AND DOES NOT AMELIORATE TRANSPLANT-ASSOCIATED ARTERIOSCLEROSIS IN …
  795. Effect of berberine on PPARα/δ/γexpression in type 2 diabetic rat kidney
  796. PPARα agonists acutely dilate the mouse middle cerebral artery
  797. 3. PPARα AND FEMALE REPRODUCTION
  798. The Circulating Metabolic Regulator FGF21 Is Induced by Prolonged Fasting and PPARα Activation in Man
  799. SQUIRRELnovo: de novo design of a PPARα agonist by bioisosteric replacement
  800. Combined effects of PPARγ2 P12A and PPARα L162V polymorphisms on glucose and insulin homeostasis: the Québec Family Study
  801. PPARα L162V polymorphism alters the potential of N-3 fatty acids to increase lipoprotein lipase activity
  802. Proteomic profiling of salt‐induced changes in protein expression in PPARα null mice
  803. Neonatal leptin exposure induces altered expression of specific PPARα transcripts in adipose tissue of adult rats
  804. Effect of berberine on PPARα/δ/γ expression in type 2 diabetic rat kidney.
  805. Design and Synthesis of Naphthalimides as PPARα Agonists, Antihyperlipidemic, and Antiatherosclerotic Agents
  806. Activation of PPARα Is Positively Associated with the Upregulation of AMPKα Expression Impaired by Palmitate in INS-1 Beta Cells.
  807. PPARα Agonist Increases HDL Particle Size Through the Expression of Hepatic ABCG1 mRNA in the Zucker Diabetic Fatty Rat.
  808. Inside Cover: Design and Biological Evaluation of Novel, Balanced Dual PPARα/γ Agonists (ChemMedChem 6/2009)
  809. Maternal diet alters expression of specific PPARα transcripts in the hearts of their female offspring
  810. Research Article Molecular Characterization of the Onset and Progression of Colitis in Inoculated Interleukin-10 Gene-Deficient Mice: A Role for PPARα
  811. Bioassay-guided purification and identification of PPARα/γ agonists from Chlorella sorokiniana.
  812. The PPARα/γ dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats.
  813. Short term consumption of lycopene and phytofluene decreases PPARα and PPARγ expression in selected rat tissues
  814. Effects of PPARα ligand on circadian rhythms and EEG delta power in mice
  815. Effect of berberine on PPARα/δ/γ expression in type 2 diabetic rat retinae.
  816. The involvement of PPARα in epoxide‐induced activation of adenosine receptors in angiogenesis
  817. Homocysteine-mediated PPARα, γ DNA methylation and its potential pathogenic mechanism in monocytes.
  818. PPARα Activation with Fenofibrate Attenuates Diabetic Nephropathy in Zucker Diabetic Fatty Rats
  819. Cardiomyocyte‐restricted PPARδ deletion in PPARα null mice leads to cardiac hypertrophy and heart failure
  820. Role of COX-2 in MCD Diet Induced Fibrosis and Its Corelation with PPARα
  821. Sargaquinoic acid and sargahydroquinoic acid from Sargassum yezoense stimulate adipocyte differentiation through PPARα/γ activation in 3T3-L1 cells.
  822. Changes in liver PPARα mRNA expression in response to two levels of high-safflower-oil diets correlate with changes in adiposity and serum leptin in rats and mice.
  823. Gender difference in PPARα regulation of inflammation and demyelination in EAE model of multiple sclerosis (50.1)
  824. Beneficial effect of berberine on hepatic insulin resistance in diabetic hamsters possibly involves in SREBPs, LXRα and PPARα transcriptional programs.
  825. A Novel Selective PPARα Agonist, CP900691, Improves Plasma Lipids, Lipoproteins, Glycemic Control and Reduces Body Weight in Diabetic Monkeys.
  826. Metabolic alterations beyond fatty acid oxidation defects in PPARα null mice hearts
  827. Phenotype of peroxisome proliferator-activated receptor-α (PPARα) deficient mice on mixed background fed high fat diet.
  828. The hepatic aquaporin 9 (AQP9) expression is regulated in response to castration and PPARα‐agonist treatment
  829. Effects of restraint on expression of PPARα, PPARβ and M-CPT-I mRNA in myocardium of rats.
  830. PPARα agonist protects against salt‐mediated increases in endogenous carbon monoxide production and blood pressure in Dahl salt‐sensitive rats
  831. Molecular mechanism of age-specific hepatic lipid accumulation in PPARα (+/-): LDLR (+/-) mice, an obese mouse model.
  832. Effects of high dietary fat and cholesterol on expression of PPARα, LXRα, and their responsive genes in the liver of apoE and LDLR double deficient mice.
  833. Combination Therapy with PPARα and Pparγ Agonists in Type 2 Diabetes Blunts the Reduction in Intra-Organ Triglyceride Content Seen with Pparγ Monotherapy.
  834. The Korean traditional medicine Gyeongshingangjeehwan inhibits obesity through the regulation of leptin and PPARα action in OLETF rats.
  835. Arachidonic acid modulation of Ca2+-regulated exocytosis via PPARα/cGMP in gastric antral mucous cells of guinea pig
  836. Peroxisome Proliferator-Activated Receptor β/δ (PPARβ/δ) but Not PPARα Serves as a Plasma Free Fatty Acid Sensor in Liver
  837. Fractionation and identification of 9c, 11t, 13t-conjugated linolenic acid as an activator of PPARα in bitter gourd (Momordica charantia L.).
  838. Coordinate regulation of the expression of the fatty acid transporter protein (FATP) and acyl CoA synthetase (ACS) genes by PPARα and PPARγ activators
  839. The Korean traditional medicine Gyeongshingangjeehwan inhibits adipocyte hypertrophy and visceral adipose tissue accumulation by activating PPARα actions in rat …
  840. Altered mRNA expression of hepatic lipogenic enzyme and PPARα in rats fed dietary levan from Zymomonas mobilis.
  841. ACh‐stimulated exocytosis enhanced by arachidonic acid in guinea pig antral mucous cells: cGMP accumulation via PPARα
  842. Prevention of diet-induced obesity by safflower oil: insights at the levels of PPARα, Orexin, and Ghrelin gene expression of adipocytes in mice.
  843. Toxicogenomics/proteomics report: Proteomics analysis of cardiac muscle from rats with peroxisomal proliferator-activated receptorα (PPARα) stimulation
  844. Omega-3 fatty acids regulate gene expression levels differently in subjects carrying the PPARα L162V polymorphism
  845. The effects of Jiangzhiyigan Granules on the expression of Trx (thiordcoxin) and PPARα (peroxisome proliferator-activated receptor α) in liver tissues of rats with non …
  846. Omega‐3 fatty acids regulate gene expression levels differently in macrophages of men carrying the PPARα‐L162V polymorphism
  847. Reduced fat mass in rats fed a high oleic acid-rich safflower oil diet is associated with changes in expression of hepatic PPARα and adipose SREBP-1c-regulated …
  848. Effects of 12 weeks of exercise on hepatic TNF-α and PPARα in an animal model of high-fat diet-induced nonalcoholic steatohepatitis.
  849. P-442 DISCOVERY OF NOVEL PPARα LIGANDS BY THE MINOR STRUCTURAL MODIFICATIONS OF A PPARγ LIGAND
  850. Oxidized frying oil up-regulates hepatic acyl-CoA oxidase and cytochrome P450 4 A1 genes in rats and activates PPARα.
  851. PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-α (PPARα) REGULATES ISCHEMIC LIVER INJURY: 209
  852. Integrated physiology and systems biology of PPARα
  853. The potential of natural products for targeting PPARα
  854. Regulation of ketone body metabolism and the role of PPARα
  855. Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD
  856. Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease
  857. Identification and characterization of PPARα ligands in the hippocampus
  858. PPARα is regulated by miR-21 and miR-27b in human liver
  859. Therapeutic effects of PPARα agonists on diabetic retinopathy in type 1 diabetes models
  860. Bilirubin binding to PPARα inhibits lipid accumulation
  861. PPARα gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis
  862. Variation in the PPARα gene in Polish rowers
  863. PPARα Expression Protects Male Mice from High Fat–Induced Nonalcoholic Fatty Liver1–3
  864. PPARα as a therapeutic target in inflammation-associated diseases
  865. Sirt1 acts in association with PPARα to protect the heart from hypertrophy, metabolic dysregulation, and inflammation
  866. A map of the PPARα transcription regulatory network for primary human hepatocytes
  867. The PPARα-dependent rodent liver tumor response is not relevant to humans: addressing misconceptions
  868. PPARα-independent transcriptional targets of perfluoroalkyl acids revealed by transcript profiling
  869. PPARα activation by culinary herbs and spices
  870. Protective and antioxidant effects of PPARα in the ischemic retina
  871. PPARα activation protects against cholestatic liver injury
  872. Insights into the role of hepatocyte PPARα activity in response to fasting
  873. PPARα-Sirt1 complex mediates cardiac hypertrophy and failure through suppression of the ERR transcriptional pathway
  874. Interaction of PPARα with the canonic Wnt pathway in the regulation of renal fibrosis
  875. Human NPC1L1 expression is positively regulated by PPARα
  876. Impairment of PPARα and the fatty acid oxidation pathway aggravates renal fibrosis during aging
  877. MicroRNA‑518d regulates PPARα protein expression in the placentas of females with gestational diabetes mellitus
  878. PPARα Activation Can Help Prevent and Treat Non–Small Cell Lung Cancer
  879. Nutrient-sensing nuclear receptors PPARα and FXR control liver energy balance
  880. Effect of miR-34a in regulating steatosis by targeting PPARα expression in nonalcoholic fatty liver disease
  881. Mechanisms and metabolic regulation of PPARα activation in Nile tilapia (Oreochromis niloticus)
  882. HMG-CoA reductase inhibitors bind to PPARα to upregulate neurotrophin expression in the brain and improve memory in mice
  883. CREB3L3 controls fatty acid oxidation and ketogenesis in synergy with PPARα
  884. Human SREBP1c expression in liver is directly regulated by peroxisome proliferator-activated receptor α (PPARα)
  885. PPARα induces cell apoptosis by destructing Bcl2
  886. An ideal PPAR response element bound to and activated by PPARα
  887. The PPARα-FGF21 hormone axis contributes to metabolic regulation by the hepatic JNK signaling pathway
  888. Saroglitazar, a novel PPARα/γ agonist with predominant PPARα activity, shows lipid‐lowering and insulin‐sensitizing effects in preclinical models
  889. Activation of mouse and human peroxisome proliferator-activated receptor-alpha (PPARα) by perfluoroalkyl acids (PFAAs): Further investigation of C4–C12 …
  890. Neuroprotective properties of peroxisome proliferator-activated receptor alpha (PPARα) and its lipid ligands
  891. The impact of PPARα activation on whole genome gene expression in human precision cut liver slices
  892. PPARα regulates tumor progression, foe or friend?
  893. Fenofibrate, a PPARα agonist, has renoprotective effects in mice by enhancing renal lipolysis
  894. Fenofibrate suppresses growth of the human hepatocellular carcinoma cell via PPARα-independent mechanisms
  895. Homeostatic PPARα signaling limits inflammatory responses to commensal microbiota in the intestine
  896. Aspirin binds to PPARα to stimulate hippocampal plasticity and protect memory
  897. Oleoylethanolamine and palmitoylethanolamine modulate intestinal permeability in vitro via TRPV1 and PPARα
  898. PPARα modulates gene expression profiles of mitochondrial energy metabolism in oral tumorigenesis
  899. Implications of a peroxisome proliferator-activated receptor alpha (PPARα) ligand clofibrate in breast cancer
  900. A specific ChREBP and PPARα cross-talk is required for the glucose-mediated FGF21 response
  901. PPARα signaling in the hippocampus: crosstalk between fat and memory
  902. PPARα is essential for retinal lipid metabolism and neuronal survival
  903. Palmitoleic acid improves metabolic functions in fatty liver by PPARα‐dependent AMPK activation
  904. Effects of the new dual PPARα/δ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose …
  905. Hepatic IRE1α regulates fasting-induced metabolic adaptive programs through the XBP1s–PPARα axis signalling
  906. Molecular association model of PPARα and its new specific and efficient ligand, pemafibrate: structural basis for SPPARMα
  907. Peroxisome proliferator-activated receptor α (PPARα) induces PPARγ coactivator 1α (PGC-1α) gene expression and contributes to thermogenic activation of …
  908. Steatogenesis in adult-onset type II citrullinemia is associated with down-regulation of PPARα
  909. On the pivotal role of PPARα in adaptation of the heart to hypoxia and why fat in the diet increases hypoxic injury
  910. Fatty acid chain length and saturation influences PPARα transcriptional activation and repression in HepG2 cells
  911. CD147 reprograms fatty acid metabolism in hepatocellular carcinoma cells through Akt/mTOR/SREBP1c and P38/PPARα pathways
  912. Sustained activation of PPARα by endogenous ligands increases hepatic fatty acid oxidation and prevents obesity in ob/ob mice
  913. Functional and biochemical interaction between PPARα receptors and TRPV1 channels: Potential role in PPARα agonists-mediated analgesia
  914. PPARα inhibition modulates multiple reprogrammed metabolic pathways in kidney cancer and attenuates tumor growth
  915. Negatively regulating TLR4/NF-κB signaling via PPARα in endotoxin-induced uveitis
  916. Periostin promotes liver steatosis and hypertriglyceridemia through downregulation of PPARα
  917. Kaempferol regulates the lipid-profile in high-fat diet-fed rats through an increase in hepatic PPARα levels
  918. PPARα activation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats
  919. Cloning, identification and accurate normalization expression analysis of PPARα gene by GeNorm in Megalobrama amblycephala
  920. PPARα and fatty acid oxidation mediate glucocorticoid resistance in chronic lymphocytic leukemia
  921. Hippocampal PPARα is a novel therapeutic target for depression and mediates the antidepressant actions of fluoxetine in mice
  922. PPARα-UGT axis activation represses intestinal FXR-FGF15 feedback signalling and exacerbates experimental colitis
  923. AMPK activation enhances PPARα activity to inhibit cardiac hypertrophy via ERK1/2 MAPK signaling pathway
  924. PIK3R3 regulates PPARα expression to stimulate fatty acid β-oxidation and decrease hepatosteatosis
  925. Adipose triglyceride lipase is a TG hydrolase of the small intestine and regulates intestinal PPARα signaling
  926. PPARα-deficient ob/ob obese mice become more obese and manifest severe hepatic steatosis due to decreased fatty acid oxidation
  927. In vitro and in vivo pharmacology of NXT629, a novel and selective PPARα antagonist
  928. Activation of PPARα by clofibrate sensitizes pancreatic cancer cells to radiation through the Wnt/β-catenin pathway
  929. Activation of PPARα ameliorates hepatic insulin resistance and steatosis in high fructose–fed mice despite increased endoplasmic reticulum stress
  930. Coenzyme Q10 increases the fatty acid oxidation through AMPK-mediated PPARα induction in 3T3-L1 preadipocytes
  931. Coordinated regulation of hepatic phase I and II drug-metabolizing genes and transporters using AhR-, CAR-, PXR-, PPARα-, and Nrf2-null mice
  932. Adiponectin inhibits insulin function in primary trophoblasts by PPARα-mediated ceramide synthesis
  933. Mice with hyperbilirubinemia due to Gilbert’s syndrome polymorphism are resistant to hepatic steatosis by decreased serine 73 phosphorylation of PPARα
  934. Effects of PPARα inhibition in head and neck paraganglioma cells
  935. PPARα/γ agonists and antagonists differently affect hepatic lipid metabolism, oxidative stress and inflammatory cytokine production in steatohepatitic rats
  936. Interspecies NASH disease activity whole-genome profiling identifies a fibrogenic role of PPARα-regulated dermatopontin
  937. Identification of modulators of the nuclear receptor peroxisome proliferator-activated receptor α (PPARα) in a mouse liver gene expression compendium
  938. Metabolic reprogramming via PPARα signaling in cardiac hypertrophy and failure: from metabolomics to epigenetics
  939. Hepatic mitochondrial and ER stress induced by defective PPARα signaling in the pathogenesis of hepatic steatosis
  940. KLF15 and PPARα Cooperate to Regulate Cardiomyocyte Lipid Gene Expression and Oxidation
  941. The novel selective PPARα modulator (SPPARMα) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and …
  942. PPARα modulation of mesolimbic dopamine transmission rescues depression-related behaviors
  943. Betaine prevented fructose-induced NAFLD by regulating LXRα/PPARα pathway and alleviating ER stress in rats
  944. The urinary metabolites of DINCH® have an impact on the activities of the human nuclear receptors ERα, ERβ, AR, PPARα and PPARγ
  945. Proximal tubule PPARα attenuates renal fibrosis and inflammation caused by unilateral ureteral obstruction
  946. Comparative gene expression profiles induced by PPARγ and PPARα/γ agonists in human hepatocytes
  947. Direct transcriptional regulation of human hepatic cytochrome P450 3A4 (CYP3A4) by peroxisome proliferator–activated receptor alpha (PPARα)
  948. Does bilirubin prevent hepatic steatosis through activation of the PPARα nuclear receptor?
  949. Aspirin induces lysosomal biogenesis and attenuates amyloid plaque pathology in a mouse model of Alzheimer’s disease via PPARα
  950. Ligand‐dependent nucleo‐cytoplasmic shuttling of peroxisome proliferator‐activated receptors, PPARα and PPARγ
  951. Perfluorooctanoic acid (PFOA)–induced liver lesions in two strains of mice following developmental exposures: PPARα is not required
  952. Aberrant miR199a-5p/caveolin1/PPARα axis in hepatic steatosis
  953. High fructose consumption induces DNA methylation at PPARα and CPT1A promoter regions in the rat liver
  954. Activation and desensitization of TRPV1 channels in sensory neurons by the PPARα agonist palmitoylethanolamide
  955. Constituents from Terminalia species increase PPARα and PPARγ levels and stimulate glucose uptake without enhancing adipocyte differentiation
  956. PPARα agonist fenofibrate enhances fatty acid β-oxidation and attenuates polycystic kidney and liver disease in mice
  957. Clofibrate PPARα activation reduces oxidative stress and improves ultrastructure and ventricular hemodynamics in no-flow myocardial ischemia
  958. PPARα and Sirt1 mediate erythropoietin action in increasing metabolic activity and browning of white adipocytes to protect against obesity and metabolic disorders
  959. Treatment in vitro with PPARα and PPARγ ligands drives M1-to-M2 polarization of macrophages from T. cruzi-infected mice
  960. The ubiquitin ligase MuRF1 regulates PPARα activity in the heart by enhancing nuclear export via monoubiquitination
  961. Wogonin ameliorates hyperglycemia and dyslipidemia via PPARα activation in db/db mice
  962. PPARα regulates tumor cell proliferation and senescence via a novel target gene carnitine palmitoyltransferase 1C
  963. Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: a randomized, double blind, active-and placebo-controlled, phase …
  964. Inhibition of PPARα induces cell cycle arrest and apoptosis, and synergizes with glycolysis inhibition in kidney cancer cells
  965. Extrahepatic PPARα modulates fatty acid oxidation and attenuates fasting-induced hepatosteatosis in mice
  966. The hepatic BMAL1/AKT/lipogenesis axis protects against alcoholic liver disease in mice via promoting PPARα pathway
  967. Chromatin recruitment of activated AMPK drives fasting response genes co-controlled by GR and PPARα
  968. Therapeutic Effects of PPARα on Neuronal Death and Microvascular Impairment
  969. Nuciferine ameliorates hepatic steatosis in high‐fat diet/streptozocin‐induced diabetic mice through a PPARα/PPARγ coactivator‐1α pathway
  970. Icariin attenuates cerebral ischemia–reperfusion injury through inhibition of inflammatory response mediated by NF-κB, PPARα and PPARγ in rats
  971. Identification of picrasidine C as a subtype-selective PPARα agonist
  972. Astragaloside IV alleviates heart failure via activating PPARα to switch glycolysis to fatty acid β-oxidation
  973. Genomewide comparison of the inducible transcriptomes of nuclear receptors CAR, PXR and PPARα in primary human hepatocytes
  974. Overfeeding dairy cattle during late-pregnancy alters hepatic PPARα-regulated pathways including hepatokines: Impact on metabolism and peripheral insulin …
  975. PARP1-mediated PPARα poly (ADP-ribosyl) ation suppresses fatty acid oxidation in non-alcoholic fatty liver disease
  976. … –Dawley rats from dietary exposure to potassium perfluorooctanesulfonate results from increased expression of xenosensor nuclear receptors PPARα and CAR/PXR
  977. Sleep deprivation induces dry eye through inhibition of PPARα expression in corneal epithelium
  978. The protective effect of the Cornus mas fruits (cornelian cherry) on hypertriglyceridemia and atherosclerosis through PPARα activation in hypercholesterolemic rabbits
  979. A role for PPARα in the regulation of arginine metabolism and nitric oxide synthesis
  980. Evaluation of PPARα activation by known blueberry constituents
  981. PPARα regulates cholinergic-driven activity of midbrain dopamine neurons via a novel mechanism involving α7 nicotinic acetylcholine receptors
  982. Hugan Qingzhi medication ameliorates hepatic steatosis by activating AMPK and PPARα pathways in L02 cells and HepG2 cells
  983. Adiponectin reduces ER stress-induced apoptosis through PPARα transcriptional regulation of ATF2 in mouse adipose
  984. Activation of peroxisome proliferator-activated receptor α (PPARα) suppresses hypoxia-inducible factor-1α (HIF-1α) signaling in cancer cells
  985. Fibrate-derived N-(methylsulfonyl) amides with antagonistic properties on PPARα
  986. Farnesol, an isoprenoid, improves metabolic abnormalities in mice via both PPARα-dependent and-independent pathways
  987. Impairments of hepatic gluconeogenesis and ketogenesis in PPARα-deficient neonatal mice
  988. PPARα augments heart function and cardiac fatty acid oxidation in early experimental polymicrobial sepsis
  989. The human liver fatty acid binding protein (FABP1) gene is activated by FOXA1 and PPARα; and repressed by C/EBPα: Implications in FABP1 down-regulation in …
  990. The beneficial effects of AMP kinase activation against oxidative stress are associated with prevention of PPARα-cyclophilin D interaction in cardiomyocytes
  991. The olive constituent oleuropein, as a PPARα agonist, markedly reduces serum triglycerides
  992. Peroxisome proliferator-activated receptor (PPAR) β/δ, a possible nexus of PPARα-and PPARγ-dependent molecular pathways in neurodegenerative diseases …
  993. Impact of L-FABP and glucose on polyunsaturated fatty acid induction of PPARα-regulated β-oxidative enzymes
  994. Fatty acid-specific alterations in leptin, PPARα, and CPT-1 gene expression in the rainbow trout
  995. The role of PPARα in metformin-induced attenuation of mitochondrial dysfunction in acute cardiac ischemia/reperfusion in rats
  996. Effects of pemafibrate, a novel selective PPARα modulator, on lipid and glucose metabolism in patients with type 2 diabetes and hypertriglyceridemia: a randomized …
  997. Potent PPARα activator derived from tomato juice, 13-oxo-9, 11-octadecadienoic acid, decreases plasma and hepatic triglyceride in obese diabetic mice
  998. Peroxisome proliferator-activated receptor (PPAR) γ and PPARα agonists modulate mitochondrial fusion-fission dynamics: relevance to reactive oxygen …
  999. PPARα-dependent Insig2a overexpression inhibits SREBP-1c processing during fasting
  1000. … extract of diabetes-and oleic acid-induced non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) via modulation of PPARα and SREBP-1
  1001. Cardiac dysfunction in adipose triglyceride lipase deficiency: treatment with a PPARα agonist
  1002. Stimulation of PPARα normalizes the skin lipid ratio and improves the skin barrier of normal and filaggrin deficient reconstructed skin
  1003. Dose and effect thresholds for early key events in a PPARα-mediated mode of action
  1004. Effects of PPARα/PGC-1α on the energy metabolism remodeling and apoptosis in the doxorubicin induced mice cardiomyocytes in vitro
  1005. Glucocorticoid receptor-PPARα axis in fetal mouse liver prepares neonates for milk lipid catabolism
  1006. Decrease of blood lipids induced by Shan-Zha (fruit of Crataegus pinnatifida) is mainly related to an increase of PPARα in liver of mice fed high-fat diet
  1007. Icariin is a PPARα activator inducing lipid metabolic gene expression in mice
  1008. The peroxisome proliferator-activated receptor α (PPARα) agonist pemafibrate protects against diet-induced obesity in mice
  1009. FGF21 is not a major mediator for bone homeostasis or metabolic actions of PPARα and PPARγ agonists
  1010. New PPARα/γ/δ optimal activator rationally designed by computational methods
  1011. Protective effects of adiponectin against renal ischemia‐reperfusion injury via prostacyclin‐PPARα‐heme oxygenase‐1 signaling pathway
  1012. Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARα agonist with moderate PPARγ agonist activity in healthy human …
  1013. PPARα agonist, fenofibrate, ameliorates age-related renal injury
  1014. Inhibition of JNK signalling mediates PPARα‐dependent protection against intrahepatic cholestasis by fenofibrate
  1015. PPARα agonist stimulated angiogenesis by improving endothelial precursor cell function via a NLRP3 inflammasome pathway
  1016. Hepatic PPARα function is controlled by polyubiquitination and proteasome‐mediated degradation through the coordinated actions of PAQR3 and HUWE1
  1017. Ligand-activated PPARα-dependent DNA demethylation regulates the fatty acid β-oxidation genes in the postnatal liver
  1018. Therapeutic effects of PPARα agonist on ocular neovascularization in models recapitulating neovascular age-related macular degeneration
  1019. Bixin activates PPARα and improves obesity-induced abnormalities of carbohydrate and lipid metabolism in mice
  1020. The dietary isoflavone daidzein reduces expression of pro-inflammatory genes through PPARα/γ and JNK pathways in adipocyte and macrophage co-cultures
  1021. Hepatic hypoxia-inducible factors inhibit PPARα expression to exacerbate acetaminophen induced oxidative stress and hepatotoxicity
  1022. Apigenin protects against alcohol-induced liver injury in mice by regulating hepatic CYP2E1-mediated oxidative stress and PPARα-mediated lipogenic gene …
  1023. Liraglutide protects cardiac function in diabetic rats through the PPARα pathway
  1024. PPARα-dependent exacerbation of experimental colitis by the hypolipidemic drug fenofibrate
  1025. Nutrient-dependent phosphorylation channels lipid synthesis to regulate PPARα
  1026. Comparative molecular profiling of the PPARα/γ activator aleglitazar: PPAR selectivity, activity and interaction with cofactors
  1027. Suppression of ERR targets by a PPARα/Sirt1 complex in the failing heart
  1028. Differential effects on lung cancer cell proliferation by agonists of glucocorticoid and PPARα receptors
  1029. PPARα mediates the hepatoprotective effects of nutmeg
  1030. Localization of cannabinoid receptors CB1, CB2, GPR55, and PPARα in the canine gastrointestinal tract
  1031. Effect of cold stress on expression of AMPKα–PPARα pathway and inflammation genes
  1032. PPARα protects against trans-fatty-acid-containing diet-induced steatohepatitis
  1033. Benzothiazole-based N-(phenylsulfonyl) amides as a novel family of PPARα antagonists
  1034. Oleoylethanolamide dose‐dependently attenuates cocaine‐induced behaviours through a PPARα receptor‐independent mechanism
  1035. The whole transcriptome effects of the PPARα agonist fenofibrate on livers of hepatocyte humanized mice
  1036. … of aqueous extract of syzigium cumini for its antihyperglycemic and antidyslipidemic properties in diabetic rats fed a high cholesterol diet—Role of PPARγ and PPARα
  1037. Wogonin mitigates nonalcoholic fatty liver disease via enhancing PPARα/AdipoR2, in vivo and in vitro
  1038. LT175 is a novel PPARα/γ ligand with potent insulin-sensitizing effects and reduced adipogenic properties
  1039. High-fat diet-induced renal cell apoptosis and oxidative stress in spontaneously hypertensive rat are ameliorated by fenofibrate through the PPARα–FoxO3a–PGC-1α …
  1040. The PPARα agonist fenofibrate suppresses B-cell lymphoma in mice by modulating lipid metabolism
  1041. Anti-diabetic effect of amorphastilbol through PPARα/γ dual activation in db/db mice
  1042. Ophiopogonin D and EETs ameliorate Ang II-induced inflammatory responses via activating PPARα in HUVECs
  1043. Free fatty acids increase intracellular lipid accumulation and oxidative stress by modulating PPARα and SREBP-1c in L-02 cells
  1044. Sensitive bioassay for detection of PPARα potentially hazardous ligands with gold nanoparticle probe
  1045. HMGCS2 enhances invasion and metastasis via direct interaction with PPARα to activate Src signaling in colorectal cancer and oral cancer
  1046. Fenofibrate lowers lipid accumulation in myotubes by modulating the PPARα/AMPK/FoxO1/ATGL pathway
  1047. Auraptene regulates gene expression involved in lipid metabolism through PPARα activation in diabetic obese mice
  1048. A novel selective PPARα modulator (SPPARMα), K-877 (pemafibrate), attenuates postprandial hypertriglyceridemia in mice
  1049. Transcriptome analysis of K-877 (a novel selective PPARα modulator (SPPARMα))-regulated genes in primary human hepatocytes and the mouse liver
  1050. Ammonium perfluorooctanoate may cause testosterone reduction by adversely affecting testis in relation to PPARα
  1051. Modulation of ammonium perfluorooctanoate-induced hepatic damage by genetically different PPARα in mice
  1052. Total synthesis and dual PPARα/γ agonist effects of amorphastilbol and its synthetic derivatives
  1053. Proline-and acidic amino acid-rich basic leucine zipper proteins modulate peroxisome proliferator-activated receptor α (PPARα) activity
  1054. Sesamin ameliorates hepatic steatosis and inflammation in rats on a high-fat diet via LXRα and PPARα
  1055. Activating PPARα Prevents Post–Ischemic Contractile Dysfunction in Hypertrophied Neonatal Hearts
  1056. DHA attenuates postprandial hyperlipidemia via activating PPARα in intestinal epithelial cells [S]
  1057. PPARα in lysosomal biogenesis: a perspective
  1058. Upregulation of hepatic VLDLR via PPARα is required for the triglyceride-lowering effect of fenofibrate
  1059. Puerarin ameliorates hepatic steatosis by activating the PPARα and AMPK signaling pathways in hepatocytes
  1060. Role of PPARα and HNF4α in stress-mediated alterations in lipid homeostasis
  1061. PPARα Regulates the Proliferation of Human Glioma Cells through miR-214 and E2F2
  1062. A grape seed procyanidin extract inhibits HDAC activity leading to increased PPARα phosphorylation and target‐gene expression
  1063. Targeting vascular NADPH oxidase 1 blocks tumor angiogenesis through a PPARα mediated mechanism
  1064. Dietary grape seed proanthocyanidin extract regulates metabolic disturbance in rat liver exposed to lead associated with PPARα signaling pathway
  1065. … oleifera stem extract protect skin keratinocytes against oxidative stress injury by enhancement of antioxidant defense systems and activation of PPARα
  1066. Over-expression of PPARα in obese mice adipose tissue improves insulin sensitivity
  1067. Role of peroxisome proliferator-activated receptor alpha (PPARα) and PPARα-mediated species differences in triclosan-induced liver toxicity
  1068. PPARα agonist fenofibrate ameliorates learning and memory deficits in rats following global cerebral ischemia
  1069. In vivo and ex vivo regulation of breast cancer resistant protein (Bcrp) by peroxisome proliferator‐activated receptor alpha (PPARα) at the blood–brain barrier
  1070. Linalool is a PPARα ligand that reduces plasma TG levels and rewires the hepatic transcriptome and plasma metabolome [S]
  1071. PPARα promotes cancer cell Glut1 transcription repression
  1072. Arctigenin inhibits liver cancer tumorigenesis by inhibiting gankyrin expression via C/EBPα and PPARα
  1073. Peroxisome proliferator activated receptor-alpha (PPARα) and PPAR gamma coactivator-1alpha (PGC-1α) regulation of cardiac metabolism in diabetes
  1074. Hypoxia-mediated down-regulation of OCTN2 and PPARα expression in human placentas and in BeWo cells
  1075. PPARα-dependent cholesterol/testosterone disruption in Leydig cells mediates 2, 4-dichlorophenoxyacetic acid-induced testicular toxicity in mice
  1076. Therapeutic potential of panduratin A, LKB1‐dependent AMP‐activated protein kinase stimulator, with activation of PPARα/δ for the treatment of obesity
  1077. Proteome changes in the myocardium of experimental chronic diabetes and hypertension: role of PPARα in the associated hypertrophy
  1078. The Hepatoprotection by Oleanolic Acid Preconditioning: Focusing on PPARα Activation
  1079. Idebenone and coenzyme Q10 are novel PPARα/γ ligands, with potential for treatment of fatty liver diseases
  1080. CYP1A1 induction in the colon by serum: involvement of the PPARα pathway and evidence for a new specific human PPREα site
  1081. Hypoxia induces peroxisome proliferator‐activated receptor α (PPARα) and lipid metabolism peroxisomal enzymes in human glioblastoma cells
  1082. In search for novel strategies towards neuroprotection and neuroregeneration: is PPARα a promising therapeutic target?
  1083. PPARα gene variants as predicted performance-enhancing polymorphisms in professional Italian soccer players
  1084. GC-MS metabolomics on PPARα-dependent exacerbation of colitis
  1085. MiR-34a regulates mitochondrial content and fat ectopic deposition induced by resistin through the AMPK/PPARα pathway in HepG2 cells
  1086. PPARα: A Master Regulator of Bilirubin Homeostasis
  1087. Plasma mannose-binding lectin is stimulated by PPARα in humans
  1088. Lack of expression of the proteins GMPR2 and PPARα are associated with the basal phenotype and patient outcome in breast cancer
  1089. Regulation of Genes Involved in Carnitine Homeostasis by PPARα across Different Species (Rat, Mouse, Pig, Cattle, Chicken, and Human)
  1090. Eupatilin, an activator of PPARα, inhibits the development of oxazolone-induced atopic dermatitis symptoms in Balb/c mice
  1091. Gemfibrozil disrupts lysophosphatidylcholine and bile acid homeostasis via PPARα and its relevance to hepatotoxicity
  1092. Protectin DX ameliorates palmitate-or high-fat diet-induced insulin resistance and inflammation through an AMPK-PPARα-dependent pathway in mice
  1093. Hepatic cerebroside sulfotransferase is induced by PPARα activation in mice
  1094. A novel structural class of coumarin-chalcone fibrates as PPARα/γ agonists with potent antioxidant activities: Design, synthesis, biological evaluation and molecular …
  1095. New role of hispidulin in lipid metabolism: PPARα activator
  1096. Association and Interaction of PPARα, δ, and γ Gene Polymorphisms with Low-Density Lipoprotein-Cholesterol in a Chinese Han Population
  1097. Fenofibrate, a PPARα agonist, decreases atrogenes and myostatin expression and improves arthritis-induced skeletal muscle atrophy
  1098. PPARα activation inhibits endothelin-1-induced cardiomyocyte hypertrophy by prevention of NFATc4 binding to GATA-4
  1099. PPARα agonist fenofibrate attenuates TNF-α-induced CD40 expression in 3T3-L1 adipocytes via the SIRT1-dependent signaling pathway
  1100. Association between APOE, SCARB1, PPARα polymorphisms and serum lipids in a population of Lithuanian adults
  1101. PPARα antagonist AA452 triggers metabolic reprogramming and increases sensitivity to radiation therapy in human glioblastoma primary cells
  1102. Hepatic-specific PPARα-FGF21 action in NAFLD
  1103. PPARα–LXR as a novel metabolostatic signalling axis in skeletal muscle that acts to optimize substrate selection in response to nutrient status
  1104. … PPARβ/δ activator GW501516 prevents the down-regulation of AMPK caused by a high-fat diet in liver and amplifies the PGC-1α-Lipin 1-PPARα pathway leading to …
  1105. Activation of peroxisome proliferator-activated receptor-α (PPARα) suppresses postprandial lipidemia through fatty acid oxidation in enterocytes
  1106. PPARα-independent actions of omega-3 PUFAs contribute to their beneficial effects on adiposity and glucose homeostasis
  1107. PPARα regulates mobilization and homing of endothelial progenitor cells through the HIF-1α/SDF-1 pathway
  1108. The truncated splice variant of peroxisome proliferator-activated receptor alpha, PPARα-tr, autonomously regulates proliferative and pro-inflammatory genes
  1109. Effects of the lipid regulating drug clofibric acid on PPARα-regulated gene transcript levels in common carp (Cyprinus carpio) at pharmacological and …
  1110. Alcoholic fatty liver is enhanced in CYP2A5 knockout mice: The role of the PPARα-FGF21 axis
  1111. Bile acid-regulated peroxisome proliferator-activated receptor-α (PPARα) activity underlies circadian expression of intestinal peptide absorption transporter …
  1112. PPARα agonists inhibit inflammatory activation of macrophages through upregulation of β-defensin 1
  1113. AVE8134, a novel potent PPARα agonist, improves lipid profile and glucose metabolism in dyslipidemic mice and type 2 diabetic rats
  1114. Resveratrol enhances HBV replication through activating Sirt1-PGC-1α-PPARα pathway
  1115. MicroRNA-33a promotes cell proliferation and inhibits apoptosis by targeting PPARα in human hepatocellular carcinoma
  1116. PPARα is necessary for radiation-induced activation of noncanonical TGFβ signaling in the heart
  1117. PPARα activation alleviates damage to the cytoskeleton during acute myocardial ischemia/reperfusion in rats
  1118. Identification of Eupatilin from Artemisia argyi as a Selective PPARα Agonist Using Affinity Selection Ultrafiltration LC-MS
  1119. Feedback looping between ChREBP and PPARα in the regulation of lipid metabolism in brown adipose tissues
  1120. Identification of novel multitargeted PPARα/γ/δ pan agonists by core hopping of rosiglitazone
  1121. Sesamol alleviates diet-induced cardiometabolic syndrome in rats via up-regulating PPARγ, PPARα and e-NOS
  1122. Periodic variation in bile acids controls circadian changes in uric acid via regulation of xanthine oxidase by the orphan nuclear receptor PPARα
  1123. Activation of the nuclear receptor PPARα regulates lipid metabolism in foetal liver from diabetic rats: implications in diabetes‐induced foetal overgrowth
  1124. p21Cip1 plays a critical role in the physiological adaptation to fasting through activation of PPARα
  1125. Adiponectin regulates AQP3 via PPARα in human hepatic stellate cells
  1126. Liver microRNA-21 is overexpressed in non-alcoholic steatohepatitis and contributes to the disease in experimental models by inhibiting PPARα expression
  1127. High glucose potentiates L-FABP mediated fibrate induction of PPARα in mouse hepatocytes
  1128. Hepatic AQP9 expression in male rats is reduced in response to PPARα agonist treatment
  1129. Targeted metabolomics reveals a protective role for basal PPARα in cholestasis induced by α-naphthylisothiocyanate
  1130. … regulates lipid metabolism and improves hepatic steatosis partly by AMPK activation and up-regulation of expression of PPARα/LPL and LDLR
  1131. PPARα agonist suppresses inflammation after corneal alkali burn by suppressing proinflammatory cytokines, MCP-1, and nuclear translocation of NF-κB
  1132. PPARα mediates the anti‐inflammatory effect of simvastatin in an experimental model of zymosan‐induced multiple organ failure
  1133. Coordination among lipid droplets, peroxisomes, and mitochondria regulates energy expenditure through the CIDE-ATGL-PPARα pathway in adipocytes
  1134. Effects of PPARα/PGC-1α on the myocardial energy metabolism during heart failure in the doxorubicin induced dilated cardiomyopathy in mice
  1135. Scutellarin from Scutellaria baicalensis Suppresses Adipogenesis by Upregulating PPARα in 3T3-L1 Cells
  1136. Pyrazinamide induced hepatic injury in rats through inhibiting the PPARα pathway
  1137. Regulation of miR-200c by nuclear receptors PPARα, LRH-1 and SHP
  1138. Targeting Nuclear Hormone Receptors: PPARα Agonists as Potential Disease-Modifying Drugs for Rheumatoid Arthritis
  1139. … is independent from the presence of PPARα in the intestine and the nodose ganglion, while the impact of OEA on energy expenditure requires the presence of PPARα …
  1140. Identification of the first PPARα/γ dual agonist able to bind to canonical and alternative sites of PPARγ and to inhibit its cdk5-mediated phosphorylation
  1141. Bilobetin ameliorates insulin resistance by PKA‐mediated phosphorylation of PPARα in rats fed a high‐fat diet
  1142. Hydrogen-rich saline improves non‑alcoholic fatty liver disease by alleviating oxidative stress and activating hepatic PPARα and PPARγ
  1143. Renoprotective effect of a novel selective PPARα modulator K-877 in db/db mice: a role of diacylglycerol-protein kinase C-NAD (P) H oxidase pathway
  1144. PPARα activation differently affects microparticle content in atherosclerotic lesions and liver of a mouse model of atherosclerosis and NASH
  1145. Phosphatidic acid (PA) can displace PPARα/LXRα binding to the EGFR promoter causing its transrepression in luminal cancer cells
  1146. … cerebral hypoperfusion by inhibiting the amyloidogenic pathway: Involvement of BDNF/TrkB/CREB signaling and up-regulation of PPARα and PPARγ in rats
  1147. Effects of K-877, a novel selective PPARα modulator, on small intestine contribute to the amelioration of hyperlipidemia in low-density lipoprotein receptor …
  1148. Eupatilin with PPARα agonistic effects inhibits TNFα-induced MMP signaling in HaCaT cells
  1149. PPARα/HNF4α interplay on diversified responsive elements. Relevance in the regulation of liver peroxisomal fatty acid catabolism
  1150. Energy metabolism in glioblastoma stem cells: PPARα a metabolic adaptor to intratumoral microenvironment
  1151. Effects of MHY908, a new synthetic PPARα/γ dual agonist, on inflammatory responses and insulin resistance in aged rats
  1152. … hepatocyte proliferation associated with constitutive active/androstane receptor (CAR) or peroxisome proliferator-activated receptor α (PPARα) is enhanced by …
  1153. Inhibitors of Fatty Acid Synthesis Induce PPARα-Regulated Fatty Acid β-Oxidative Genes: Synergistic Roles of L-FABP and Glucose
  1154. Selected Extracts of Chinese Herbal Medicines: Their Effect on NF-κB, PPARα and PPARγ and the Respective Bioactive Compounds
  1155. Oleoylethanolamide exerts anti-inflammatory effects on LPS-induced THP-1 cells by enhancing PPARα signaling and inhibiting the NF-κB and ERK1/2/AP-1 …
  1156. Effect of DanQi Pill on PPARα, lipid disorders and arachidonic acid pathway in rat model of coronary heart disease
  1157. … Indian fermented soybean food prevents hepatic steatosis via regulating AMPK-mediated SREBP/FAS/ACC/HMGCR and PPARα/CPT1A/UCP2 pathways
  1158. Transcriptional regulation of the human, porcine and bovine OCTN2 gene by PPARα via a conserved PPRE located in intron 1
  1159. Improvement of cardiometabolic markers after fish oil intervention in young Mexican adults and the role of PPARα L162V and PPARγ2 P12A
  1160. Analysis on the association between PPARα/γ polymorphisms and lipoprotein (a) in a Chinese Han population
  1161. PPARα Is Required for PPARδ Action in Regulation of Body Weight and Hepatic Steatosis in Mice
  1162. 5, 7‐Dimethoxyflavone, an activator of PPARα/γ, inhibits UVB‐induced MMP expression in human skin fibroblast cells
  1163. PPARα, a predictor of patient survival in glioma, inhibits cell growth through the E2F1/miR-19a feedback loop
  1164. Dietary umbelliferone attenuates alcohol-induced fatty liver via regulation of PPARα and SREBP-1c in rats
  1165. Adipose triglyceride lipase decrement affects skeletal muscle homeostasis during aging through FAs-PPARα-PGC-1α antioxidant response
  1166. PPARα-independent arterial smooth muscle relaxant effects of PPARα agonists
  1167. The transcription factor PPARα is overexpressed and is associated with a favourable prognosis in IDH‐wildtype primary glioblastoma
  1168. Effect of Berberine on PPARα/NO Activation in High Glucose- and Insulin-Induced Cardiomyocyte Hypertrophy
  1169. PPARα and PPARγ protect against HIV-1-induced MMP-9 overexpression via caveolae-associated ERK and Akt signaling
  1170. Two butenolides with PPARα agonistic activity from a marine-derived Streptomyces
  1171. Resveratrol protects RPE cells from sodium iodate by modulating PPARα and PPARδ
  1172. Environmental enrichment, age, and PPARα interact to regulate proliferation in neurogenic niches
  1173. Protective effects of Brassica oleracea sprouts extract toward renal damage in high-salt-fed SHRSP: role of AMPK/PPARα/UCP2 axis
  1174. MiR‐19a affects hepatocyte autophagy via regulating lncRNA NBR2 and AMPK/PPARα in D‐GalN/Lipopolysaccharide‐Stimulated hepatocytes
  1175. L-carnitine protects against carboplatin-mediated renal injury: AMPK-and PPARα-dependent inactivation of NFAT3
  1176. Comparative gene expression profiles induced by PPARγ and PPARα/γ agonists in rat hepatocytes
  1177. Transcriptional coordination of hepatic autophagy by nutrient-sensing nuclear receptor PPARα and FXR
  1178. HMGB1 Is Involved in the Protective Effect of the PPARα Agonist Fenofibrate against Cardiac Hypertrophy
  1179. Wild bitter gourd extract up-regulates mRNA expression of PPARα, PPARγ and their target genes in C57BL/6J mice
  1180. Antioxidant Stress and Anti-Inflammation of PPARα on Warm Hepatic Ischemia-Reperfusion Injury
  1181. PPARα agonist prevented the apoptosis induced by glucose and fatty acid in neonatal cardiomyocytes
  1182. Osthole improves glucose and lipid metabolism via modulation of PPARα/γ-mediated target gene expression in liver, adipose tissue, and skeletal muscle in fatty liver …
  1183. Fenofibrate, a PPARα agonist, protect proximal tubular cells from albumin-bound fatty acids induced apoptosis via the activation of NF-kB
  1184. Discovery of gemfibrozil analogues that activate PPARα and enhance the expression of gene CPT1A involved in fatty acids catabolism
  1185. PPARα deficiency inhibits the proliferation of neuronal and glial precursors in the zebrafish central nervous system
  1186. Apelin protects against liver X receptor-mediated steatosis through AMPK and PPARα in human and mouse hepatocytes
  1187. Identification of dual PPARα/γ agonists and their effects on lipid metabolism
  1188. PPARα and PPARγ regulate the nucleoside transporter hENT1
  1189. Identification and characterization of a novel PPARα-regulated and 7α-hydroxyl bile acid-preferring cytosolic sulfotransferase mL-STL (Sult2a8)[S]
  1190. PPARα (peroxisome proliferator-activated receptor α) activation reduces hepatic CEACAM1 protein expression to regulate fatty acid oxidation during fasting …
  1191. Palmitoleic acid (n-7) increases white adipocyte lipolysis and lipase content in a PPARα-dependent manner
  1192. Pathogenic Role of microRNA-21 in Diabetic Retinopathy Through Downregulation of PPARα
  1193. Timed high-fat diet in the evening affects the hepatic circadian clock and PPARα-mediated lipogenic gene expressions in mice
  1194. Improved insulin sensitivity after treatment with PPARγ and PPARα ligands is mediated by genetically modulated transcripts
  1195. Astragalus polysaccharides affect insulin resistance by regulating the hepatic SIRT1-PGC-1α/PPARα-FGF21 signaling pathway in male Sprague Dawley rats …
  1196. Effect of berberine on PPARα-NO signalling pathway in vascular smooth muscle cell proliferation induced by angiotensin IV
  1197. Upregulation of rat liver PPARα‐FGF21 signaling by a docosahexaenoic acid and thyroid hormone combined protocol
  1198. Effect of phase delay lighting rotation schedule on daily expression of per2, bmal1, rev-erbα, PPARα, and pdk4 genes in the heart and liver of Wistar rats
  1199. Wogonin suppresses osteopontin expression in adipocytes by activating PPARα
  1200. Transcriptomic signatures of peroxisome proliferator-activated receptor α (PPARα) in different mouse liver models identify novel aspects of its biology
  1201. Activation of PPARα by Wy-14643 ameliorates systemic lipopolysaccharide-induced acute lung injury
  1202. Fenofibrate induces G0/G1 phase arrest by modulating the PPARα/FoxO1/p27kip pathway in human glioblastoma cells
  1203. Reduced expression of 11β-hydroxysteroid dehydrogenase type 2 in preeclamptic placentas is associated with decreased PPARγ but increased PPARα expression
  1204. PPARα polymorphisms as risk factors for dyslipidemia in a Brazilian population
  1205. Lack of PPARα exacerbates lipopolysaccharide-induced liver toxicity through STAT1 inflammatory signaling and increased oxidative/nitrosative stress
  1206. The PPARα agonists fenofibrate and CP-778875 cause increased β-oxidation, leading to oxidative injury in skeletal and cardiac muscle in the rat
  1207. Elaidyl-sulfamide, an oleoylethanolamide-modelled PPARα agonist, reduces body weight gain and plasma cholesterol in rats
  1208. Novel PPARα agonist MHY553 alleviates hepatic steatosis by increasing fatty acid oxidation and decreasing inflammation during aging
  1209. JAZF1 regulates visfatin expression in adipocytes via PPARα and PPARβ/δ signaling
  1210. MAPK–PPARα/γ signal transduction pathways are involved in Chlamydia pneumoniae-induced macrophage-derived foam cell formation
  1211. Opposing effects of PPARα agonism and antagonism on refractive development and form deprivation myopia in guinea pigs
  1212. Gene–gene interactions among PPARα/δ/γ polymorphisms for hypertriglyceridemia in Chinese Han population
  1213. A systems biology approach to the hepatic role of the oxysterol receptor LXR in the regulation of lipogenesis highlights a cross-talk with PPARα
  1214. PPARα agonists based on stilbene and its bioisosteres: Biological evaluation and docking studies
  1215. Is PPARα intron 7 G/C polymorphism associated with muscle strength characteristics in nonathletic young men?
  1216. Pretreatment by low-dose fibrates protects against acute free fatty acid-induced renal tubule toxicity by counteracting PPARα deterioration
  1217. PPARα protein expression was increased by four weeks of intermittent hypoxic training via AMPKα2-dependent manner in mouse skeletal muscle
  1218. Nordihydroguaiaretic acid improves metabolic dysregulation and aberrant hepatic lipid metabolism in mice by both PPARα-dependent and-independent pathways
  1219. Adiponectin ameliorates iron-overload cardiomyopathy through the PPARα–PGC-1–dependent signaling pathway
  1220. PPARα via HNF4α regulates the expression of genes encoding hepatic amino acid catabolizing enzymes to maintain metabolic homeostasis
  1221. Disruption of Stard10 gene alters the PPARα-mediated bile acid homeostasis
  1222. Peroxisome proliferator-activated receptor alpha, PPARα, directly regulates transcription of cytochrome P450 CYP2C8
  1223. HIV-1 viral protein R (Vpr) induces fatty liver in mice via LXRα and PPARα dysregulation: implications for HIV-specific pathogenesis of NAFLD
  1224. Hovenia Dulcis Extract Reduces Lipid Accumulation in Oleic Acid‐Induced Steatosis of Hep G2 Cells via Activation of AMPK and PPARα/CPT‐1 Pathway and in …
  1225. Pitavastatin increases ABCA1 expression by dual mechanisms: SREBP2-driven transcriptional activation and PPARα-dependent protein stabilization but without …
  1226. Cocoa protective effects against abnormal fat storage and oxidative stress induced by a high-fat diet involve PPARα signalling activation
  1227. PPARα enhances cancer cell chemotherapy sensitivity by autophagy induction
  1228. Perilipin 3 Deficiency Stimulates Thermogenic Beige Adipocytes Through PPARα Activation
  1229. Screening of medicinal plants for PPARα and PPARγ activation and evaluation of their effects on glucose uptake and 3T3-L1 adipogenesis
  1230. Synthesis and biological evaluations of marine oxohexadecenoic acids: PPARα/γ dual agonism and anti-diabetic target gene effects
  1231. … endogenous apolipoprotein AI expression and secretion by human monocytes and macrophages: role of MAP-kinases, NF-κB, and nuclear receptors PPARα and …
  1232. Scaffold-based pan-agonist design for the PPARα, PPARβ and PPARγ receptors
  1233. PPARα, PPARγ and SREBP-1 pathways mediated waterborne iron (Fe)-induced reduction in hepatic lipid deposition of javelin goby Synechogobius hasta
  1234. Down-regulation of PPARα in the spinal cord contributes to augmented peripheral inflammation and inflammatory hyperalgesia in diet-induced obese rats
  1235. Peroxisome proliferator-activated receptor α (PPARα) contributes to control of melanogenesis in B16 F10 melanoma cells
  1236. … present at high levels in bitter melon seed favorably affects lipid metabolism in hepatocytes by increasing NAD+/NADH ratio and activating PPARα, AMPK and SIRT1 …
  1237. Peroxisome proliferator-activated receptors (PPARα, PPARγ and PPARβ/δ) gene expression profile on ram spermatozoa and their relation to the sperm …
  1238. Peroxisome proliferator-activated receptor α (PPARα) activation advances locomotor activity and feeding daily rhythms in mice
  1239. The PPARα/γ Agonist, Tesaglitazar, Improves Insulin Mediated Switching of Tissue Glucose and Free Fatty Acid Utilization In Vivo in the Obese Zucker Rat
  1240. The induction of cytochrome P450 2E1 by ethanol leads to the loss of synaptic proteins via PPARα down-regulation
  1241. Differential modulation of AMPK/PPARα/UCP2 axis in relation to hypertension and aging in the brain, kidneys and heart of two closely related spontaneously …
  1242. Activation of PPARα by fatty acid accumulation enhances fatty acid degradation and sulfatide synthesis
  1243. Tumour necrosis factor alpha down-regulates the expression of peroxisome proliferator activated receptor alpha (PPARα) in human hepatocarcinoma HepG2 cells by …
  1244. Sargahydroquinoic acid inhibits TNFα-induced AP-1 and NF-κB signaling in HaCaT cells through PPARα activation
  1245. The relationship between KLF5 and PPARα in the heart: it’s complicated
  1246. Danshen protects against early-stage alcoholic liver disease in mice via inducing PPARα activation and subsequent 4-HNE degradation
  1247. PPARα is down-regulated following liver transplantation in mice
  1248. PPARα ligand clofibrate ameliorates blood pressure and vascular reactivity in spontaneously hypertensive rats
  1249. Increased expression of oxidative enzymes in adipose tissue following PPARα-activation
  1250. … prevents augmented peripheral inflammation and inflammatory hyperalgesia in high-fat diet-induced obese rats by restoring downregulated spinal PPARα
  1251. PPARα-L162V polymorphism is not associated with schizophrenia risk in a Croatian population
  1252. Testosterone Replacement Modulates Cardiac Metabolic Remodeling after Myocardial Infarction by Upregulating PPARα
  1253. Swimming’s prevention of ovariectomy-induced obesity through activation of skeletal-muscle PPARα
  1254. Differential regulation of stimulated glucose transport by free fatty acids and PPARα or-δ agonists in cardiac myocytes
  1255. Hydrogen sulfide up-regulates the expression of ATP-binding cassette transporter A1 via promoting nuclear translocation of PPARα
  1256. PPARα-independent action against metabolic syndrome development by fibrates is mediated by inhibition of STAT3 signalling
  1257. Study on genetic variations of PPARα gene and its effects on thermal tolerance in Chinese Holstein
  1258. PPARα/γ antagonists reverse the ameliorative effects of osthole on hepatic lipid metabolism and inflammatory response in steatohepatitic rats
  1259. Exenatide Activates the APPL1-AMPK-PPARα Axis to Prevent Diabetic Cardiomyocyte Apoptosis
  1260. 5‐Caffeoylquinic acid decreases diet‐induced obesity in rats by modulating PPARα and LXRα transcription
  1261. Spectroscopic and molecular modeling approaches to investigate the interaction of bisphenol A, bisphenol F and their diglycidyl ethers with PPARα
  1262. Perfluorooctanoic acid induced-developmental cardiotoxicity: are peroxisome proliferator activated receptor α (PPARα) and bone morphorgenic protein 2 (BMP2) …
  1263. Discovery of peroxisome proliferator–activated receptor α (PPARα) activators with a ligand-screening system using a human PPARα-expressing cell line
  1264. Therapy with Astragalus polysaccharides rescues lipotoxic cardiomyopathy in MHC-PPARα mice
  1265. Activation of PPARα decreases bile acids in livers of female mice while maintaining bile flow and biliary bile acid excretion
  1266. Enalaprilat increases PPARβ/δ expression, without influence on PPARα and PPARγ, and modulate cardiac function in sub-acute model of daunorubicin-induced …
  1267. … adverse reproductive outcomes in mice is associated with altered expression of apolipoprotein AI and inflammatory mediators PPARα, interferon-γ, and …
  1268. An association between the PPARα-L162V polymorphism and nicotine dependency among patients with schizophrenia
  1269. DHEA administration activates transcription of muscular lipid metabolic enzymes via PPARα and PPARδ in obese rats
  1270. Prostacyclin and PPARα agonists control vascular smooth muscle cell apoptosis and phenotypic switch through distinct 14-3-3 isoforms
  1271. Metabolism of methiocarb and carbaryl by rat and human livers and plasma, and effect on their PXR, CAR and PPARα activities
  1272. Soymorphin-5, a soy-derived μ-opioid peptide, decreases glucose and triglyceride levels through activating adiponectin and PPARα systems in diabetic KKAy mice
  1273. Zinc reduces hepatic lipid deposition and activates lipophagy via Zn2+/MTF‐1/PPARα and Ca2+/CaMKKβ/AMPK pathways
  1274. Maresin 1 attenuates pro-inflammatory reactions and ER stress in HUVECs via PPARα-mediated pathway
  1275. Interference with acute nausea and anticipatory nausea in rats by fatty acid amide hydrolase (FAAH) inhibition through a PPARα and CB1 receptor mechanism …
  1276. Differential regulation of the expressions of the PGC-1α splice variants, lipins, and PPARα in heart compared to liver
  1277. SIK2 regulates fasting-induced PPARα activity and ketogenesis through p300
  1278. The effects of dual PPARα/γ agonism compared with ACE inhibition in the BTBRob/ob mouse model of diabetes and diabetic nephropathy
  1279. Adiponectin deficiency-induced diabetes increases TNFα and FFA via downregulation of PPARα
  1280. Revisiting glitazars: Thiophene substituted oxazole containing α-ethoxy phenylpropanoic acid derivatives as highly potent PPARα/γ dual agonists devoid of adverse …
  1281. Pro-inflammatory effect of fibrinogen on vascular smooth muscle cells by regulating the expression of PPARα, PPARγ and MMP-9
  1282. The PPARα agonist fenofibrate prevents formation of protein aggregates (Mallory-Denk bodies) in a murine model of steatohepatitis-like hepatotoxicity
  1283. γ-Mangostin from Garcinia Mangostana Pericarps as a Dual Agonist That Activates Both PPARα and PPARδ
  1284. PPARα Agonist WY-14643 Induces SIRT1 Activity in Rat Fatty Liver Ischemia-Reperfusion Injury
  1285. Xuezhikang contributes to greater triglyceride reduction than simvastatin in hypertriglyceridemia rats by up-regulating apolipoprotein A5 via the PPARα …
  1286. Acyl-CoA thioesterase 1 (ACOT1) regulates PPARα to couple fatty acid flux with oxidative capacity during fasting
  1287. The herbal composition GGEx18 from Laminaria japonica, Rheum palmatum, and Ephedra sinica inhibits high-fat diet-induced hepatic steatosis via hepatic PPARα …
  1288. Hyper-and hypo-nutrition studies of the hepatic transcriptome and epigenome suggest that PPARα regulates anaerobic glycolysis
  1289. Direct effects of PPARα agonists on retinal inflammation and angiogenesis may explain how fenofibrate lowers risk of severe proliferative diabetic retinopathy
  1290. Dietary alanyl-glutamine and vitamin E supplements could considerably promote the expression of GPx and PPARα genes, antioxidation, feed utilization, growth, and …
  1291. Cardiomyocyte-Restricted Deletion of PPARβ/δ in PPARα-Null Mice Causes Impaired Mitochondrial Biogenesis and Defense, but No Further Depression of …
  1292. … effects of Coreopsis tinctoria flowers phenolic extract against D-galactosamine/lipopolysaccharide-induced acute liver injury by up-regulation of Nrf2, PPARα, and …
  1293. N-oleoylethanolamide suppresses intimal hyperplasia after balloon injury in rats through AMPK/PPARα pathway
  1294. Fenofibrate down-regulates renal OCT2-mediated organic cation transport via PPARα-independent pathways
  1295. Fetal alcohol-induced hyperactivity is reversed by treatment with the PPARα agonist fenofibrate in a rat model
  1296. The PPARα agonist fenofibrate improves the musculoskeletal effects of exercise in ovariectomized rats
  1297. Caloric restriction in leptin deficiency does not correct myocardial steatosis: Failure to normalize PPARα/PGC1α and thermogenic glycerolipid/fatty acid cycling
  1298. The effects of kefir, koumiss, yogurt and commercial probiotic formulations on PPARα and PPAR-β/δ expressions in mouse kidney
  1299. Spinal cord injury induced changes of nuclear receptors PPARα and LXRβ and modulation with oleic acid/albumin treatment
  1300. Discovery of potent dual PPARα agonists/CB1 ligands
  1301. Aqueous extract of black maca prevents metabolism disorder via regulating the glycolysis/gluconeogenesis-TCA cycle and PPARα signaling activation in …
  1302. … impair angiotensin II-induced arterial mononuclear cell adhesion through inhibition of Nox5 signaling pathways and increased RXR/PPARα and RXR/PPARγ …
  1303. Effect of stilbene and chalcone scaffolds incorporation in clofibric acid on PPARα agonistic activity
  1304. Synthesis of novel PPARα/γ dual agonists as potential drugs for the treatment of the metabolic syndrome and diabetes type II designed using a new de novo design …
  1305. Oleoylethanolamide alleviates macrophage formation via AMPK/PPARα/STAT3 pathway
  1306. Palmitoleic Acid (N-7) Attenuates the Immunometabolic Disturbances Caused by a High-Fat Diet Independently of PPARα
  1307. Treatment with PPARα Agonist Clofibrate Inhibits the Transcription and Activation of SREBPs and Reduces Triglyceride and Cholesterol Levels in Liver of …
  1308. … determinants for improved activity at PPARα: structure–activity relationship of pirinixic acid derivatives, docking study and site-directed mutagenesis of PPARα
  1309. Inhibition of FAAH confers increased stem cell migration via PPARα
  1310. IL-1β-induced downregulation of the multifunctional PDZ adaptor PDZK1 is attenuated by ERK inhibition, RXRα, or PPARα stimulation in enterocytes
  1311. … well as the expression of sterol-regulatory element binding protein-1c (SREBP-1c) and peroxisome proliferator activated receptors α (PPARα) in diabetic rat
  1312. Ubiquinol affects the expression of genes involved in PPARα signalling and lipid metabolism without changes in methylation of CpG promoter islands in the liver of …
  1313. Antidiabetic effect of SN158 through PPARα/γ dual activation in ob/ob mice
  1314. PPARα activation sensitizes cancer cells to epigallocatechin-3-gallate (EGCG) treatment via suppressing heme oxygenase-1
  1315. Interleukin-6 affects aging-related changes of the PPARα-PGC-1α axis in the myocardium
  1316. Naoxintong retards atherosclerosis by inhibiting foam cell formation through activating PPARα pathway
  1317. Propane-2-sulfonic acid octadec-9-enyl-amide, a novel PPARα/γ dual agonist, protects against ischemia-induced brain damage in mice by inhibiting inflammatory …
  1318. Betahistine co-treatment ameliorates dyslipidemia induced by chronic olanzapine treatment in rats through modulation of hepatic AMPKα-SREBP-1 and PPARα …
  1319. Peroxisome proliferator-activated receptor α (PPARα) mRNA expression in human hepatocellular carcinoma tissue and non-cancerous liver tissue
  1320. Dietary heme-mediated PPARα activation does not affect the heme-induced epithelial hyperproliferation and hyperplasia in mouse colon
  1321. Co‐treatment with retinyl retinoate and a PPARα agonist reduces retinoid dermatitis
  1322. Omega 3 polyunsaturated fatty acid improves spatial learning and hippocampal peroxisome proliferator activated receptors (PPARα and PPARγ) gene …
  1323. Pravastatin activates PPARα/PPARγ expression in the liver and gallbladder epithelium of hamsters
  1324. Carnitine regulates myocardial metabolism by Peroxisome Proliferator-Activated Receptor-α (PPARα) in alcoholic cardiomyopathy
  1325. PPARα activation attenuates amyloid-β-dependent neurodegeneration by modulating Endo G and AIF translocation
  1326. Chronic activation of PPARα with fenofibrate reduces autophagic proteins in the liver of mice independent of FGF21
  1327. Aleglitazar, a balanced dual PPARα and-γ agonist, protects the heart against ischemia-reperfusion injury
  1328. Restoration of Endothelial Function in PPARα−/− Mice by Tempol
  1329. Age-dependent PPARα activation induces hepatic sulfatide accumulation in transgenic mice carrying the hepatitis C virus core gene
  1330. A novel function of hepatic FOG2 in insulin sensitivity and lipid metabolism through PPARα
  1331. The role of nuclear receptor PPARα in the sleep-wake cycle modulation. A tentative approach for treatment of sleep disorders
  1332. PPARα agonists reduce alcohol drinking: do they act in the brain or in the liver?
  1333. Role of AMPK and PPARα in the anti‐skin cancer effects of ursolic acid
  1334. MEK1 inhibits cardiac PPARα activity by direct interaction and prevents its nuclear localization
  1335. Localization of peroxisome proliferator-activated receptor alpha (PPARα) and N-acyl phosphatidylethanolamine phospholipase D (NAPE-PLD) in cells expressing the …
  1336. GW501516 acts as an efficient PPARα activator in the mouse liver
  1337. Loss of PPARα perpetuates sex differences in stroke reflected by peripheral immune mechanisms
  1338. Transcription of genes involved in fat metabolism in chicken embryos exposed to the peroxisome proliferator-activated receptor alpha (PPARα) agonist GW7647 or to …
  1339. Naoxintong/PPARα Signaling Inhibits H9c2 Cell Apoptosis and Autophagy in Response to Oxidative Stress
  1340. The Correlation of PPARα Activity and Cardiomyocyte Metabolism and Structure in Idiopathic Dilated Cardiomyopathy during Heart Failure Progression
  1341. Identification of the first potent, selective and bioavailable PPARα antagonist
  1342. Monocarboxylate transporters 1 and 4: expression and regulation by PPARα in ovine ruminal epithelial cells
  1343. Testing the PPAR hypothesis of tobacco use disorder in humans: A randomized trial of the impact of gemfibrozil (a partial PPARα agonist) in smokers
  1344. Suppression of acute and anticipatory nausea by peripherally restricted fatty acid amide hydrolase inhibitor in animal models: role of PPARα and CB1 receptors
  1345. Structure-guided evolution of a 2-phenyl-4-carboxyquinoline chemotype into PPARα selective agonists: New leads for oculovascular conditions
  1346. Structure–activity relationship studies of non-carboxylic acid peroxisome proliferator-activated receptor α/δ (PPARα/δ) dual agonists
  1347. Inhibition of PPARα attenuates vimentin phosphorylation on Ser-83 and collapse of vimentin filaments during exposure of rat Sertoli cells in vitro to DBP
  1348. Hydrocellular foam dressing promotes wound healing along with increases in hyaluronan synthase 3 and PPARα gene expression in epidermis
  1349. Activation of PPARα by oral clofibrate increases renal fatty acid oxidation in developing pigs
  1350. The 4′-hydroxyl group of resveratrol is functionally important for direct activation of PPARα
  1351. Contribution of PPARα/β/γ, AP-1, importin-α3, and RXRα to the protective effect of 5, 14-HEDGE, a 20-HETE mimetic, against hypotension, tachycardia, and …
  1352. Extracts of black and brown rice powders improve hepatic lipid accumulation via the activation of PPARα in obese and diabetic model mice
  1353. … diet through inhibition of sterol regulatory element binding transcription factor 1 (Srebf1) and activation of peroxisome proliferator activated receptor alpha (PPARα)
  1354. Δ9-THC modulation of fatty acid 2-hydroxylase (FA2H) gene expression: Possible involvement of induced levels of PPARα in MDA-MB-231 breast cancer cells
  1355. PPARα regulates endothelial progenitor cell maturation and myeloid lineage differentiation through a NADPH oxidase-dependent mechanism in mice
  1356. Characterization of the binding between phthalate esters and mouse PPARα for the development of a fluorescence polarization-based competitive binding assay
  1357. PPARα/CB1 receptor dual ligands as a novel therapy for alcohol use disorder: Evaluation of a novel oleic acid conjugate in preclinical rat models
  1358. RETRACTED ARTICLE: Estradiol Inhibits Cytokine-Induced Expression of VCAM-1 and ICAM-1 in Cultured Human Endothelial Cells Via AMPK/PPARα Activation
  1359. Extracts of pomelo peels prevent high-fat diet-induced metabolic disorders in c57bl/6 mice through activating the PPARα and GLUT4 pathway
  1360. Effects of dietary polyunsaturated fatty acids on DNA methylation and the expression of DNMT3b and PPARα genes in rats
  1361. Peroxisome proliferator-activated receptor (PPAR) gene profiling uncovers insulin-like growth factor-1 as a PPARα target gene in cardioprotection
  1362. The herbal composition GGEx18 from Laminaria japonica, Rheum palmatum, and Ephedra sinica reduces obesity via skeletal muscle AMPK and PPARα
  1363. PPARα-mediated responses in human adult liver stem cells: In vivo/in vitro and cross-species comparisons
  1364. Synergetic neuroprotective effect of docosahexaenoic acid and aspirin in SH-Y5Y by inhibiting miR-21 and activating RXRα and PPARα
  1365. A novel PPARα agonist propane-2-sulfonic acid octadec-9-enyl-amide inhibits inflammation in THP-1 cells
  1366. Cyp1b1 affects external control of mouse hepatocytes, fatty acid homeostasis and signaling involving HNF4α and PPARα
  1367. Effects of the PPARα agonist WY-14,643 on plasma lipids, enzymatic activities and mRNA expression of lipid metabolism genes in a marine flatfish, Scophthalmus …
  1368. G0S2a1 (G0/G1 switch gene 2a1) is downregulated by TNF-α in grass carp (Ctenopharyngodon idellus) hepatocytes through PPARα inhibition
  1369. 17β-estradiol inhibits PPARα of skeletal muscle
  1370. Alleviation of toxicity caused by overactivation of PPARα through PPARα-inducible mir-181a2
  1371. Peroxisome proliferator-activated receptor alpha (PPARα), a key regulator of lipid metabolism in Avians
  1372. Rice Koji Extract Enhances Lipid Metabolism through Peroxisome Proliferator-Activated Receptor Alpha (PPARα) Activation in Mouse Liver
  1373. … acid, a triterpenoid compound from Antrodia camphorata, by regulation of Akt phosphorylation, gluconeogenesis, and PPARα in streptozotocin-induced …
  1374. … on peroxisome proliferator-activated receptor gamma coactivator-1α,(PGC-1α), peroxisome proliferator-activated receptor α (PPARα) and estrogen related …
  1375. Identification of novel PPARα/γ dual agonists by virtual screening, ADMET prediction and molecular dynamics simulations
  1376. Synthesis and biological evaluation of novel pyrrolidine acid analogs as potent dual PPARα/γ agonists
  1377. Donor PPARα gene polymorphisms influence the susceptibility to glucose and lipid disorders in liver transplant recipients: a strobe-compliant observational …
  1378. IL-15 Mediates Mitochondrial Activity through a PPARδ-Dependent-PPARα-Independent Mechanism in Skeletal Muscle Cells
  1379. Impaired T cell-mediated hepatitis in peroxisome proliferator activated receptor alpha (PPARα)-deficient mice
  1380. Protective effects of Acyl-coA thioesterase 1 on diabetic heart via PPARα/PGC1α signaling
  1381. 17-OxoDHA is a PPARα/γ dual covalent modifier and agonist
  1382. 5, 7-Dihydroxy-6-geranylflavanone improves insulin sensitivity through PPARα/γ dual activation
  1383. Computational and Biological Evaluation of N-octadecyl-N′-propylsulfamide, a Selective PPARα Agonist Structurally Related to N-acylethanolamines
  1384. Retracted Article: Metabolomics reveals that PPARα activation protects against lithocholic acid-induced liver injury
  1385. Activation of intestinal GR–FXR and PPARα–UGT signaling exacerbates ibuprofen-induced enteropathy in mice
  1386. Molecular characterization and functional analysis of PPARα promoter in yellow catfish Pelteobagrus fulvidraco
  1387. Hepatic fasting-induced PPARα activity does not depend on essential fatty acids
  1388. Editor’s highlight: Clofibrate decreases bile acids in livers of male mice by increasing biliary bile acid excretion in a PPARα-dependent manner
  1389. Evidence that activation of nuclear peroxisome proliferator-activated receptor alpha (PPARα) modulates sleep homeostasis in rats
  1390. PPARγ2 gene Pro12Ala and PPARα gene Leu162Val single nucleotide polymorphisms interact with dietary intake of fat in determination of plasma lipid …
  1391. The PPARα pathway in Vγ9Vδ2 T cell anergy
  1392. A Comparative Study of Mouse Hepatic and Intestinal Gene Expression Profiles under PPARα Knockout by Gene Set …
  1393. Acot1 is a sensitive indicator for PPARα activation after perfluorooctanoic acid exposure in primary hepatocytes of Sprague-Dawley rats
  1394. Possible Role of Interaction between PPARα and Cyclophilin D in Cardioprotection of AMPK against In Vivo Ischemia-Reperfusion in Rats
  1395. PPARα downregulates hepatic glutaminase expression in mice fed diets with different protein: carbohydrate ratios
  1396. PPARα mediates sunitinib resistance via NF-κB activation in clear cell renal cell carcinoma
  1397. Activation of peroxisome proliferator-activated receptor-α (PPARα) in proximal intestine improves postprandial lipidemia in obese diabetic KK-Ay mice
  1398. … -increased expression and activation of NADPH oxidase in human vascular smooth muscle cells is mediated by 4-hydroxynonenal-activated PPARα and PPARβ/δ
  1399. Kinsenoside-mediated lipolysis through an AMPK-dependent pathway in C3H10T1/2 adipocytes: Roles of AMPK and PPARα in the lipolytic effect of kinsenoside
  1400. Virtual identification of novel PPARα/γ dual agonists by scaffold hopping of saroglitazar
  1401. PPARα activation by MHY908 attenuates age-related renal inflammation through modulation of the ROS/Akt/FoxO1 pathway
  1402. Tissue-specific 5′ heterogeneity of PPARα transcripts and their differential regulation by leptin
  1403. The combined strategy with PPARα agonism and AT1 receptor antagonism is not superior relative to their individual treatment approach in preventing the induction of …
  1404. Mouse cardiac Pde1C is a direct transcriptional target of PPARα
  1405. Switching subtype-selectivity: Fragment replacement strategy affords novel class of peroxisome proliferator-activated receptor α/δ (PPARα/δ) dual agonists
  1406. Reduced PPARα expression is associated with decreased survival and increased tissue bacterial load in sepsis
  1407. PPARα attenuates palmitate-induced endoplasmic reticulum stress in human cardiac cells by enhancing AMPK activity
  1408. Molecular cloning and tissue distribution of peroxisome proliferator-activated receptor-alpha (PPARα) and gamma (PPARγ) in the pigeon (Columba livia domestica)
  1409. L-carnitine and PPARα-agonist fenofibrate are involved in the regulation of Carnitine Acetyltransferase (CrAT) mRNA levels in murine liver cells
  1410. Artificial zinc-finger transcription factor of A20 suppresses restenosis in Sprague Dawley rats after carotid injury via the PPARα pathway
  1411. Treatment with pharmacological PPARα agonists stimulates the ubiquitin proteasome pathway and myofibrillar protein breakdown in skeletal muscle of rodents
  1412. Relationship between PPARα mRNA expression and mitochondrial respiratory function and ultrastructure of the skeletal muscle of patients with COPD
  1413. Differential tissue regulation of peroxisome proliferator-activated receptor α (PPARα) and cannabinoid receptor 1 (CB1) gene transcription pathways by diethylene …
  1414. Protection of endothelial cells against Ang II-induced impairment: Involvement of both PPARα and PPARγ via PI3K/Akt pathway
  1415. Pharmacological PPARα activation markedly alters plasma turnover of the amino acids glycine, serine and arginine in the rat
  1416. OxLDL up-regulates Niemann–Pick type C1 expression through ERK1/2/COX-2/PPARα-signaling pathway in macrophages
  1417. PPARα gene polymorphisms modulate the association between physical activity and cardiometabolic risk
  1418. Binding interactions of halogenated bisphenol A with mouse PPARα: In vitro investigation and molecular dynamics simulation
  1419. Interleukin 6 modulates PPARα and PGC-1α and is involved in high-fat diet induced cardiac lipotoxicity in mouse
  1420. A role for the peroxisomal 3-ketoacyl-CoA thiolase B enzyme in the control of PPARα-mediated upregulation of SREBP-2 target genes in the liver
  1421. 3D-QSAR study of tyrosine and propanoic acid derivatives as PPARα/γ dual agonists using CoMSIA
  1422. PPARα induced NOS1 phosphorylation via PI3K/Akt in guinea pig antral mucous cells: NO-enhancement in Ca2+-regulated exocytosis
  1423. Clofibrate induces heme oxygenase 1 expression through a PPARα-independent mechanism in human cancer cells
  1424. Hepatic amino acid-degrading enzyme expression is downregulated by natural and synthetic ligands of PPARα in rats
  1425. PPARα activation by fenofibrate protects against acute myocardial ischemia/reperfusion injury by inhibiting mitochondrial apoptosis
  1426. Gemfibrozil not fenofibrate decreases systemic glucose level via PPARα
  1427. The Proatherogenic Effect of Chronic Nitric Oxide Synthesis Inhibition in ApoE-Null Mice Is Dependent on the Presence of PPARα
  1428. Effects of EPA supplementation on plasma fatty acids composition in hypertriglyceridemic subjects with FABP2 and PPARα genotypes
  1429. PPARα-dependent induction of uncoupling protein 2 protects against acetaminophen-induced liver toxicity
  1430. The dipeptide H-Trp-Arg-OH (WR) is a PPARα agonist and reduces hepatic lipid accumulation in lipid-loaded H4IIE cells
  1431. cis-9,trans-11,cis-15 and cis-9,trans-13,cis-15 CLNA Mixture Activates PPARα in HEK293 and Reduces Triacylglycerols in 3T3-L1 cells
  1432. Osthol inhibits fatty acid synthesis and release via PPARα/γ-mediated pathways in 3T3-L1 adipocytes
  1433. PPARα agonist Wy14643 suppresses cathepsin B in human endothelial cells via transcriptional, post-transcriptional and post-translational mechanisms
  1434. Effect of polyene phosphatidyl choline on hepatocyte steatosis via PPARα/CPT-1A pathway
  1435. … -AβPP 695 cells revealed mitochondrial dysfunction prior to amyloid-β pathology and potential therapeutic effects of both PPARγ and PPARα agonisms for Alzheimer’s …
  1436. Abietic acid inhibits UVB‐induced MMP‐1 expression in human dermal fibroblast cells through PPARα/γ dual activation
  1437. Red clover extract ameliorates dyslipidemia in streptozotocin‐induced diabetic C57BL/6 mice by activating hepatic PPARα
  1438. Functional genetic variants of PPARγ and PPARα encoding peroxisome proliferator-activated receptors and susceptibility to ischemic stroke in Chinese Han …
  1439. PPARα activation drives demethylation of the CpG islands of the Gadd45b promoter in the mouse liver
  1440. Design, synthesis and evaluation of novel zwitterionic compounds as PPARα/γ dual agonists (1)
  1441. Increased nitric oxide production and gender-dependent changes in PPARα expression and signaling in the fetal lung from diabetic rats
  1442. Treatment of lactating sows with clofibrate as a synthetic agonist of PPARα does not influence milk fat content and gains of litters
  1443. Osthole regulates TGF-β1 and MMP-2/9 expressions via activation of PPARα/γ in cultured mouse cardiac fibroblasts stimulated with angiotensin II
  1444. A human relevance investigation of PPARα-mediated key events in the hepatocarcinogenic mode of action of propaquizafop in rats
  1445. Development of a new class of benzoylpyrrole-based PPARα/γ activators
  1446. Flow Cytometry Analysis of PPARα Receptors in Metabolic Syndrome/Studiul Receptorilor PPARα prin Metoda Citometriei în Flux în Sindromul Metabolic
  1447. Synergistic mechanism of traditional Chinese medicine based on target combination of PepT1 and PPARα
  1448. Omega-3 fatty acids attenuate constitutive and insulin-induced CD36 expression through a suppression of PPARα/γ activity in microvascular endothelial cells
  1449. Effects of ERK1/2/PPARα/SCAD signal pathways on cardiomyocyte hypertrophy induced by insulin-like growth factor 1 and phenylephrine
  1450. Circ5379-6, a circular form of tumor suppressor PPARα, participates in the inhibition of hepatocellular carcinoma tumorigenesis and metastasis
  1451. Prediction of the PPARα agonism of fibrates by combined MM–docking approaches
  1452. PPARα Stimulation Modulates Myocardial Ischemia-induced Activation of Renin–Angiotensin System
  1453. PPARβ/δ Activation prevents hypertriglyceridemia caused by a high fat diet. Involvement of AMPK and PGC-1α-Lipin1-PPARα pathway
  1454. Identification of novel PPARα/γ dual agonists by virtual screening of specs database
  1455. β-arrestin-1 contributes to brown fat function and directly interacts with PPARα and PPARγ
  1456. Nuclear Receptor PPARα Agonist Wy-14,643 Ameliorates Hepatic Cell Death in Hepatic IKKβ-Deficient Mice
  1457. The fatty acid profile in muscles and expression of PPARα, FADS2 and ME1 genes in liver of Chinese Wanxi White geese in fattening period.
  1458. Aleglitazar, a balanced PPARα/γ agonist, has no clinically relevant pharmacokinetic interaction with high-dose atorvastatin or rosuvastatin
  1459. MDG-1, a potential regulator of PPARα and PPARγ, ameliorates dyslipidemia in mice
  1460. Association of PPAR𝜶 Intron 7 Polymorphism with Coronary Artery Disease: A Cross-Sectional Study
  1461. Editor’s highlight: neonatal activation of the xenobiotic-sensors PXR and CAR results in acute and persistent down-regulation of PPARα-signaling in mouse liver
  1462. Dual PPARα/γ ligand TZD18 improves myocardial metabolic remodeling after myocardial infarction in rats.
  1463. PPARα ligands make memories
  1464. Gene-Gene Interactions among PPARα/δ/γ Polymorphisms for Apolipoprotein (Apo) AI/Apob Ratio in Chinese Han Population
  1465. Transcription factor GATA-6 recruits PPARα to cooperatively activate Glut4 gene expression
  1466. The effect of PPARα gene polymorphism on some athletic performances of non-athletic 10-12 year-old boys of marand
  1467. Discovery of cyclic amine-substituted benzoic acids as PPARα agonists
  1468. Pretreatment with Proteasome Inhibitors Protects against Oxidative Injuries via PPARα-Dependent and-Independent Pathways in ARPE-19 Cells
  1469. Interaction Effects of the Leu162Val PPARα and Pro12Ala PPARγ2 Gene Variants with Renal Function in Metabolic Syndrome Population
  1470. Role of PPARα in the attenuation of bile acid-induced apoptosis by omega-3 long-chain polyunsaturated fatty acids in cultured hepatocytes
  1471. Prenatal PPARα activation by clofibrate increases subcutaneous fat browning in male C57BL/6J mice fed a high-fat diet during adulthood
  1472. PPARα autocrine regulation of Ca2+-regulated exocytosis in guinea pig antral mucous cells: NO and cGMP accumulation
  1473. A novel partial PPARα/γ dual agonist SN159 improves insulin sensitivity
  1474. Transcriptome analyses demonstrate that Peroxisome Proliferator-Activated Receptor α (PPARα) activity of an ultraviolet absorber, 2-(2′-hydroxy-3′, 5′-di-tert …
  1475. A novel PPARα/γ agonist, propane-2-sulfonic acid octadec-9-enyl-amide, ameliorates insulin resistance and gluconeogenesis in vivo and vitro
  1476. Proliferative and Molecular Effects of the Dual PPARα/γ Agonist Tesaglitazar in Rat Adipose Tissues: Relevance for Induction of Fibrosarcoma
  1477. Identification of pirinixic acid derivatives bearing a 2-aminothiazole moiety combines dual PPARα/γ activation and dual 5-LO/mPGES-1 inhibition
  1478. Lauric acid beneficially modulates apolipoprotein secretion and enhances fatty acid oxidation via PPARα-dependent pathways in cultured rat hepatocytes
  1479. 4′,6-Dimethoxyisoflavone-7-O-β-d-glucopyranoside (wistin) is a peroxisome proliferator-activated receptor α (PPARα) agonist in mouse hepatocytes
  1480. Research Advance on PPARα Gene in Livestock and Poultry
  1481. Peroxisome Proliferator-Activated Receptor Alpha (PPARα) in Redlip Mullet, Liza haematocheila:Molecular Cloning, Mrna Tissue Expression, and Response to …
  1482. Inhibition of pulmonary β-carotene 15, 15′-oxygenase expression by glucocorticoid involves PPARα
  1483. Expression of peroxisome proliferator-activated receptor alpha (PPARα) in non-somatotroph pituitary tumours and the effects of PPARα agonists on MMQ cells
  1484. Discovery and preclinical evaluation of BMS-711939, an oxybenzylglycine based PPARα selective agonist
  1485. The PPARα activator fenofibrate inhibits voltage-dependent K+ channels in rabbit coronary arterial smooth muscle cells
  1486. PPARα-mediated peroxisome induction compensates PPARγ-deficiency in bronchiolar club cells
  1487. Citral effect in male NMRI mice nonalcoholic steatosis model: assessing biochemical and histological parameters and PPARα gene expression
  1488. Di-(2-ethylhexyl) phthalate suppresses IL-12p40 production by GM-CSF-dependent macrophages via the PPARα/TNFAIP3/TRAF6 axis after lipopolysaccharide …
  1489. Effect of beta-3 adrenoceptor stimulation on the levels of ApoA-I, PPARα, and PPARγ in apolipoprotein E–deficient mice
  1490. Synthesis and biological evaluation of gemfibrozil chiral analogues as potential PPARα agonists
  1491. PPARα Agonist Fenofibrate Reduced the Secreting Load of β-Cells in Hypertriglyceridemia Patients with Normal Glucose Tolerance
  1492. Inhibitory effect of isorhamnetin on lipid accumulation in free fatty acid-induced steatotic hepatocytes through the PPARα pathway
  1493. Abstract PR428: Association of PPARα Rs4253728 G> A Gene Polymorphisms with Cyp3A4 Enzyme Activity And Fentanyl Post-Operative Intravenous Analgesic Effect
  1494. PPARα receptor expression in patients with metabolic syndrome
  1495. Effects of perfluorooctanoic acid on oxidative stress and PPARα and its related CYP4A1 gene expression in rat liver
  1496. Neonatal Activation of the Xenobiotic-Sensors PXR and CAR Results in Acute and Persistent Down-regulation of PPARα-Signaling in Mouse Liver.
  1497. Effects on lipid metabolism and expression of PPARα and FABP of Schizothorax prenanti by oxidized Konjac glucomannan
  1498. Characterization of chemical constituents from Thymelaea hirsuta with PPARα/γ modulation activity
  1499. Changes in gene expression in PBMCs profiles of PPARα target genes in obese and non-obese individuals during fasting
  1500. Regulation of the expression of the avian uncoupling protein 3 by isoproterenol and fatty acids in chick myoblasts: possible involvement of AMPK and PPARα?
  1501. Restore islet β-cells dysfunction and study the expression of PPARα and PPARγ in Stevia rebaudiana treated mice
  1502. A Novel Selective PPARα Modulator
  1503. The interaction of PPARα and CYP7B1 with ERα, β impacted the occurrence and development of intrahepatic cholestasis in pregnant Rats
  1504. Modulation of PPAR subtype selectivity. Part 2: Transforming PPARα/γ dual agonist into α selective PPAR agonist through bioisosteric modification
  1505. … fed saturated fat/cholesterol have a blunted hypothalamic-pituitary-adrenal function, are insulin resistant and have decreased expression of IRS-1, PGC1α and PPARα
  1506. C/EBP‐β Is Differentially Affected by PPARα Agonists Fenofibric Acid and GW7647, But Does Not Change Apolipoprotein A‐I Production During ER‐Stress and …
  1507. KLF6 activates PPARα signalling in hepatic steatosis
  1508. Association of functional genetic variants in PPARγ and PPARα encoding peroxisome proliferator-activated receptors with ischemic stroke in a unique Chinese …
  1509. … , 4-oxadiazol-5-yl) ethyl) acetamides as novel acetyl-CoA carboxylase 2 (ACC2) inhibitors with peroxisome proliferator-activated receptor α/δ (PPARα/δ) dual agonistic …
  1510. E2/ERβ Inhibits PPARα to Regulate Cell-Proliferation and Enhance Apoptosis in Hep3B-Hepatocellular Carcinoma
  1511. … Aging and Other Inflammatory Disease States by Dehydroepian-drosterone-3ẞ-Sulfate, an Activator of the Peroxisome Proliferator-Activated Receptor Alpha (PPARα)
  1512. MiR‐21 role in aspirin‐dependent PPARα and multidrug resistance protein 4 upregulation
  1513. 5-aminosalicylic acid improves lipid profile in mice fed a high-fat cholesterol diet through its dual effects on intestinal PPARγ and PPARα
  1514. A meta-analysis study of gene expression datasets in mouse liver under PPARα knockout
  1515. Peroxisome Proliferator Activated Receptor Alpha (PPARα) Agonists: A Potential Tool for a Healthy Aging Brain
  1516. Novel synthesis of butyl (S)-2-hydroxybutanoate, the key intermediate of PPARα agonist (R)-K-13675 from butyl (2S, 3R)-epoxybutanoate and butyl (S)-2, 3 …
  1517. Influence of aerobic exercise on oxidative stress and PPARα in myocardium in metabolic syndrome rats
  1518. PPARα-target gene expression requires TIS21/btg2 gene in liver of the C57Bl/6 mice under fasting condition
  1519. Effect of genistein on the changes of PPARα expression and glycolipid level in oleic acid-induced steatosis in HepG2 cells.
  1520. MK886 inhibits the pioglitazone-induced anti-invasion of MDA-MB-231 cells is associated with PPARα/γ, FGF4 and 5LOX
  1521. Polymorphisms in the Egl nine homolog 3 (EGLN3) and Peroxisome proliferator activated receptor-alpha (PPARα) genes and their correlation with hypoxia …
  1522. The involvement of the cd40-cd40l pathway in activated platelet-induced changes in huvec cox-2 and PPARα expression
  1523. Proteomic Analysis of Salt-Induced Changes in Protein Expression in PPARα Null Mice
  1524. Design, synthesis, and biological evaluation of resveratrol derivatives as PPARα agonists
  1525. PPARα and PPARγ as main regulators of fatty acid metabolism.
  1526. … of the Hepatic and Splenic Immune Status and Immunoglobulin Synthesis in Aged Male Mice Lacking the Peroxisome Proliferator‐Activated Receptor‐Alpha (PPARα)
  1527. The application of comparative molecular field analysis for the design of α-anilino substituted-3-phenyl propanoic acids as novel PPARα/γ dual ligands
  1528. Salvianolic acid B ameliorates cardiac hypertrophy in T2 DM mice by activating PPARα
  1529. Hepatitis B virus upregulates host expression of α-1, 2-mannosidases via the PPARα pathway
  1530. … statistical approach to compare transcriptomics data across experiments: a case study on the identification of candidate target genes of the transcription factor PPARα
  1531. A moderate zinc deficiency does not impair gene expression of PPARα, PPARγ, and mitochondrial enoyl-CoA delta isomerase in the liver of growing rats
  1532. Muscle Ring Finger‐1 (MuRF1), MuRF2, and MuRF3 Differentially Regulate the transcription factors PPARα, PPARγ, and PPARβ/δ, respectively, in vivo
  1533. Analyzing PPARα/ligand interactions by chemical cross-linking and high-resolution mass spectrometry
  1534. Research Progress on Pathogenesis of Obesity-Induced Insulin Resistance and Its Therapeutic Targets: PPARα/γ
  1535. Fenofibrate, a specific peroxisome proliferator-actívated receptor alpha (PPARα) agonist, up-regulates MDR3/ABCB4 expression in human hepatocytes: 731
  1536. Regulation of hypoxia inducible factor/prolyl hydroxylase binding domain proteins 1 by PPARα and high salt diet
  1537. Odd-chain fatty acids predict insulin sensitivity in people with T2DM and protect HepG2 cells from palmitate-induced insulin resistance via PPARα
  1538. QSAR STUDY OF INDANE-URIEDO-THIOISOBUTYRIC ACIDS AS A PPARα AGONISTS
  1539. A HIGHLY SELECTIVE PPARα AGONIST K-877 SUPPRESSES NEOINTIMA FORMATION FOLLOWING CORONARY STENTING IN SWINE
  1540. Correction to rice koji extract enhances lipid metabolism through peroxisome proliferator-activated receptor alpha (PPARα) activation in mouse liver
  1541. PPARα Signaling is Activated by Cocoa in Mouse Liver
  1542. Application research on PPARα-transgenic mice in preclinical safety evaluation of gemfibrozil
  1543. PPARα as a Transcriptional Regulator for Detoxification of Plant Diet-Derived Unfavorable Compounds
  1544. Effects of Gubentongluo Formula on Oxidative Stress Reflected by Expressions of PPARα and L-FABP in Mice with IgA Nephropathy
  1545. PPARα Association With Sirt1 Suppresses Cardiac Fatty Acid Metabolism in the Failing Heart
  1546. Identifying Changes in Punitive Transcriptional Factor Binding Sites Created by PPARα/δ/γ SNPs Associated with Disease
  1547. CLINICAL EFFICIENCY AND SAFETY OF FENOFIBRATE, A PPARα AGONIST, IN THE PATIENTS WITH DIABETESASSOCIATED OSTEOARTHRITIS: A CROSS …
  1548. PPARα Activation Suppresses Cytochrome P450 Induction Potential in Mice Treated with Gemfibrozil
  1549. induction of peroxiSome proliferator-activated RecePToR α (PPARα)-mediated gene expreSSion by extractS of tomato
  1550. Fenofibrate rescues diabetes-related impairment of ischaemia-mediated angiogenesis by a PPARα independent pathway
  1551. A secretome analysis reveals that PPARα is upregulated by fractionated-dose γ-irradiation in three-dimensional keratinocyte cultures
  1552. PPARα in diabetic keratopathy
  1553. Reactivity of the Immune System and Activities of PPARα and PPARγ in the Liver under Conditions of LPS-Induced Acute Infl ammatory Response in Hypertensive …
  1554. Effect of adiponectin on PPARα, ApoA5 and triglyceride in HepG2 cells and its mechanism
  1555. The Intestinal-Liver Axis of FGF15-FGFR4-PPARα Signal Control Liver Ischemia Reperfusion Injury Through Regulating Autophagy
  1556. Comparative analysis of the nuclear receptors CAR, PXR and PPARα in the regulation of hepatic energy homeostasis and xenobiotic metabolism
  1557. Functional contribution by PPARα expression to emmetropization in mice
  1558. PPARα Activation Induces N ε-Lys-Acetylation of Rat Liver Peroxisomal Multifunctional Enzyme Type 1
  1559. … causes depression of the immune response and increases the sensitivity to endotoxin in association with low level of HDL and PPARα activity in hypertensive ISIAH …
  1560. Non-hematopoietic PPARα protects against cardiac injury and enhances survival in experimental polymicrobial sepsis
  1561. Expression of Peroxisome Proliferator-Activated Receptor alpha (PPARα) in somatotropinomas: Relationship with Aryl hydrocarbon receptor Interacting Protein (AIP) …
  1562. PPARα agonists and TGFβ inhibitors stimulate red blood cell production by enhancing self-renewal of BFU-E erythroid progenitors
  1563. Nuclear receptor PPARα activation triggers hepatic cell death in Ikkβ-deficient mice
  1564. Effects of Rhizoma Alismatis decoction on lipid metabolism and PPARα and ACO expression in rats with hyperlipemia
  1565. Effects of Leonurus japonicus Houtt. and its N-containing constituents leonurine and stachydrine on the activity of PPARα, β/δ, and γ in a newly developed in vitro …
  1566. CYP2C8 is a Novel Target of Peroxisome Proliferator-activated α (PPARα) In Human Liver
  1567. Simulation of the PPARα regulome predicts PPARα activation exacerbates the development of hepatic steatosis
  1568. PPAR𝛼 is required for PPAR𝛿 action in regulation of body weight and hepatic steatosis in mice
  1569. Muscle Ring Finger‐1 (MuRF1) inhibits cardiac PPARα activity by directing its nuclear export and not its degradation
  1570. Mechanisms of PPARα, sterol regulatory element binding proteins and AMP-activated protein kinase in alcoholic fatty liver diseases
  1571. PPARα and PPARβ/δ Activation by Oat (Avena sativa) Oil Stimulates Keratinocyte Differentiation and Ceramide Synthesis
  1572. PPARα gene variation and phisycal performance in italian soccer players
  1573. The Relationship of miR‐21‐5p and PPARα in CKD‐Related NAFLD and Dyslipidemia
  1574. The transcriptional co-regulation of hepatic lipid metabolism by GR and PPARα
  1575. Design and Synthesis of 3-(2-Ethyl-4-{2-[2-(4-fluorophenyl)-5-methyloxazol-4-yl] ethoxy} phenyl) propanoic Acid: A Novel Triple-acting PPARα,-γ, and-δ Agonist
  1576. Characterization and modeling of acute effects of PPARα activation in rat liver cells
  1577. PPARα is Essential for Retinal Neuronal Survival and Lipid Metabolism
  1578. Integrative analysis and modeling of PPARα function in murine liver and small intestine
  1579. Structural and Functional Alteration of Full Length PPARα and LXRα by Fatty Acids and their Thioesters
  1580. PPARα activation in portal hypertension
  1581. Structural Requirement of PPARα Agonist Through QSARs and Molecular Simulation Analyses
  1582. Down-Regulation of PPARα through MicroRNA-Associated Mechanism in Diabetic Retinopathy
  1583. Possible mechanism of PPARα/γ activator TZD18 in gastric cancer
  1584. Neural plasticity: Role of PPARα activation
  1585. Hepatoprotective effects of PPARα: molecular basis and pathophysiological role of PPARα in acute inflammation and non-alcoholic steatohepatitis
  1586. PPARα Inhibition as a Novel Target for Renal Cell Carcinoma (RCC)
  1587. QSAR STUDY OF INDANE-URIEDO-THIOISOBUTYRIC ACIDS AS A PPARα AGONISTS
  1588. Cloning and bioinformatics analysis of PPARα gene in Tibetan chicken.
  1589. Effects of medicinal plants of the genus Leonurus and seventeen of their isolated constituents on the activity of PPARα, β/δ, and γ in an in vitro luciferase reporter gene …
  1590. Effects of PPARα Activation and the Role of HO‐1 in Acute SAH‐Induced Fall in Cerebral Blood Flow in Rat
  1591. Dietary protein regulates gene expression of amino acid‐degrading enzymes through PPARα
  1592. Studies on the attenuation effects of intestinal PPARα activation on postprandial hyperlipidemia
  1593. Role of PPARα in the oxidative damage of rat liver cells BRL-3A induced by perfluorooctanoic acid
  1594. Contribution of PPARα and Ketone Body to Sleep Homeostasis in Mice
  1595. Fibrate Acids and Esters for the Treatment of Hyperlipidemia (PPARα Activators)
  1596. PGC1α Activation Corrects Cardiac Dysfunction Caused by Anti-diabetic Dual-PPARα/γ Therapy
  1597. Design, Synthesis And Biological Evaluation of New Analogs of The Dual PPARα/γ Agonist Lt175
  1598. Identification of lead molecules capable of the simultaneous agonism of the PPARƴ and PPARα subtypes for the dual management of diabetes mellitus and …
  1599. Identification of natural PPARα transactivating compounds and their effects on apolipoprotein AI transcription in HepG2 cells
  1600. Demonstration of interaction of full‐length PPARα and LXRα
  1601. Klf5 Mediates Glucose-driven Changes ofCcardiac PPARα in Diabetes
  1602. The role of peroxisome proliferator activated receptor alpha (PPARα) in the effect of piroxicam on colon cancer
  1603. Abstract P233: PPARα-Sirt1 Complex Mediates Metabolic Adaptation in Response to Starvation in the Heart
  1604. Therapeutic Effects of PPARα Agonist on Experimental Neovascular Age-Related Macular Degeneration
  1605. PPARα expression in acs lymphocytes and its correlation with TNFα and hs-CRP in serum
  1606. Estimation of the PPARα agonism of fibrates by a combined MM-docking approach
  1607. PPARα agonist protects Aristolochic acid‐induced nephropathy by increasing mediated lipid metabolism (LB554)
  1608. Biological Evaluation of New Fluorinated Analogues With PPARα and PPARγ Agonist Activity
  1609. Expression of PPARα, β, and γ in the Hartley guinea pig model of primary osteoarthritis
  1610. Mogat1 is a fasting‐induced PPARα target gene that plays a role in coordinating the hepatic response to food deprivation
  1611. Effect of eicosanoic acid on Ap generation of rat cortical neurons and intervention of activated-PPARα.
  1612. Research Article Consequences of PPARα Invalidation on Glutathione Synthesis: Interactions with Dietary Fatty Acids
  1613. GW26-e1825 Regulation of lipid metabolism and inflammation response by Danqi Pill through PPARα in coronary heart disease
  1614. Bilirubin Induces the Burning of Fat via the Nuclear Receptor PPARα
  1615. PPARα activation differently affects microparticle content in atherosclerotic lesions and liver of a mouse model of…
  1616. Exenatide Treatment Improves Nonalcoholic Fatty Liver Phenotype by Regulation of PPARα and ACOX1
  1617. Anti-Diabetic Activity from a Marine Lipid Analogue-Analysis of a Potential New Therapeutic Agent Targeting the Nuclear Receptors PPARα and-γ
  1618. Activation of PPARα During the Progressive Phase of Heart Failure Improved Myocardial Energetics and Function in Pressure Overload Heart Failure
  1619. Abstract B7: Activation of PPARα suppresses HIF-1α signaling in human cancer cells.
  1620. PPARα-dependent increase of mouse urine output by gemfibrozil and fenofibrate
  1621. Modulation of fatty acid and bile acid metabolism by PPARα protects against alcoholic liver disease
  1622. Wy14643, an agonist for PPARα, down-regulates expression of TARC and RANTES in cultured human keratinocytes
  1623. Nutritional regulation of the hepatokine FGF21 in the liver: interdependence of the transcription factors ChREBP and PPARα
  1624. PPARα Activation Bypasses the Transcription Elongation Defect in Mutant tif1γ Erythroid Differentiation
  1625. Elucidating novel role of bezafibrate, a PPARα agonist as potential anticancer agent in the treatment of renal cell carcinoma
  1626. Effect of Compound Zhenzhu Tiaozhi Recipe on expressions of liver PPARα and its downstream genes in non-alcoholic fatty liver disease.
  1627. Effect of EPA supplementation on body mass index in overweight hypertriglyceridemic subjects with different FABP2 and PPARα genotypes
  1628. PPARα-dependent exacerbation of experimental colitis by the hypolipidemic drug fenofibrate 2
  1629. The effects of PPARα and PPARγ agonists on proteinuria and oxidative stress in patients with type 2 diabetes mellitus.
  1630. Hepatic mitochondrial and ER stress induced by defective PPARα signaling in the pathogenesis of hepatic steatosis 2
  1631. Modulation of Inflammatory Signaling by PPARα and PPARγ in Acrolein-Treated gp91phox Knockout Mice
  1632. PPARα activation promotes macrophage reverse cholesterol transport through an LXR-dependent pathway
  1633. Modulation of PPARα Activity by Bile Acids Causes Circadian Changes in the Intestinal Expression of Octn1/Slc22a4 in Mice
  1634. Effect of Danqi pill on PPARα, lipid disorders and arachidonic acid pathway in rat model of coronary heart disease.
  1635. Sesamol alleviates diet-induced cardiometabolic syndrome in rats via up-regulating PPARγ, PPARα and e-NOS☆
  1636. Post-Translational Regulation of FAS-Mediated PPARα Activation
  1637. Potential interest of InsR, CPT1A, SLC27A2, FASN and PPARα expression in blood cells as biomarkers of dyslipidemia in children
  1638. Chronic Kidney Disease and Fibrosis: Proximal tubule PPARα attenuates renal fibrosis and inflammation caused by unilateral ureteral obstruction
  1639. PPARα/γ Agonist Tesaglitazar Reduces Inflammatory Macrophage Numbers And Induces Adipose Ucp-1 Expression In Diabetic Ob/ob Mice
  1640. Research Article Selected Extracts of Chinese Herbal Medicines: Their Effect on NF-κB, PPARα and PPARγ and the Respective Bioactive Compounds
  1641. PPARγ2 gene Pro12Ala and PPARα gene Leu162Val SNPs interact with dietary intake of fat in determination of plasma lipid concentrations
  1642. Regulatory interactions between the metabolic sensors SIRT1 and AMPK in modulating PPARα linked functions, in obesity-dependent type 2 diabetes mellitus
  1643. Wy14643, a PPARα agonist, down-regulates expressions of TARC and RANTES and up-regulates those of filaggrin in cultured human keratinocytes
  1644. Antagonism of Peroxisome Proliferator Activated Receptor Alpha (PPARα) by TPST-1120 Suppresses Tumor Growth and Stimulates Anti-Tumor Immunity
  1645. PPARα and Nrf2 Govern Metabolic Deregulation and Oxidative Stress in a Murine Model for Nonalcoholic Steatohepatitis (NASH)
  1646. The fatty acid profile in muscles and expression of PPARα, FADS2 and ME1 genes in liver of Chinese Wanxi White geese in fattening period.
  1647. Deletion of Aryl Hydrocarbon Receptor Nuclear Translocator (HIF1-β) in the Heart Leads to Cardiomyopathy and Lipid Accumulation via PPARα
  1648. PPARα signalling reduces subchondral bone thickening and inflammation, but does not prevent cartilage damage in STR/Ort mice
  1649. PPARα/CB1 receptor dual ligands as a novel therapy for alcohol use disorder: evaluation of a novel oleic acid conjugate in preclinical rat models
  1650. GW9662, A PPAR γ-ANTAGONIST, INHIBITS TELMISARTAN-MEDIATED GENE MODULATION, AND ACTIVATED PPARα: PP. 18.98
  1651. PPARα positively regulates human MDR3/ABCB4 transcription and increases biliary phosphatidylcholine secretion: 228
  1652. … receptors (PPARs) are directly influenced by permeability barrier abrogation and inflammatory cytokines and depressed PPARα modulates expressions of …
  1653. PPARα as Potential Therapeutic Target for Neurodegenerative Diseases
  1654. Umbelliferone supplementation attenuates alcohol‐induced hepatic steatosis by regulating PPARα‐and SREBP‐1c pathway in rats (1116.2)
  1655. Hugan Qingzhi medication ameliorates hepatic steatosis by activating AMPK and PPARα pathways in L02 cells and HepG2 cells.
  1656. Dietary alanyl-glutamine and vitamin E supplements could considerably promote the expression of GPx and PPARα genes, antioxidation, feed utilization, growth, and …
  1657. The inhibitory effect of hydroalcoholic extract of black punica granatum pericarp on melanoma tumor angiogenesis through PPARα and PPARγ pathways in C57BL6 …
  1658. Combination of SGLT2 Inhibitor and Novel Selective PPARα Modulator, Tofogliflozin (Tofo) and Pemafibrate (Pema), Improves Survival Rate in STAM Mice as a …
  1659. Perfluorooctanoic Acid Reduces Viability and Decreases Expression of Peroxisome Proliferator‐Activated Receptor Alpha (PPARα) and Estrogen Receptor Alpha …
  1660. … of aqueous extract of syzigium cumini for its antihyperglycemic and antidyslipidemic properties in diabetic rats fed a high cholesterol diet – role of PPARγ and PPARα.
  1661. Beyond Peroxisome: ABCD2 Modifies PPARα Signaling and Identifies a Subclass of Peroxisomes in Mouse Adipose Tissue
  1662. ABCD2 Alters PPARα Signaling in Vitro, but Does Not Impair Responses to Fenofibrate Therapy in a Mouse Model of Diet-induced Obesity
  1663. Muscle Ring Finger‐1 (MuRF1) inhibits PPARα through mono‐ubiquitination of specific lysines adjacent to a novel nuclear export sequence (NES)
  1664. Oleoylethanolamine and palmitoylethanolamine modulate intestinal permeability in vitro via TRPV1 and PPARα: a new potential class of therapeutic agents for …
  1665. PPARα, PPARγ and SREBP-1 pathways mediated waterborne iron (Fe)-induced reduction in hepatic lipid deposition of javelin goby Synechogobius hasta.
  1666. Renoprotective effect of a novel selective PPARα modulator K-877 in db/db mice: A role of diacylglycerol-protein kinase C-NAD (P) H oxidase pathway
  1667. Heme Oxygenase-PPARα Induction of FGF21 in Hepatocytes Recruits pAMPK/pAKT and Attenuates Insulin Resistance in Obese Mice
  1668. Aqueous extract of black maca prevents metabolism disorder via regulating the glycolysis/gluconeogenesis-TCA cycle and PPARα signaling activation in golden …
  1669. IL-15 Mediates Mitochondrial Activity through a PPAR𝛿-Dependent-PPAR𝛼-Independent Mechanism in Skeletal Muscle Cells
  1670. Molecular research on a hypotensive herb formula and PPARα activation
  1671. Fatty acids and their thioester derivatives as ligands for human PPARα–A comparison to murine PPARα
  1672. Study on the tnf-α-stimulated nf-κb pathway regulating peroxisome proliferator-activated receptor alpha (PPARα) expression in hepg2 cells
  1673. P04. 15LIGAND-ACTIVATED TRANSCRIPTION FACTORS PPARγ AND PPARα EXPRESSION IN HUMAN GLIOMA
  1674. Protective effect of fasting in hearts and arteries of PPARα−/− mice
  1675. GW501516 acts as an efficient PPARα activator in the mouse liver
  1676. P63LIGAND-ACTIVATED TRANSCRIPTION FACTORS PPARγ AND PPARα EXPRESSION IN HUMAN GLIOMA
  1677. High-fat diet-induced renal cell apoptosis and oxidative stress in spontaneously hypertensive rat are ameliorated by fenofibrate through the PPARα-FoxO3a-PGC-1α …
  1678. Increased accumulation of 4-hydroxynonenal adducts in male GSTA4/PPARα double knockout mice enhances injury during early stages of alcoholic liver disease …
  1679. T1-10 Oleoylethanolamide protects against ischemic stroke by modulating microglia M1/M2 polarization in PPARα-dependent manner
  1680. Restoration of endothelial function in PPARα−/− mice by Tempol
  1681. Comprehensive analysis of PPARα-induced gene expression in rat liver
  1682. PPAR𝛼 Enhances Cancer Cell Chemotherapy Sensitivity by Autophagy Induction
  1683. PPARα/β agonist MHY2013 attenuates age-associated renal fibrosis
  1684. A selective PPARα modulator has preventive effects in murine models of retinopathy
  1685. Effect of Donor Hepatic PPARα Gene Polymorphisms on Glucose and Lipid Disorders after Liver Transplantation.: Abstract# P-391
  1686. Effects of Synthetic Ligands on Heterodimer Pairs Regarding PPARα, RXRα and LXRα
  1687. Hepatocyte PI3Kα controls the PPARα-FGF21 axis and regulates whole body fatty acid homeostasis
  1688. Interaction of PPARα, CD36 and Th17 in angiotensin II‐induced hypertension (1136.9)
  1689. Amplification of PRDM16, BMP7, PPARα, COX II and PGC-1α Genes Tupaia belangeri
  1690. High Fat Diet Upregulates Il-6 in the Heart Through PPARα
  1691. Modeling PPARα activation of Benzoxazole-Phenoxyalkyl-Phenoxybutyric acids using diverse descriptors
  1692. Omega 3 polyunsaturated fatty acid improves spatial learning and hippocampal peroxisome Peroxisome Proliferator Activated Receptors (PPARα and PPARγ) gene …
  1693. IDDF2018-ABS-0165 Circular RNA circ5379–6 performs functions in inhibiting tumorigenesis and metastasis of hepatocellular carcinoma via the regulation of PPARα
  1694. Research Article PPAR𝛼 Is Required for PPAR𝛿 Action in Regulation of Body Weight and Hepatic Steatosis in Mice
  1695. The impact of PPARα gene on the physiology, biochemistry of mouse
  1696. GSK-3α Directly Regulates Lipid Metabolism Through Obesity-linked Phosphorylation of PPARα
  1697. PPAR𝜶-Independent Arterial Smooth Muscle Relaxant Effects of PPAR𝜶 Agonists
  1698. Research Article PPAR𝛼 Agonist WY-14643 Induces SIRT1 Activity in Rat Fatty Liver Ischemia-Reperfusion Injury
  1699. Mechanisms and metabolic regulation of PPARα activation in Nile tilapia (Oreochromis niloticus).
  1700. CYP1A1 induction in the colon by serum: involvement of the PPARα pathway and evidence for a new specific human PPREα site
  1701. PPARα agonists—an emerging concept in the management of neuropathic and visceral pain
  1702. Cloning, identification and accurate normalization expression analysis of PPARα gene by GeNorm in Megalobrama amblycephala.
  1703. HUMAN FABP1 T94A VARIANT IMPACTS FATTY ACID METABOLISM AND PPARα ACTIVATION IN 2 CULTURED HUMAN FEMALE HEPATOCYTES 3
  1704. Study on genetic variations of PPARα gene and its effects on thermal tolerance in Chinese Holstein.
  1705. Abstract O-1: Klf5 Regulates Cardiac PPARα and Med13 and affects Cardiac Fatty Acid Metabolism And Obesity
  1706. Sphingosine Kinase 1 is regulated by PPARα in response to free fatty acids and mediates skeletal muscle IL‐6 production and signaling in diet‐induced obesity
  1707. Interactions of PPARα and Acid Sensing Ion Channels on Cerebral Perfusion in Mice
  1708. Effect of cold stress on expression of AMPKα-PPARα pathway and inflammation genes.
  1709. New role of hispidulin in lipid metabolism: PPARα activator.
  1710. Constituents from Bupleurum chinense and their effects on PPARα and related nuclear receptors
  1711. Mechanism-Based Inhibitory and PPARα-Dependent Modulating Effects of Silybin on Principle Hepatic Drug-Metabolizing Enzymes
  1712. The study of novel PPARα agonist K-877 regulated genes in mouse liver and primary human hepatocytes
  1713. Swimming’s prevention of ovariectomy-induced obesity through activation of skeletal-muscle PPARα.
  1714. Homeostatic PPARα signaling limits inflammatory responses to commensal microbiota in the intestine.
  1715. The whole genome effects of the PPARα agonist fenofibrate on livers of hepatocyte humanized mice
  1716. Retraction: 5-aminosalicylic acid improves lipid profile in mice fed a high-fat cholesterol diet through its dual effects on intestinal PPARγ and PPARα
  1717. Effect of berberine on PPARα-NO signalling pathway in vascular smooth muscle cell proliferation induced by angiotensin IV.
  1718. Application of PPARα Transgenic Mice in Drug Evaluation
  1719. Depressed PPARα accelerates a vicious cycle between allergic inflammation and barrier dysfunction
  1720. Effect of the PPARα-activator gemfibrozil on whole blood drug transporter gene expression in humans
  1721. Therapeutic Effect of PPARα Agonist on Pericyte Loss in Diabetic Retinopathy
  1722. Effect of eicosanoic acid on Ap generation of rat cortical neurons and intervention of activated-PPARα.
  1723. PPARα-Independent actions of omega-3 PUFAs contribute to their beneficial effects on adiposity and glucose homeostasis.
  1724. L-carnitine protects against carboplatin-mediated renal injury: AMPK-and PPARα-dependent inactivation of NFAT3.
  1725. A Novel Selective PPARα Modulator, Pemafibrate Promotes Ischemia-Induced Revascularization
  1726. Caloric Restriction in Leptin Deficiency Does Not Correct Myocardial Steatosis: Failure to 1 Normalize PPARα/PGC1α and Thermogenic Glyecrolipid/Fatty Acid …
  1727. PPARα Modulates Acrolein‐Induced Inflammatory Signaling in gp91phox Knock‐Out Mice
  1728. Role of PPARα/PGC-1αin doxorubicin induced mouse dilated cardio-myopathy
  1729. Effects of the Constituents of Terminalia Species on PPARα and PPARγ, Glucose Uptake and Adipogenesis
  1730. PPARα protects against trans-fatty-acid-containing diet-induced steatohepatitis.
  1731. miRNA-mediated anticancer properties of the PPARα-activator fenofibrate on glioblastoma cell growth and migration.
  1732. Cloning of PPARα and PPARγ partial cDNA sequence and differential expression in tissues in grass carp (Ctenopharyngodon idella).
  1733. Echinococcus granulosus stimulates high PPARα/γ expression and drives polarization of macrophages in vitro
  1734. Bilobetin ameliorates insulin resistance by PKA-mediated phosphorylation of PPARα in rats fed a high-fat diet.
  1735. Transcriptional regulation of the human, porcine and bovine OCTN2 gene by PPARα via a conserved PPRE located in intron 1.
  1736. The PPARα agonist fenofibrate suppresses B-cell lymphoma in mice by modulating lipid metabolism.
  1737. PW296 Fenofibrate Rescues Diabetes-related Impairment of Ischaemia-mediated Angiogenesis by PPARα Independent Modulation of Thioredoxin Interacting Protein
  1738. The lipogenic transcription factors PPARα and Pparγ as possible linkage between lipid metabolism and Hedgehog-Signalling Pathway?
  1739. Eupatilin with PPARα agonistic effects inhibits TNFα-induced MMP signaling in HaCaT cells.
  1740. Icariin is a PPARα activator inducing lipid metabolic gene expression in mice.
  1741. Dietary procyanidins lower serum triglyceride levels via up‐regulation in PPARα and its downstream target gene expression
  1742. Dietary grape seed proanthocyanidin extract regulates metabolic disturbance in rat liver exposed to lead associated with PPARα signaling pathway.
  1743. Novel PPARα activators extracted from natural herbs suppress eczema lesion in oxazolone induced atopic dermatitis murine model
  1744. Wogonin ameliorates hyperglycemia and dyslipidemia via PPARα activation in db/db mice.
  1745. Peroxisome proliferator-activated receptor alpha (PPARα) in redlip mullet, Liza Haematocheila: molecular cloning, mRNA tissue expression, and response to dietary …
  1746. Wogonin suppresses osteopontin expression in adipocytes by activating PPARα.
  1747. PPARα activation sensitizes cancer cells to epigallocatechin-3-gallate (EGCG) treatment via suppressing heme oxygenase-1.
  1748. Identification of eupatilin from Artemisia argyi as a selective PPARα agonist using affinity selection ultrafiltration LC-MS.
  1749. Effect of berberine on PPARα/NO activation in high glucose-and insulin-induced cardiomyocyte hypertrophy.
  1750. Ablation of Aryl Hydrocarbon Nuclear Translocator (ARNT) in the Heart Leads to Diabetic Cardiomyopathy Phenotype Through PPARα Activity
  1751. Effect of genistein on the changes of PPARα expression and glycolipid level in oleic acid-induced steatosis in HepG2 cells.
  1752. Topical eupatilin as a PPARα activator is effective for atopic dermatitis
  1753. GW29-e0256 Puerarin attenuates oxidized LDL-induced macrophage foam cell formation via PPARα signaling pathway
  1754. Betaine prevented fructose-induced NAFLD by regulating LXRα/PPARα pathway and alleviating ER stress in rats.
  1755. Gene-gene interactions among PPARα/δ/γ polymorphisms for hypertriglyceridemia in Chinese Han population.
  1756. The Lipid Droplet Associated Protein CIDEC/Fsp27 is Regulated by PPARα and Prevents Hepatic Triglyceride Utilization
  1757. Naoxintong/PPARα signaling inhibits H9c2 cell apoptosis and autophagy in response to oxidative stress.
  1758. Peroxisome proliferator activator receptor alpha (PPARα) activation using free fatty acid library; fatty acids compared
  1759. Icariin attenuates cerebral ischemia-reperfusion injury through inhibition of inflammatory response mediated by NF-κB, PPARα and PPARγ in rats.
  1760. Nuclear receptornuclear receptor CAR down-regulates hepatic PPARα-mediated expression of HMGCS2, a key enzyme of ketogenesis
  1761. Sesamin ameliorates hepatic steatosis and inflammation in rats on a high-fat diet via LXRα and PPARα.
  1762. Potent PPARα activator derived from tomato juice, 13-oxo-9, 11-octadecadienoic acid, decreases plasma and hepatic triglyceride in obese diabetic mice.
  1763. Biochanin A suppresses the secretion of proinflammatory cytokines from lipopolysaccharide-stimulated porcine peripheral blood mononuclear cells via PPARα/γ …
  1764. The dipeptide H-Trp-Arg-OH (WR) is a PPARα agonist and reduces hepatic lipid accumulation in lipid-loaded H4IIE cells.
  1765. Kaempferol regulates the lipid-profile in high-fat diet-fed rats through an increase in hepatic PPARα levels.
  1766. Improvement of synaptic plasticity by pharmacological activation of RXR nuclear receptors is PPARα dependent.
  1767. Osthole improves glucose and lipid metabolism via modulation of PPARα/γ-mediated target gene expression in liver, adipose tissue, and skeletal muscle in fatty liver …
  1768. Shugan Xiaozhi decoction attenuates nonalcoholic steatohepatitis by enhancing PPARα and L-FABP expressions in high-fat-fed rats.
  1769. Wild bitter gourd extract up-regulates mRNA expression of PPARα, PPARγ and their target genes in C57BL/6J mice.
  1770. Free fatty acids increase intracellular lipid accumulation and oxidative stress by modulating PPARα and SREBP-1c in L-02 cells.
  1771. Astragaloside IV alleviates heart failure via activating PPARα to switch glycolysis to fatty acid β-oxidation.
  1772. Timed high-fat diet in the evening affects the hepatic circadian clock and PPARα-mediated lipogenic gene expressions in mice.
  1773. INCREASED 4-HYDROXYNONENAL PROTEIN ADDUCTS IN MALE GSTA4-3 4/PPARα DOUBLE KNOCKOUT MICE ENHANCE INJURY DURING EARLY 4 …
  1774. Sargahydroquinoic acid inhibits TNFα-induced AP-1 and NF-κB signaling in HaCaT cells through PPARα activation.
  1775. Dietary umbelliferone attenuates alcohol-induced fatty liver via regulation of PPARα and SREBP-1c in rats.
  1776. Effects of walnut on lipid profile and expression of SREBP-1c and PPARα in diabetic rat
  1777. … NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)/NON-ALCOHOLIC STEATOHEPATITIS (NASH) BYCHICORY SEED EXTRACT VIA MODULATION OF PPARα …
  1778. The hypolipidemic and hypoglycemic activities of fermented brown rice fibers by regulating PPARα and ChREBP in the livers of C57BL/6J mice.
  1779. Prenatal PPARα activation by clofibrate increases subcutaneous fat browning in male C57BL/6J mice fed a high-fat diet during adulthood.
  1780. Peroxisome proliferator-activated receptor-alpha (PPARα) suppresses T helper 1 (Th1) cytokine production in male mice by inducing post-translational histone …
  1781. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
  1782. The herbal composition GGEx18 from Laminaria japonica, Rheum palmatum, and Ephedra sinica reduces obesity via skeletal muscle AMPK and PPARα.
  1783. REMOVED: PPARα and PPARδ nuclear receptor regulation of body weight and hepatic steatosis
  1784. The herbal composition GGEx18 from Laminaria japonica, Rheum palmatum, and Ephedra sinica inhibits high-fat diet-induced hepatic steatosis via hepatic PPARα …
  1785. P35 Treatment with oleic acid and a PPARα agonist increases fatty acid oxidation in beating human inducible pluripotent stem cell-derived cardiomyocytes
  1786. … present at high levels in bitter melon seed favorably affects lipid metabolism in hepatocytes by increasing NAD+/NADH ratio and activating PPARα, AMPK and SIRT1 …
  1787. SUPPLEMENTAL DATA PPARα-INDEPENDENT ACTIVATION OF THE SREBP-2 PATHWAY IN NEWBORN PEROXISOME-DEFICIENT PEX2 KNOCK-OUT MICE
  1788. Non‐peptide Agonist of the Receptor MAS, AVE 0991, Increases PPARα Expression in Muscle of Rats Fed Fructose‐Rich Diet
  1789. … by Chronic Cerebral Hypoperfusion by Inhibiting the Amyloidogenic Pathway: Involvement of BDNF/TrkB/CREB Signaling and Up-Regulation of PPARα and PPARγ in …
  1790. Hovenia dulcis extract reduces lipid accumulation in oleic acid-induced steatosis of Hep G2 cells via activation of AMPK and PPARα/CPT-1 pathway and in acute …
  1791. … North-East Indian fermented soybean food prevents hepatic steatosis via regulating AMPK-mediated SREBP/FAS/ACC/HMGCR and PPARα/CPT1A/UCP2 pathways.
  1792. Screening of 19 traditional Mexican medicinal plants for effects on the metabolic syndrome related targets PPARα, β/δ, and γ in an in vitro luciferase reporter gene …
  1793. The Peroxisome proliferator-activated receptor alpha (PPARα) intron 7 G/C polymorphism is associated with muscle strength in a young-adult population.
  1794. Synergetic neuroprotective effect of docosahexaenoic acid and aspirin in SH-Y5Y by inhibiting miR-21 and activating RXRα and PPARα.
  1795. Effects of ERK1/2/PPARα/SCAD signal pathways on physiological car-diac hypertrophy and pathological cardiac hypertrophy
  1796. Extracts of pomelo peels prevent high-fat diet-induced metabolic disorders in C57BL/6 mice through activating the PPARα and GLUT4 pathway.
  1797. … Editors (2018) Retraction: 5-aminosalicylic acid improves lipid profile in mice fed a high-fat cholesterol diet through its dual effects on intestinal PPARγ and PPARα
  1798. Kinsenoside-mediated lipolysis through an AMPK-dependent pathway in C3H10T1/2 adipocytes: roles of AMPK and PPARα in the lipolytic effect of kinsenoside.
  1799. 5-aminosalicylic acid improves lipid profile in mice fed a high-fat cholesterol diet through its dual effects on intestinal PPARγ and PPARα.
  1800. Design and Synthesis of 3-(2-Ethyl-4-{2-[2-(4-fluorophenyl)-5-methyloxazol-4-yl] ethoxy} phenyl) propanoic Acid: A Novel Triple-acting PPARα,-γ, and-δ Agonist
  1801. Red clover extract ameliorates dyslipidemia in streptozotocin-induced diabetic C57BL/6 mice by activating hepatic PPARα.
  1802. … transcriptomics data across experiments: a case study on the identification of candidate target genes of the transcription factor PPARα. Bioinformatics and Biology …
  1803. Effect of Gain-of-Function Mutations in NHR-49/PPARα on Longevity and Stress-Resistance
  1804. PPARα: An emerging target of metabolic syndrome, neurodegenerative and cardiovascular diseases
  1805. Targeting PPARα for the treatment and understanding of cardiovascular diseases
  1806. The PPARα and PPARγ epigenetic landscape in cancer and immune and metabolic disorders
  1807. Identification and characterization of phytocannabinoids as novel dual PPARα/γ agonists by a computational and in vitro experimental approach
  1808. PPARα at the crossroad of metabolic–immune regulation in cancer
  1809. Activation of PPARα enhances astroglial uptake and degradation of β-amyloid
  1810. Mechanisms mediating the regulation of peroxisomal fatty acid beta-oxidation by PPARα
  1811. Hepatic PPARα is critical in the metabolic adaptation to sepsis
  1812. Hepatocyte-specific deletion of PPARα promotes NAFLD in the context of obesity
  1813. PPARα: A potential therapeutic target of cholestasis
  1814. PPARα signaling: A candidate target in psychiatric disorder management
  1815. Loss of hepatic PPARα in mice causes hypertension and cardiovascular disease
  1816. Loss of hepatic PPARα promotes inflammation and serum hyperlipidemia in diet-induced obesity
  1817. SIRT6 promotes hepatic beta-oxidation via activation of PPARα
  1818. Dietary excess regulates absorption and surface of gut epithelium through intestinal PPARα
  1819. PPARα agonist oral therapy in diabetic retinopathy
  1820. Pemafibrate, a new selective PPARα modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases
  1821. PPARα alleviates iron overload‐induced ferroptosis in mouse liver
  1822. PPARγ and PPARα synergize to induce robust browning of white fat in vivo
  1823. Dual PPARα/γ activation inhibits SIRT1-PGC1α axis and causes cardiac dysfunction
  1824. A protective effect of PPARα in endothelial progenitor cells through regulating metabolism
  1825. PPARα modulation-based therapy in central nervous system diseases
  1826. Neuroprotective effects of PPARα in retinopathy of type 1 diabetes
  1827. A contemporary overview of PPARα/γ dual agonists for the management of diabetic dyslipidemia
  1828. Transcriptional profiling of PPARα−/− and CREB3L3−/− livers reveals disparate regulation of hepatoproliferative and metabolic functions of PPARα
  1829. MDM2 and MDMX promote ferroptosis by PPARα-mediated lipid remodeling
  1830. PPARα ligand-binding domain structures with endogenous fatty acids and fibrates
  1831. Circadian clock controls rhythms in ketogenesis by interfering with PPARα transcriptional network
  1832. ATF6α downregulation of PPARα promotes lipotoxicity-induced tubulointerstitial fibrosis
  1833. ACOX2 is a prognostic marker and impedes the progression of hepatocellular carcinoma via PPARα pathway
  1834. PPARα and PPARβ/δ are negatively correlated with proinflammatory markers in leukocytes of an obese pediatric population
  1835. Conjugated linoleic acid and brain metabolism: a possible anti-neuroinflammatory role mediated by PPARα activation
  1836. Shared PPARα/γ target genes regulate brown adipocyte thermogenic function
  1837. Hyodeoxycholic acid ameliorates nonalcoholic fatty liver disease by inhibiting RAN-mediated PPARα nucleus-cytoplasm shuttling
  1838. Functional and structural insights into the human PPARα/δ/γ targeting preferences of anti-NASH investigational drugs, lanifibranor, seladelpar, and elafibranor
  1839. Peroxisome proliferator-activated receptor-α (PPARα) regulates wound healing and mitochondrial metabolism in the cornea
  1840. PPARα inhibition overcomes tumor-derived exosomal lipid-induced dendritic cell dysfunction
  1841. Treadmill exercise reduces α-synuclein spreading via PPARα
  1842. PPARα− ACOT12 axis is responsible for maintaining cartilage homeostasis through modulating de novo lipogenesis
  1843. Intestinal PPARα protects against colon carcinogenesis via regulation of methyltransferases DNMT1 and PRMT6
  1844. Discovery of the First Subnanomolar PPARα/δ Dual Agonist for the Treatment of Cholestatic Liver Diseases
  1845. Herpetrione, a new type of PPARα ligand as a therapeutic strategy against nonalcoholic steatohepatitis
  1846. Chronic acidosis rewires cancer cell metabolism through PPARα signaling
  1847. PPARα/ACOX1 as a novel target for hepatic lipid metabolism disorders induced by per-and polyfluoroalkyl substances: An integrated approach
  1848. Clinical applications of a novel selective PPARα modulator, pemafibrate, in dyslipidemia and metabolic diseases
  1849. A new perspective on NAFLD: Focusing on the crosstalk between peroxisome proliferator-activated receptor alpha (PPARα) and farnesoid X receptor (FXR)
  1850. Activation of PPARα exhibits therapeutic efficacy in a mouse model of juvenile neuronal ceroid lipofuscinosis
  1851. Hepatic lipid catabolism via PPARα-lysosomal crosstalk
  1852. MiR-30c/PGC-1β protects against diabetic cardiomyopathy via PPARα
  1853. Ginsenoside Rb3 regulates energy metabolism and apoptosis in cardiomyocytes via activating PPARα pathway
  1854. Fenofibrate, a PPARα agonist, reduces hepatic fat accumulation through the upregulation of TFEB-mediated lipophagy
  1855. Upregulation of BDNF and hippocampal functions by a hippocampal ligand of PPARα
  1856. Hypoxia via ERK signaling inhibits hepatic PPARα to promote fatty liver
  1857. PPARα induces the expression of CAR that works as a negative regulator of PPARα functions in mouse livers
  1858. Nuclear Receptor PPARα as a Therapeutic Target in Diseases Associated with Lipid Metabolism Disorders
  1859. Resveratrol protects against nonalcoholic fatty liver disease by improving lipid metabolism and redox homeostasis via the PPARα pathway
  1860. The attenuation of diabetic nephropathy by annexin A1 via regulation of lipid metabolism through the AMPK/PPARα/CPT1b pathway
  1861. … Differences between mouse and human PPARα in modulating the hepatocarcinogenic effects of perinatal exposure to a high-affinity human PPARα agonist in mice
  1862. Feedback repression of PPARα signaling by Let-7 microRNA
  1863. PPARα agonist fenofibrate enhances cancer vaccine efficacy
  1864. LncRNA MEG8 regulates vascular smooth muscle cell proliferation, migration and apoptosis by targeting PPARα
  1865. Celastrol ameliorates acute liver injury through modulation of PPARα
  1866. Canagliflozin ameliorates obesity by improving mitochondrial function and fatty acid oxidation via PPARα in vivo and in vitro
  1867. A Photohormone for Light-Dependent Control of PPARα in Live Cells
  1868. PPARα and NCOR/SMRT corepressor network in liver metabolic regulation
  1869. Medioresinol as a novel PGC-1α activator prevents pyroptosis of endothelial cells in ischemic stroke through PPARα-GOT1 axis
  1870. Cinnamic acid activates PPARα to stimulate Lysosomal biogenesis and lower Amyloid plaque pathology in an Alzheimer’s disease mouse model
  1871. GenX Disturbs the Indicators of Hepatic Lipid Metabolism Even at Environmental Concentration in Drinking Water via PPARα Signaling Pathways
  1872. Lactobacillus plantarum FRT10 alleviated high-fat diet–induced obesity in mice through regulating the PPARα signal pathway and gut microbiota
  1873. Pemafibrate, a selective PPARα modulator, prevents non-alcoholic steatohepatitis development without reducing the hepatic triglyceride content
  1874. Mechanisms underlying the functional cooperation between PPARα and GRα to attenuate inflammatory responses
  1875. ATGL-dependent white adipose tissue lipolysis controls hepatocyte PPARα activity
  1876. CircRNA hsa_circ_0110102 inhibited macrophage activation and hepatocellular carcinoma progression via miR-580-5p/PPARα/CCL2 pathway
  1877. Regulation and Mechanism of miR-518d through the PPARα-Mediated NF-κB Pathway in the Development of Gestational Diabetes Mellitus
  1878. Design, synthesis, and biological evaluation of triazolone derivatives as potent PPARα/δ dual agonists for the treatment of nonalcoholic steatohepatitis
  1879. Regulation of PPARα by APP in Alzheimer disease affects the pharmacological modulation of synaptic activity
  1880. Activation of PPARα-catalase pathway reverses alcoholic liver injury via upregulating NAD synthesis and accelerating alcohol clearance
  1881. Fenofibrate induces PPARα and BMP2 expression to stimulate osteoblast differentiation
  1882. PPARα is one of the key targets for dendrobine to improve hepatic steatosis in NAFLD
  1883. Glyphosate-induced autophagy inhibition results in hepatic steatosis via mediating epigenetic reprogramming of PPARα in roosters
  1884. Perfluorooctanoic acid induces liver and serum dyslipidemia in humanized PPARα mice fed an American diet
  1885. PPARα activation directly upregulates thrombomodulin in the diabetic retina
  1886. STAT6 contributes to renal fibrosis by modulating PPARα-mediated tubular fatty acid oxidation
  1887. DNMT1-mediated PPARα methylation aggravates damage of retinal tissues in diabetic retinopathy mice
  1888. The protective roles of PPARα activation in triptolide-induced liver injury
  1889. Adipose-Specific PPARα Knockout Mice Have Increased Lipogenesis by PASK–SREBP1 Signaling and a Polarity Shift to Inflammatory Macrophages in White …
  1890. PPARα suppresses Th17 cell differentiation through IL-6/STAT3/RORγt pathway in experimental autoimmune myocarditis
  1891. Effects of Poria cocos extract on metabolic dysfunction-associated fatty liver disease via the FXR/PPARα-SREBPs pathway
  1892. Hepatic PPARα function and lipid metabolic pathways are dysregulated in polymicrobial sepsis
  1893. Activation of PPARα ameliorates cardiac fibrosis in Dsg2-deficient arrhythmogenic cardiomyopathy
  1894. PERM1 regulates genes involved in fatty acid metabolism in the heart by interacting with PPARα and PGC-1α
  1895. Modulation of cGAS-STING signaling by PPARα in a mouse model of ischemia-induced retinopathy
  1896. NIK links inflammation to hepatic steatosis by suppressing PPARα in alcoholic liver disease
  1897. Corynoline protects ang II-induced hypertensive heart failure by increasing PPARα and Inhibiting NF-κB pathway
  1898. Targeting PPARα in the rat valproic acid model of autism: focus on social motivational impairment and sex-related differences
  1899. Atractylodin ameliorates colitis via PPARα agonism
  1900. Macrophage SR-BI modulates autophagy via VPS34 complex and PPARα transcription of Tfeb in atherosclerosis
  1901. Systems approach to discovery of therapeutic targets for vein graft disease: PPARα pivotally regulates metabolism, activation, and heterogeneity of macrophages and …
  1902. … muciniphila are not associated with major changes in the circulating Endocannabinoidome but linked to higher Mono-Palmitoyl-Glycerol levels as new PPARα …
  1903. Metabolomics reveals the role of PPARα in Tripterygium Wilfordii-induced liver injury
  1904. Saikosaponin D attenuates metabolic associated fatty liver disease by coordinately tuning PPARα and INSIG/SREBP1c pathway
  1905. Effects of dibutyl phthalate on lipid metabolism in liver and hepatocytes based on PPARα/SREBP-1c/FAS/GPAT/AMPK signal pathway
  1906. Qingyangshen mitigates amyloid-β and Tau aggregate defects involving PPARα-TFEB activation in transgenic mice of Alzheimer’s disease
  1907. Testicular toxicity of bisphenol compounds: Homeostasis disruption of cholesterol/testosterone via PPARα activation
  1908. Formononetin ameliorates cholestasis by regulating hepatic SIRT1 and PPARα
  1909. Nicotinamide riboside promotes Mfn2-mediated mitochondrial fusion in diabetic hearts through the SIRT1-PGC1α-PPARα pathway
  1910. Muscle-building supplement β-hydroxy β-methylbutyrate binds to PPARα to improve hippocampal functions in mice
  1911. PPARα serves as a new receptor of aspirin for neuroprotection
  1912. Fat mass and obesity–associated protein promotes liver steatosis by targeting PPARα
  1913. Nanoparticle conjugation of ginsenoside Rb3 inhibits myocardial fibrosis by regulating PPARα pathway
  1914. Ginsenoside Rb1 promotes the activation of PPARα pathway via inhibiting FADD to ameliorate heart failure
  1915. PPARα-targeted mitochondrial bioenergetics mediate repair of intestinal barriers at the host–microbe intersection during SIV infection
  1916. PPARα and PPARγ activation attenuates total free fatty acid and triglyceride accumulation in macrophages via the inhibition of Fatp1 expression
  1917. … integrated network pharmacology and cell metabolomics approach to reveal the role of rhein, a novel PPARα agonist, against renal fibrosis by activating the PPARα …
  1918. mTORC1 activation is not sufficient to suppress hepatic PPARα signaling or ketogenesis
  1919. Fatty Acid Desaturase 1 Influences Hepatic Lipid Homeostasis by Modulating the PPARα‐FGF21 Axis
  1920. FABP3 deficiency exacerbates metabolic derangement in cardiac hypertrophy and heart failure via PPARα pathway
  1921. … acid activates multiple nuclear receptor pathways and skews expression of genes regulating cholesterol homeostasis in liver of humanized PPARα mice fed an …
  1922. NLRP3 inflammasome inhibition by MCC950 in aged mice improves health via enhanced autophagy and PPARα activity
  1923. PPARα agonist fenofibrate relieves acquired resistance to gefitinib in non-small cell lung cancer by promoting apoptosis via PPARα/AMPK/AKT/FoxO1 pathway
  1924. Hepatocyte-specific loss of GPS2 in mice reduces non-alcoholic steatohepatitis via activation of PPARα
  1925. The PPARα regulation of the gut physiology in regard to interaction with microbiota, intestinal immunity, metabolism, and permeability
  1926. Hederagenin improves Alzheimer’s disease through PPARα/TFEB-mediated autophagy
  1927. Targeting HIF-1α in combination with PPARα activation and postnatal factors promotes the metabolic maturation of human induced pluripotent stem cell-derived …
  1928. PPARα/β activation alleviates age-associated renal fibrosis in Sprague Dawley rats
  1929. Danthron ameliorates obesity and MAFLD through activating the interplay between PPARα/RXRα heterodimer and adiponectin receptor 2
  1930. PPARα inhibits astrocyte inflammation activation by restoring autophagic flux after transient brain ischemia
  1931. Aging‐induced aberrant RAGE/PPARα axis promotes hepatic steatosis via dysfunctional mitochondrial β oxidation
  1932. PPARα/γ-Targeting Amorfrutin Phytocannabinoids from Aerial Parts of Glycyrrhiza foetida
  1933. Pemafibrate, a selective PPARα modulator, and fenofibrate suppress microglial activation through distinct PPARα and SIRT1-dependent pathways
  1934. Integrative study of diet-induced mouse models of NAFLD identifies PPARα as a sexually dimorphic drug target
  1935. Huangqin decoction ameliorates ulcerative colitis by regulating fatty acid metabolism to mediate macrophage polarization via activating ffar4-ampk-PPARα Pathway
  1936. Metabolomics reveals gut microbiota contribute to PPARα deficiency-induced alcoholic liver injury
  1937. Efficacy and safety of K-877 (pemafibrate), a selective PPARα modulator, in European patients on statin therapy
  1938. Formononetin protects against cisplatin‑induced acute kidney injury through activation of the PPARα/Nrf2/HO‑1/NQO1 pathway
  1939. Alcoholic fatty liver disease inhibited the co-expression of Fmo5 and PPARα to activate the NF-κB signaling pathway, thereby reducing liver injury via inducing …
  1940. Therapeutic inhibition of PPARα-HIF1α-PGK1 signaling targets leukemia stem and progenitor cells in acute myeloid leukemia
  1941. PPARα and PPARγ are expressed in midbrain dopamine neurons and modulate dopamine-and cannabinoid-mediated behavior in mice
  1942. PPARα in the Epigenetic Driver Seat of NAFLD: New Therapeutic Opportunities for Epigenetic Drugs?
  1943. PPARα Targeting GDF11 Inhibits Vascular Endothelial Cell Senescence in an Atherosclerosis Model
  1944. Mangiferin Improved Palmitate-Induced-Insulin Resistance by Promoting Free Fatty Acid Metabolism in HepG2 and C2C12 Cells via PPARα: Mangiferin …
  1945. … exposure induced greater hepatotoxicity than GenX mainly via activation of PPARα pathway while caused hepatomegaly in the absence of PPARα in female mice
  1946. Berberine attenuates diabetic atherosclerosis via enhancing the interplay between KLF16 and PPARα in ApoE−/− mice
  1947. Maternal high-fructose corn syrup consumption causes insulin resistance and hyperlipidemia in offspring via DNA methylation of the PPARα promoter region
  1948. Novel selective PPARα modulator pemafibrate for dyslipidemia, nonalcoholic fatty liver disease (NAFLD), and atherosclerosis
  1949. Puerarin ameliorated pressure overload-induced cardiac hypertrophy in ovariectomized rats through activation of the PPARα/PGC-1 pathway
  1950. … CPT1A reduces lipid accumulation via PPARα/CD36 axis to suppress the cell proliferation in ccRCC: CPT1A inhibits ccRCC cell proliferation via PPARα …
  1951. Oleoylethanolamide inhibits glial activation via moudulating PPARα and promotes motor function recovery after brain ischemia
  1952. Macrophages activated by hepatitis B virus have distinct metabolic profiles and suppress the virus via IL-1β to downregulate PPARα and FOXO3
  1953. Co‐option of PPARα in the regulation of lipogenesis and fatty acid oxidation in CLA‐induced hepatic steatosis
  1954. CRISPR-mediated BMP9 ablation promotes liver steatosis via the down-regulation of PPARα expression
  1955. Bempedoic acid as a PPARα activator: New perspectives for hepatic steatosis treatment in a female rat experimental model
  1956. Down-regulation of Hrd1 protects against myocardial ischemia-reperfusion injury by regulating PPARα to prevent oxidative stress, endoplasmic reticulum stress, and …
  1957. Terpenoids from Resina Commiphora Regulating Lipid Metabolism via Activating PPARα and CPT1 Expression
  1958. Crosstalk between CYP2E1 and PPARα substrates and agonists modulate adipose browning and obesity
  1959. Design, synthesis, and biological evaluation of novel dual PPARα/δ agonists for the treatment of T2DM
  1960. Melatonin attenuates cisplatin-induced acute kidney injury in mice: Involvement of PPARα and fatty acid oxidation
  1961. Adiponectin homolog novel osmotin protects obesity/diabetes-induced NAFLD by upregulating AdipoRs/PPARα signaling in ob/ob and db/db transgenic mouse …
  1962. PPARα Ameliorates Doxorubicin-Induced Cardiotoxicity by Reducing Mitochondria-Dependent Apoptosis via Regulating MEOX1
  1963. Effects of legacy and emerging per-and polyfluoroalkyl substances on PPARα/β/γ regulation and osteogenic/adipogenic differentiation
  1964. Xinshubao tablet ameliorates myocardial injury against heart failure via the DCN/PPARα/PGC-1α/P300 pathway
  1965. Lycopene prevents DEHP-induced liver lipid metabolism disorder by inhibiting the HIF-1α-induced PPARα/PPARγ/FXR/LXR system
  1966. Artificial intelligence-rationalized balanced PPARα/γ dual agonism resets dysregulated macrophage processes in inflammatory bowel disease
  1967. Lentinan protects against nonalcoholic fatty liver disease by reducing oxidative stress and apoptosis via the PPARα pathway
  1968. … alleviates hyperlipidaemia-mediated vascular calcification via attenuating mitochondrial DNA stress triggered autophagy-dependent ferroptosis by activating PPARα
  1969. Bailing capsule (Cordyceps sinensis) ameliorates renal triglyceride accumulation through the PPARα pathway in diabetic rats
  1970. Inorganic nitrate, hypoxia, and the regulation of cardiac mitochondrial respiration—Probing the role of PPARα
  1971. Phosphorus overload promotes hepatic lipolysis by suppressing GSK3β-dependent phosphorylation of PPARα at Ser84 and Thr265 in a freshwater teleost
  1972. The marine‐derived furanone reduces intracellular lipid accumulation in vitro by targeting LXRα and PPARα
  1973. Fructose-1, 6-bisphosphatase 1 functions as a protein phosphatase to dephosphorylate histone H3 and suppresses PPARα-regulated gene transcription and tumour …
  1974. (+)-Dehydrovomifoliol Alleviates Oleic Acid-Induced Lipid Accumulation in HepG2 Cells via the PPARα–FGF21 Pathway
  1975. Identifying qualitative differences in PPARα signaling networks in human and rat hepatocytes and their significance for next generation chemical risk …
  1976. Aurantio-obtusin ameliorates obesity by activating PPARα-dependent mitochondrial thermogenesis in brown adipose tissues
  1977. PPARα agonist WY-14,643 enhances ethanol metabolism in mice: Role of catalase
  1978. Isosilybin regulates lipogenesis and fatty acid oxidation via the AMPK/SREBP-1c/PPARα pathway
  1979. PXR Suppresses PPARα-Dependent HMGCS2 Gene Transcription by Inhibiting the Interaction between PPARα and PGC1α
  1980. NAMPT maintains mitochondria content via NRF2-PPARα/AMPKα pathway to promote cell survival under oxidative stress
  1981. Regulation of NOX/p38 MAPK/PPARα pathways and miR-155 expression by boswellic acids reduces hepatic injury in experimentally-induced alcoholic liver …
  1982. Oleoylethanolamide facilitates PPARα and TFEB signaling and attenuates Aβ pathology in a mouse model of Alzheimer’s disease
  1983. Gegen qinlian decoction coordinately regulates PPARγ and PPARα to improve glucose and lipid homeostasis in diabetic rats and insulin resistance 3T3-L1 …
  1984. Secreted factors from adipose tissue reprogram tumor lipid metabolism and induce motility by modulating PPARα/ANGPTL4 and FAK
  1985. Pathogenic role of PPARα downregulation in corneal nerve degeneration and impaired corneal sensitivity in diabetes
  1986. The glitazars paradox: Cardiotoxicity of the metabolically beneficial dual PPARα and PPARγ activation
  1987. Ncor2/PPARα-dependent upregulation of MCUb in the type 2 diabetic heart impacts cardiac metabolic flexibility and function
  1988. … obtained from Cordyceps militaris ameliorates hyperlipidemia in heterozygous LDLR-deficient hamsters by modulating gut microbiota and NPC1L1 and PPARα levels
  1989. PPARα-selective antagonist GW6471 inhibits cell growth in breast cancer stem cells inducing energy imbalance and metabolic stress
  1990. TET1 promotes fatty acid oxidation and inhibits NAFLD progression by hydroxymethylation of PPARα promoter
  1991. Lipidomic alterations and PPARα activation induced by resveratrol lead to reduction in lesion size in endometriosis models
  1992. PPARα contributes to the therapeutic effect of hydrogen gas against sepsis-associated encephalopathy with the regulation to the CREB-BDNF signaling pathway and …
  1993. PPARα agonist fenofibrate attenuates iron-induced liver injury in mice by modulating the Sirt3 and β-catenin signaling
  1994. … Oxidized Fish Oil-Induced Lipotoxicity via the Inhibition of Mitochondrial Oxidative Stress, Remodeling of Usp4-Mediated Deubiquitination, and Stabilization of PPARα
  1995. PPARα knockout in mice increases the Th17 development by facilitating the IKKα/RORγt and IKKα/Foxp3 complexes
  1996. Adipolin protects against renal injury via PPARα-dependent reduction of inflammasome activation
  1997. Dietary restriction and medical therapy drives PPARα-regulated improvements in early diabetic kidney disease in male rats
  1998. Folic acid attenuates high-fat diet-induced steatohepatitis via deacetylase SIRT1-dependent restoration of PPARα
  1999. … Probiotic Lactobacillus plantarum FB003 Isolated from Salted-Fermented Shrimp and its Effect on Cholesterol Absorption by Regulation of NPC1L1 and PPARα
  2000. Moringa oleifera leaf extract influences oxidative metabolism in C2C12 myotubes through SIRT1-PPARα pathway
  2001. Regulation of monocyte activation by PPARα through interaction with the cGAS-STING pathway
  2002. Seed oil of Rosa roxburghii Tratt against non-alcoholic fatty liver disease in vivo and in vitro through PPARα/PGC-1α-mediated mitochondrial oxidative metabolism
  2003. The critical role of PPARα in the binary switch between life and death induced by endoplasmic reticulum stress
  2004. PPARα ligand, AVE8134, and cyclooxygenase inhibitor therapy synergistically suppress lung cancer growth and metastasis
  2005. … -chain chlorinated paraffins (SCCPs) disrupt hepatic fatty acid metabolism in liver of male rat via interacting with peroxisome proliferator-activated receptor α (PPARα)
  2006. Da-Chai-Hu-Tang Protects From Acute Intrahepatic Cholestasis by Inhibiting Hepatic Inflammation and Bile Accumulation via Activation of PPARα
  2007. Sex-regulated gene dosage effect of PPARα on synaptic plasticity
  2008. Gemfibrozil protects dopaminergic neurons in a mouse model of Parkinson’s disease via PPARα-dependent astrocytic GDNF pathway
  2009. PGC-1α Protects against Hepatic Ischemia Reperfusion Injury by Activating PPARα and PPARγ and Regulating ROS Production
  2010. Dihydrotrichodimerol Purified from the Marine Fungus Acremonium citrinum Prevents NAFLD by Targeting PPARα
  2011. Functional and structural insights into human PPARα/δ/γ subtype selectivity of bezafibrate, fenofibric acid, and pemafibrate
  2012. Lipid deposition in abalone Haliotis discus hannai affected by dietary lipid levels through AMPKα2/PPARα and JNK/mTOR/SREBP-1c pathway
  2013. Echinacoside ameliorates alcohol-induced oxidative stress and hepatic steatosis by affecting SREBP1c/FASN pathway via PPARα
  2014. Polycerasoidol, a natural prenylated benzopyran with a dual PPARα/PPARγ agonist activity and anti-inflammatory effect
  2015. Elevated lipolysis in adipose tissue by doxorubicin via PPARα activation associated with hepatic steatosis and insulin resistance
  2016. Lycopene prevents lipid accumulation in hepatocytes by stimulating PPARα and improving mitochondrial function
  2017. Selective PPARα modulator pemafibrate and sodium-glucose cotransporter 2 inhibitor tofogliflozin combination treatment improved histopathology in …
  2018. Reversal of obesity and liver steatosis in mice via inhibition of aryl hydrocarbon receptor and altered gene expression of CYP1B1, PPARα, SCD1, and osteopontin
  2019. The protective role of microglial PPARα in diabetic retinal neurodegeneration and neurovascular dysfunction
  2020. The role of Ap2a2 in PPARα‐mediated regulation of lipolysis in adipose tissue
  2021. Keratocytes promote corneal neovascularization through VEGFr3 induced by PPARα-inhibition
  2022. Elucidation of molecular mechanism of a selective PPARα modulator, pemafibrate, through combinational approaches of X-ray crystallography …
  2023. Diosgenin attenuates nonalcoholic hepatic steatosis through the hepatic FXR-SHP-SREBP1C/PPARα/CD36 pathway
  2024. Downregulation of PPARα mediates FABP1 expression, contributing to IgA nephropathy by stimulating ferroptosis in human mesangial cells
  2025. Protective roles of adiponectin and molecular signatures of HNF4α and PPARα as downstream targets of adiponectin in pancreatic β cells
  2026. Dietary fenofibrate attenuated high-fat-diet-induced lipid accumulation and inflammation response partly through regulation of PPARα and sirt1 in juvenile black …
  2027. Exploring the pattern of metabolic alterations causing energy imbalance via PPARα dysregulation in cardiac muscle during doxorubicin treatment
  2028. Neobavaisoflavone induces bilirubin metabolizing enzyme UGT1A1 via PPARα and PPARγ
  2029. LncRNA MALAT1 promotes PPARα/CD36-mediated hepatic lipogenesis in nonalcoholic fatty liver disease by modulating miR-206/ARNT axis
  2030. TRIB3 destabilizes tumor suppressor PPARα expression through ubiquitin-mediated proteasome degradation in acute myeloid leukemia
  2031. Critical biomarkers for myocardial damage by fine particulate matter: Focused on PPARα-regulated energy metabolism
  2032. Benzopyran hydrazones with dual PPARα/γ or PPARα/δ agonism and an anti-inflammatory effect on human THP-1 macrophages
  2033. Auraptene, a citrus peel-derived natural product, prevents myocardial infarction-induced heart failure by activating PPARα in rats
  2034. PPARα exacerbates necroptosis, leading to increased mortality in postinfluenza bacterial superinfection
  2035. The RNA degradation pathway is involved in PPARα-modulated anti-oral tumorigenesis
  2036. Potential Role of the mTORC1-PGC1α-PPARα Axis under Type-II Diabetes and Hypertension in the Human Heart
  2037. A 5: 2 intermittent fasting regimen ameliorates NASH and fibrosis and blunts HCC development via hepatic PPARα and PCK1
  2038. Gastrin, via activation of PPARα, protects the kidney against hypertensive injury
  2039. Role of PPARα in inflammatory response of C2C12 myotubes
  2040. Pristimerin protects against pathological cardiac hypertrophy through improvement of PPARα pathway
  2041. Identification of novel PPARα/γ dual agonists by pharmacophore screening, docking analysis, ADMET prediction and molecular dynamics simulations
  2042. … natural EPA-enriched phosphatidylcholine and phosphatidylethanolamine ameliorate lipid accumulation and insulin resistance via activation of PPARα/γ in mice
  2043. Chondroprotection of PPARα activation by WY14643 via autophagy involving Akt and ERK in LPS‐treated mouse chondrocytes and osteoarthritis model
  2044. Si-Miao-Yong-An decoction preserves cardiac function and regulates GLC/AMPK/NF-κB and GLC/PPARα/PGC-1α pathways in diabetic mice
  2045. Sulfated glucuronomannan hexasaccharide G6S1 enhanced lipolysis and lipophagy via PPARα pathway
  2046. PPARα and PPARβ/δ Expression is Associated with Proinflammatory Markers in an Obese Pediatric Population
  2047. PPARα-Dependent Modulation by Metformin of the Expression of OCT-2 and MATE-1 in the Kidney of Mice
  2048. Atorvastatin restores PPARα inhibition of lipid metabolism disorders by downregulating miR-21 expression to improve mitochondrial function and alleviate …
  2049. PPARα activation enhances the ability of nile tilapia (Oreochromis niloticus) to resist Aeromonas hydrophila infection
  2050. PPARα agonist, MHY3200, alleviates renal inflammation during aging via regulating ROS/Akt/FoxO1 signaling
  2051. Low-intensity exercise affects cardiac fatty acid oxidation by increasing the nuclear content of PPARα, foxo1, and lipin1 in fructose-fed rats
  2052. The PPARα agonist fenofibrate attenuates disruption of dopamine function in a maternal immune activation rat model of schizophrenia
  2053. PPARα activation partially drives NAFLD development in liver-specific Hnf4a-null mice
  2054. … oxide tetramer acid (HFPO-TeA)-induced developmental toxicities in chicken embryo: Peroxisome proliferator-activated receptor Alpha (PPARα) is involved
  2055. Loss of APOO (MIC26) aggravates obesity-related whitening of brown adipose tissue via PPARα-mediated functional interplay between mitochondria and …
  2056. Zi Shen Wan Fang regulates kynurenine metabolism to alleviate diabetes-associated cognitive impairment via activating the skeletal muscle PGC1α-PPARα signaling
  2057. Enhancement of fear learning in PPARα knockout mice
  2058. Gut‐specific inhibition of PPARα as a novel approach of NAFLD treatment
  2059. Nanotized PPARα Overexpression Targeted to Hypertrophied Myocardium Improves Cardiac Function by Attenuating the p53-GSK3β-Mediated Mitochondrial Death …
  2060. Torularhodin alleviates hepatic dyslipidemia and inflammations in high-fat diet-induced obese mice via PPARα signaling pathway
  2061. Alternate-day fasting alleviates high fat diet induced non-alcoholic fatty liver disease through controlling PPARα/Fgf21 signaling
  2062. Apigenin Alleviates Liver Fibrosis by Inhibiting Hepatic Stellate Cell Activation and Autophagy via TGF-β1/Smad3 and p38/PPARα Pathways
  2063. Diminished Hepatocarcinogenesis by a Potent, High-Affinity Human PPARα Agonist in PPARA-Humanized Mice
  2064. CEPT1-mediated phospholipogenesis regulates endothelial cell function and ischemia-induced angiogenesis through PPARα
  2065. Proanthocyanidin Alleviates Liver Ischemia/Reperfusion Injury by Suppressing Autophagy and Apoptosis via the PPARα/PGC1α Signaling Pathway
  2066. … barbarum polysaccharide combined with aerobic exercise ameliorates high-fat-induced nonalcoholic steatohepatitis via AMPK/PPARα/PGC-1α pathway
  2067. Dietary Piperine Suppresses Obesity-Associated Breast Cancer Growth and Metastasis by Regulating the miR-181c-3p/PPARα Axis
  2068. N‐glycosylation of CREBH improves lipid metabolism and attenuates lipotoxicity in NAFLD by modulating PPARα and SCD‐1
  2069. Bilirubin: a ligand of the PPARα nuclear receptor
  2070. Fenofibrate suppresses corneal neovascularization by regulating lipid metabolism through PPARα signaling pathway
  2071. PPARα gene is a diagnostic and prognostic biomarker in clear cell renal cell carcinoma by integrated bioinformatics analysis
  2072. Puerarin inhibits apoptosis and inflammation in myocardial cells via PPARα expression in rats with chronic heart failure
  2073. Fenofibrate rescues diabetes-related impairment of ischemia-mediated angiogenesis by PPARα-independent modulation of thioredoxin-interacting protein
  2074. Activation of PPARα by fenofibrate attenuates the effect of local heart high dose irradiation on the mouse cardiac proteome
  2075. Taurine protected As2O3-induced the activation of hepatic stellate cells through inhibiting PPARα-autophagy pathway
  2076. Diethyldithiocarbamate inhibits the activation of hepatic stellate cells via PPARα/FABP1 in mice with non-alcoholic steatohepatitis
  2077. Synthesis and biological studies of “Polycerasoidol” and “trans-δ-Tocotrienolic acid” derivatives as PPARα and/or PPARγ agonists
  2078. Luteolin Pretreatment Attenuates Hepatic Ischemia-Reperfusion Injury in Mice by Inhibiting Inflammation, Autophagy, and Apoptosis via the ERK/PPARα …
  2079. The Effects of New Selective PPARα Agonist CP775146 on Systematic Lipid Metabolism in Obese Mice and Its Potential Mechanism
  2080. Oroxylin A ameliorates AKI-to-CKD transition through maintaining PPARα-BNIP3 signaling-mediated mitochondrial homeostasis
  2081. … extract prevents hepatic steatosis and liver damage in T2DM rats by hypoglycemic, insulin-sensitizing, antioxidant effects, and upregulation of PPARα
  2082. Pdcd4 promotes lipid deposition by attenuating PPARα-mediated fatty acid oxidation in hepatocytes
  2083. PPARα mediates night neon light-induced weight gain: role of lipid homeostasis
  2084. … effects of n3-polyunsaturated fatty acids against non-alcoholic fatty liver disease in diabetic rats through the FOXO1/PPARα/GABARAPL1 signalling pathway
  2085. Pemafibrate pretreatment attenuates apoptosis and autophagy during hepatic ischemia-reperfusion injury by modulating JAK2/STAT3β/PPARα pathway
  2086. Polyphenols extracted from Shanxi‐aged vinegar exert hypolipidemic effects on OA‐induced HepG2 cells via the PPARα‐LXRα‐ABCA1 pathway
  2087. Down-regulation of hepatic CLOCK by PPARα is involved in inhibition of NAFLD
  2088. Fenofibrate promotes PPARα-targeted recovery of the intestinal epithelial barrier at the host-microbe interface in dogs with diabetes mellitus
  2089. … -rich extract from Sophora alopecuroides L. in HFD-and STZ-induced diabetic mice through PKC/GLUT4 pathway and regulating PPARα and PPARγ expression
  2090. Xyloketal B reverses nutritional hepatic steatosis, steatohepatitis, and liver fibrosis through activation of the PPARα/PGC1α signaling pathway
  2091. The HIF-2α/PPARα pathway is essential for liraglutide-alleviated, lipid-induced hepatic steatosis
  2092. PPARα Agonism Enhances Immune Response to Radiotherapy while Dietary Oleic Acid Results in Counteraction
  2093. … -glutamyl carboxylated Gas6 mediates the beneficial effect of vitamin K on lowering hyperlipidemia via regulating the AMPK/SREBP1/PPARα signaling cascade of …
  2094. In vivo liposomal delivery of PPARα/γ dual agonist tesaglitazar in a model of obesity enriches macrophage targeting and limits liver and kidney drug effects
  2095. PPARα-dependent effects of palmitoylethanolamide against retinal neovascularization and fibrosis
  2096. Eicosanoid-activated PPARα inhibits NFκB-dependent bacterial clearance during post-influenza superinfection
  2097. Royal Jelly and Chlorella vulgaris Mitigate Gibberellic Acid-Induced Cytogenotoxicity and Hepatotoxicity in Rats via Modulation of the PPARα/AP-1 Signaling …
  2098. Activation of PXR, CAR and PPARα by pyrethroid pesticides and the effect of metabolism by rat liver microsomes
  2099. PPARα-independent effects of nitrate supplementation on skeletal muscle metabolism in hypoxia
  2100. Diallyl biphenyl-type neolignans have a pharmacophore of PPARα/γ dual modulators
  2101. Discovery of new and highly effective quadruple FFA1 and PPARα/γ/δ agonists as potential anti-fatty liver agents
  2102. Pharmacological blockade of PPARα exacerbates inflammatory pain-related impairment of spatial memory in rats
  2103. PPARα/γ synergism activates UCP1-dependent and-independent thermogenesis and improves mitochondrial dynamics in the beige adipocytes of high-fat fed mice
  2104. Pinocembrin ameliorates acute liver failure via activating the Sirt1/PPARα pathway in vitro and in vivo
  2105. Phenylsulfonimide PPARα Antagonists enhance nrf2 activation and promote oxidative stress-induced apoptosis/pyroptosis in MCF7 breast cancer cells
  2106. Periostin contributes to renal and cardiac dysfunction in rats with chronic kidney disease: Reduction of PPARα
  2107. Upregulation of KLF14 expression attenuates kidney fibrosis by inducing PPARα-mediated fatty acid oxidation
  2108. Mitochondrial dysfunction and endoplasmic reticulum stress induced by activation of PPARα leaded testicular to apoptosis in SD rats explored to di-(2 …
  2109. Bixin Attenuates High-Fat Diet-Caused Liver Steatosis and Inflammatory Injury through Nrf2/PPARα Signals
  2110. Beta-caryophyllene inhibits cocaine addiction-related behavior by activation of PPARα and PPARγ: repurposing a FDA-approved food additive for cocaine use …
  2111. Potent and PPARα-independent anti-proliferative action of the hypolipidemic drug fenofibrate in VEGF-dependent angiosarcomas in vitro
  2112. SUMOylation of SIRT1 activating PGC-1α/PPARα pathway mediates the protective effect of LncRNA-MHRT in cardiac hypertrophy
  2113. NPY1R-targeted peptide-mediated delivery of a dual PPARα/γ agonist to adipocytes enhances adipogenesis and prevents diabetes progression
  2114. In vitro and in vivo study of the pathogenic role of PPARα in experimental periodontitis
  2115. The effect of fenofibrate, a PPARα activator on toll-like receptor-4 signal transduction in melanoma both in vitro and in vivo
  2116. Protective effects of bariatric surgery on kidney functions by inhibiting oxidative stress responses through activating PPARα in rats with diabetes
  2117. SMP30-mediated synthesis of vitamin C activates the liver PPARα/FGF21 axis to regulate thermogenesis in mice
  2118. Concomitant PPARα and FXR activation as a putative mechanism of NASH improvement after gastric bypass surgery: a GEO datasets analysis
  2119. Hepatocyte-secreted autotaxin exacerbates nonalcoholic fatty liver disease through autocrine inhibition of the PPARα/FGF21 axis
  2120. Oleoylethanolamide stabilizes atherosclerotic plaque through regulating macrophage polarization via AMPK-PPARα pathway
  2121. Luteolin mitigates diabetic dyslipidemia in rats by modulating ACAT-2, PPARα, SREBP-2 proteins, and oxidative stress
  2122. Formononetin promotes fatty acid β-oxidation to treat non-alcoholic steatohepatitis through SIRT1/PGC-1α/PPARα pathway
  2123. Anti-influenza A Virus Effects and Mechanisms of Emodin and Its Analogs via Regulating PPARα/γ-AMPK-SIRT1 Pathway and Fatty Acid Metabolism
  2124. CDKN2A/p16INK4a suppresses hepatic fatty acid oxidation through the AMPKα2-SIRT1-PPARα signaling pathway
  2125. Exposure to short-chain chlorinated paraffins inhibited PPARα-mediated fatty acid oxidation and stimulated aerobic glycolysis in vitro in human cells
  2126. PPARα alleviates inflammation via inhibiting NF-κB/Rel pathway in Vibrio splendidus challenged Apostichopus japonicus
  2127. Early microRNA indicators of PPARα pathway activation in the liver
  2128. The ubiquitin-like modifier FAT10 is induced in MASLD and impairs the lipid-regulatory activity of PPARα
  2129. PPARα agonist WY-14,643 induces the PLA2/COX-2/ACOX1 pathway to enhance peroxisomal lipid metabolism and ameliorate alcoholic fatty liver in mice
  2130. FOXO1 represses PPARα-mediated induction of FGF21 gene expression
  2131. … , a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), lowers serum triglyceride levels by targeting hepatic PPARα in mice
  2132. The effects of resveratrol supplementation on PPARα, p16, p53, p21 gene expressions, and sCD163/sTWEAK ratio in patients with type 2 diabetes mellitus: A …
  2133. Profound modification of fatty acid profile and endocannabinoid-related mediators in PPARα agonist fenofibrate-treated mice
  2134. Lanzhang Granules Ameliorate Nonalcoholic Fatty Liver Disease by Regulating the PPARα Signaling Pathway
  2135. CAR and PPARα do not perform liquid-liquid phase separation in cells
  2136. Two antibacterial and PPARα/γ-agonistic unsaturated keto fatty acids from a coral-associated actinomycete of the genus Micrococcus
  2137. … -to-subcutaneous fat ratio independently predicts the prognosis of locally advanced gastric cancer—–highlighting the role of adiponectin receptors and PPARα, β/δ, ɤ
  2138. PPARα activator irbesartan suppresses the proliferation of endometrial carcinoma cells via SREBP1 and ARID1A
  2139. Overexpression of salusin‑α upregulates AdipoR2 and activates the PPARα/ApoA5/SREBP‑1c pathway to inhibit lipid synthesis in HepG2 cells
  2140. The anti-aging effect of velvet antler polypeptide is dependent on modulation of the gut microbiota and regulation of the PPARα/APOE4 pathway
  2141. Sulfonimide and amide derivatives as novel PPARα antagonists: Synthesis, antiproliferative activity, and docking studies
  2142. Common Alterations in Parallel Metabolomic Profiling of Serum and Spinal Cord and Mechanistic Studies on Neuropathic Pain following PPARα Administration
  2143. Deficiency of telomere-associated repressor activator protein 1 precipitates cardiac aging in mice via p53/PPARα signaling
  2144. A novel selective PPARα modulator, pemafibrate promotes ischemia-induced revascularization through the eNOS-dependent mechanisms
  2145. Effect of CAPE-pNO2 against type 2 diabetes mellitus via the AMPK/GLUT4/GSK3β/PPARα pathway in HFD/STZ-induced diabetic mice
  2146. Atherosclerosis plaque reduction by lycopene is mediated by increased energy expenditure through AMPK and PPARα in ApoE KO mice fed with a high fat …
  2147. Dual PPARα/γ agonist aleglitazar confers stroke protection in a model of mild focal brain ischemia in mice
  2148. Staphylococcus aureus oleate hydratase produces ligands that activate host PPARα
  2149. Ficus carica L. Attenuates Denervated Skeletal Muscle Atrophy via PPARα/NF-κB Pathway
  2150. Hepatic Ago2 regulates PPARα for oxidative metabolism linked to glycemic control in obesity and post bariatric surgery
  2151. Dapagliflozin mediates Plin5/PPARα signaling axis to attenuate cardiac hypertrophy
  2152. Icariin ameliorates endothelial dysfunction in type 1 diabetic rats by suppressing ER stress via the PPARα/Sirt1/AMPKα pathway
  2153. PAQR9 regulates hepatic ketogenesis and fatty acid oxidation during fasting by modulating protein stability of PPARα
  2154. Design and synthesis of novel quinazolinone‐based fibrates as PPARα agonists with antihyperlipidemic activity
  2155. Downregulation of PPARα during experimental left ventricular hypertrophy is critically dependent on Nox2 NADPH oxidase signalling
  2156. PPARα activation stimulates autophagic flux through lipid catabolism-independent route
  2157. Depdc5 deficiency exacerbates alcohol-induced hepatic steatosis via suppression of PPARα pathway
  2158. PPARα/γ signaling pathways are involved in Chlamydia pneumoniae-induced foam cell formation via upregulation of SR-A1 and ACAT1 and downregulation of …
  2159. PRDX6 Promotes Fatty Acid Oxidation via PLA2-Dependent PPARα Activation in Rats Fed High-Fat Diet
  2160. PPARα activation promotes liver progenitor cell-mediated liver regeneration by suppressing YAP signaling in zebrafish
  2161. Low-dose mono (2-ethylhexyl) phthalate promotes ovarian cancer development through PPARα-dependent PI3K/Akt/NF-κB pathway
  2162. shRNA‐mediated PPARα knockdown in human glioma stem cells reduces in vitro proliferation and inhibits orthotopic xenograft tumour growth
  2163. The role of PPARα in autosomal dominant polycystic kidney disease
  2164. PPARα Senses Bisphenol S to Trigger EP300-Mediated Autophagy Blockage and Hepatic Steatosis
  2165. Bcl-2 inhibition combined with PPARα activation synergistically targets leukemic stem cell-like cells in acute myeloid leukemia
  2166. TRPV1 activation inhibits phenotypic switching and oxidative stress in vascular smooth muscle cells by upregulating PPARα
  2167. ABCC6 knockdown fuels cell proliferation by regulating PPARα in hepatocellular carcinoma
  2168. Fish oil and chicoric acid combination protects better against palmitate-induced lipid accumulation via regulating AMPK-mediated SREBP-1/FAS and PPARα/UCP2 …
  2169. Phytanic acid activates PPARα to promote beige adipogenic differentiation of preadipocytes
  2170. Attenuation of high-fat diet-induced fatty liver through PPARα activation by stevioside
  2171. The impact of hepatocyte-specific deletion of hypoxia-inducible factors on the development of polymicrobial sepsis with focus on GR and PPARα function
  2172. Di-2-ethylhexyl phthalate (DEHP) induced lipid metabolism disorder in liver via activating the LXR/SREBP-1c/PPARα/γ and NF-κB signaling pathway
  2173. NPRA promotes fatty acid metabolism and proliferation of gastric cancer cells by binding to PPARα
  2174. The reversal of PXR or PPARα activation-induced hepatomegaly
  2175. Deletion of fatty acid transport protein 2 (FATP2) in the mouse liver changes the metabolic landscape by increasing the expression of PPARα-regulated genes
  2176. Oleoylethanolamide Protects against Acute Ischemic Stroke by Promoting PPARα-Mediated Microglia/Macrophage M2 Polarization
  2177. Multi-omics analysis revealed NMBA induced esophageal carcinoma tumorigenesis via regulating PPARα signaling pathway
  2178. Upregulation of miR-181a impairs lipid metabolism by targeting PPARα expression in nonalcoholic fatty liver disease
  2179. LncRNA H19/microRNA-675/PPARα axis regulates liver cell injury and energy metabolism remodelling induced by hepatitis BX protein via Akt/mTOR signalling
  2180. Gene expression profiling reveals that PXR activation inhibits hepatic PPARα activity and decreases FGF21 secretion in male C57BL6/J mice
  2181. Highly selective PPARα (peroxisome proliferator‐activated receptor α) agonist Pemafibrate inhibits stent inflammation and restenosis assessed by multimodality …
  2182. Discovery of novel dual PPARα/δ agonists based on benzimidazole scaffold for the treatment of non-alcoholic fatty liver disease
  2183. Verbenalin attenuates hepatic damage and mitochondrial dysfunction in alcohol-associated steatohepatitis by regulating MDMX/PPARα-mediated ferroptosis
  2184. … of a phenolic-rich extract from Hypericum attenuatum Choisy in KK-Ay mice mediated through AMPK/PI3K/Akt/GSK3β signaling and GLUT4, PPARγ, and PPARα …
  2185. Comparison of transcriptomic profiles between HFPO-DA and prototypical PPARα, PPARγ, and cytotoxic agents in mouse, rat, and pooled human hepatocytes
  2186. PPARα agonist alleviates tumor growth and chemo-resistance associated with the inhibition of glucose metabolic pathway
  2187. Melatonin Ameliorates Cisplatin-Induced Renal Tubular Epithelial Cell Damage through PPARα/FAO Regulation
  2188. N-acylethanolamine regulation of TLR3-induced hyperthermia and neuroinflammatory gene expression: A role for PPARα
  2189. … the role of RNA-binding protein QKI 5 in the synthesis of triglycerides in non-alcoholic fatty liver disease mice via the PPARα/FoxO1 signaling pathway
  2190. L-theanine regulates the immune function of SD rats fed high-protein diets through the FABP5/IL-6/STAT3/PPARα pathway
  2191. Fenofibrate mediated activation of PPARα negatively regulates trophoblast invasion
  2192. Clofibrate, a peroxisome proliferator–activated receptor-alpha (PPARα) agonist, and its molecular mechanisms of action against sodium fluoride–induced toxicity
  2193. Effect of potential probiotic Leuconostoc mesenteroides FB111 in prevention of cholesterol absorption by modulating NPC1L1/PPARα/SREBP-2 pathways in …
  2194. PPARα regulates the expression of human arylacetamide deacetylase involved in drug hydrolysis and lipid metabolism
  2195. Inhibition of PCSK9 prevents and alleviates cholesterol gallstones through PPARα-mediated CYP7A1 activation
  2196. PPARα/RXRα downregulates amino acid catabolism in the liver via interaction with HNF4α promoting its proteasomal degradation
  2197. Hepatic PPARα Is destabilized by SIRT1 deacetylase in undernourished male mice
  2198. Curcumin promotes AApoAII amyloidosis and peroxisome proliferation in mice by activating the PPARα signaling pathway
  2199. Phytochemical wedelolactone reverses obesity by prompting adipose browning through SIRT1/AMPK/PPARα pathway via targeting nicotinamide N-methyltransferase
  2200. Dietary Conjugated Linoleic Acid Modulates the Hepatic Circadian Clock Program via PPARα/REV-ERBα-Mediated Chromatin Modification in Mice
  2201. … ‐Trp Ameliorates Hepatic Steatosis and Oxidative Stress in Free Fatty Acids‐Treated HepG2 Cells and High‐Fat Diet‐Induced NAFLD Mice by Activating the PPARα …
  2202. Marein ameliorates Ang II/hypoxia‐induced abnormal glucolipid metabolism by modulating the HIF‐1α/PPARα/γ pathway in H9c2 cells
  2203. Retinoic Acid–PPARα Mediates β-Carotene Resistance to Placental Dysfunction Induced by Deoxynivalenol
  2204. CXCL6 promotes the progression of NAFLD through regulation of PPARα
  2205. Reactivation of PPARα alleviates myocardial lipid accumulation and cardiac dysfunction by improving fatty acid β-oxidation in Dsg2-deficient arrhythmogenic …
  2206. PPARα and PPARγ signaling is enhanced in the brain of the naked mole-rat, a mammal that shows intrinsic neuroprotection from oxygen deprivation
  2207. Oleic acid stimulates cell proliferation and BRD4–L-MYC-dependent glucose transporter transcription through PPARα activation in ovarian cancer cells
  2208. Reversal of diet-induced hepatic steatosis by peripheral CB1 receptor blockade in mice is p53/miRNA-22/SIRT1/PPARα dependent
  2209. Design and Synthesis of Novel Indole Ethylamine Derivatives as a Lipid Metabolism Regulator Targeting PPARα/CPT1 in AML12 Cells
  2210. Discovery of potent and selective PPARα/δ dual antagonists and initial biological studies
  2211. Distinct differences in lipoprotein particle number evaluation between GP-HPLC and NMR: Analysis in dyslipidemic patients administered a selective PPARα …
  2212. Gentiopicroside improves non-alcoholic steatohepatitis by activating PPARα and suppressing HIF1
  2213. … saponins from Panax japonicus attenuate acute alcoholic liver oxidative stress and hepatosteatosis by p62-related Nrf2 pathway and AMPK-ACC/PPARα axis in vivo …
  2214. The omega-3 hydroxy fatty acid 7(S)-HDHA is a high-affinity PPARα ligand that regulates brain neuronal morphology
  2215. Regulation of hepatic circadian metabolism by the E3 ubiquitin ligase HRD1-controlled CREBH/PPARα transcriptional program
  2216. PPARα agonist and metformin co-treatment ameliorates NASH in mice induced by a choline-deficient, amino acid-defined diet with 45% fat
  2217. PPARα is involved in high-fat diet-induced risk avoidance impairment via the regulation of hippocampal BDNF
  2218. Hepatic carboxylesterases are differentially regulated in PPARα-null mice treated with perfluorooctanoic acid
  2219. Valproic acid-induced upregulation of multidrug efflux transporter ABCG2/BCRP via PPARα-dependent mechanism in human brain endothelial cells
  2220. Vitamin D3 alleviates nonalcoholic fatty liver disease in rats by inhibiting hepatic oxidative stress and inflammation via the SREBP-1-c/PPARα-NF-κB/IR-S2 …
  2221. The class 3 PI3K coordinates autophagy and mitochondrial lipid catabolism by controlling nuclear receptor PPARα
  2222. Peroxisome proliferator–activated receptor α (PPARα)–dependent regulation of fibroblast growth factor 23 (FGF23)
  2223. Treadmill workout activates PPARα in the hippocampus to upregulate ADAM10, decrease plaques and improve cognitive functions in 5XFAD mouse model of …
  2224. Enhancement of PPARα-Inhibited Leucine Metabolism-Stimulated β-Casein Synthesis and Fatty Acid Synthesis in Primary Bovine Mammary Epithelial Cells
  2225. PPARα/δ dual agonist H11 alleviates diabetic kidney injury by improving the metabolic disorders of tubular epithelial cells
  2226. PPARα and γ activation effects of new nor-triterpenoidal saponins from the aerial parts of Anabasis articulata
  2227. The lncRNA H19/miR-675 axis regulates myocardial ischemic and reperfusion injury by targeting PPARα
  2228. Peroxisome Proliferator-Activated Receptor-α (PPARα) Expression in a Clinical Population of Pakistani Patients with Type 2 Diabetes and Dyslipidemia
  2229. Prevotellaceae produces butyrate to alleviate PD-1/PD-L1 inhibitor-related cardiotoxicity via PPARα-CYP4X1 axis in colonic macrophages
  2230. Rosa rugosa flavonoids exhibited PPARα agonist-like effects on genetic severe hypertriglyceridemia of mice
  2231. PPARα Agonist WY-14643 Relieves Neuropathic Pain through SIRT1-Mediated Deacetylation of NF-κB
  2232. Bile acid metabolism disorder mediates hepatotoxicity of Nafion by-product 2 and perfluorooctane sulfonate in male PPARα-KO mice
  2233. Identification of a hormone response element that mediates suppression of APOF by LXR and PPARα agonists
  2234. The effects of sodium butyrate supplementation on the expression levels of PGC-1α, PPARα, and UCP-1 genes, serum level of GLP-1, metabolic parameters …
  2235. … Effect of γ-Oryzanol (OZ) and N-Acetylcysteine (NAC) against Experimentally Induced NAFLD in Rats Entails Hypoglycemic, Antioxidant, and PPARα …
  2236. Ablation of Selenbp1 alters lipid metabolism via the PPARα pathway in mouse kidney
  2237. In silico identification and experimental validation of (−)-muqubilin A, a marine norterpene peroxide, as PPARα/γ-RXRα agonist and RARα positive allosteric …
  2238. An association between PPARα-L162V polymorphism and increased plasma LDL cholesterol levels after risperidone treatment
  2239. Therapeutic potential of PPARα agonist in ligature-induced experimental periodontitis
  2240. … bile acids and activates hepatic farnesoid X receptor (FXR) but requires intact peroxisome proliferator activator receptor alpha (PPARα) signaling to significantly …
  2241. Omega-6 DPA and its 12-lipoxygenase–oxidized lipids regulate platelet reactivity in a nongenomic PPARα-dependent manner
  2242. Hippocampal PPARα plays a role in the pharmacological mechanism of vortioxetine, a multimodal-acting antidepressant
  2243. The KRAB Domain‐Containing Protein ZFP961 Represses Adipose Thermogenesis and Energy Expenditure through Interaction with PPARα
  2244. RAE1 promotes nitrosamine-induced malignant transformation of human esophageal epithelial cells through PPARα-mediated lipid metabolism
  2245. Discovery of novel peroxisome proliferator-activated receptor α (PPARα) agonists by virtual screening and biological evaluation
  2246. Development of an analytical platform for the affinity screening of natural extracts by SEC-MS towards PPARα and PPARγ receptors
  2247. Expression of cannabinoid (CB1 and CB2) and cannabinoid-related receptors (TRPV1, GPR55, and PPARα) in the synovial membrane of the horse …
  2248. LncRNA MALAT1 regulates proliferation and apoptosis of vascular smooth muscle cells by targeting miRNA-124-3p/PPARα axis.
  2249. Treatment with the PPARα agonist fenofibrate improves the efficacy of CD8+ T cell therapy for melanoma
  2250. High-fat diet induces fibrosis in mice lacking CYP2A5 and PPARα: a new model for steatohepatitis-associated fibrosis
  2251. Hepatic Krüppel-like factor 16 (KLF16) targets PPARα to improve steatohepatitis and insulin resistance
  2252. The lack of PPARα exacerbated the progression of non-alcoholic steatohepatitis in mice with spleen deficiency syndrome by triggering an inflammatory …
  2253. Paternal hyperglycemia induces transgenerational inheritance of susceptibility to hepatic steatosis in rats involving altered methylation on PPARα promoter
  2254. Crosstalk between EP2 and PPARα modulates hypoxic signaling and myopia development in Guinea pigs
  2255. Hippocampal PPARα is involved in the antidepressant-like effects of venlafaxine in mice
  2256. VX-765 inhibits pyroptosis and reduces inflammation to prevent acute liver failure by upregulating PPARα expression
  2257. SIRT6 activates PPARα to improve doxorubicin-induced myocardial cell aging and damage
  2258. CD24 negativity reprograms mitochondrial metabolism to PPARα and NF-κB-driven fatty acid β-oxidation in triple-negative breast cancer
  2259. WY14643 increases herpesvirus replication and inhibits IFNβ production independently of PPARα expression
  2260. The tissue‐specific metabolic effects of the PPARα agonist ciprofibrate in insulin‐resistant male individuals: a double‐blind, randomized, placebo‐controlled crossover …
  2261. Lemon balm extract ALS-L1023 regulates obesity and improves insulin sensitivity via activation of hepatic PPARα in high-fat diet-fed obese C57BL/6J mice
  2262. Phenolic Acids from Fructus Chebulae Immaturus Alleviate Intestinal Ischemia-Reperfusion Injury in Mice through the PPARα/NF-κB Pathway
  2263. Computational investigation reveals Picrasidine C as selective PPARα lead: binding pattern, selectivity mechanism and ADME/tox profile
  2264. PPARα activation by fenofibrate ameliorates radiation‐induced skin injury.
  2265. Anti-Diabetic Effect of a Shihunine-Rich Extract of Dendrobium loddigesii on 3T3-L1 Cells and db/db Mice by Up-Regulating AMPK–GLUT4–PPARα
  2266. Inflammation-induced nitric oxide suppresses PPARα expression and function via downregulation of Sp1 transcriptional activity in adipocytes
  2267. The anti-hyperlipidemic effects of Poria cocos (Schw.) Wolf extract: Modulating cholesterol homeostasis in hepatocytes via PPARα pathway
  2268. PPARα, PPARδ or both–that is the question!
  2269. Silibinin-induced autophagy mediated by PPARα-sirt1-AMPK pathway participated in the regulation of type I collagen-enhanced migration in murine 3T3-L1 …
  2270. Cinnamic acid, a natural plant compound, exhibits neuroprotection in a mouse model of Sandhoff disease via PPARα
  2271. Promoting the hippocampal PPARα expression participates in the antidepressant mechanism of reboxetine, a selective norepinephrine reuptake inhibitor
  2272. Structurally Diverse Metabolites from the Ophiorrhiza japonica Bl. and Their Antioxidant Activities In Vitro and PPARα Agonistic Activities In Silico
  2273. PPARα agonist relieves spinal cord injury in rats by activating Nrf2/HO-1 via the Raf-1/MEK/ERK pathway
  2274. … d alleviates high-fat-diet induced hepatic steatosis in hybrid grouper (Epinephelus lanceolatus♂× Epinephelus fuscoguttatus♀) by targeting AMPK/PPARα pathway
  2275. The E3 ligase Trim63 promotes podocyte injury and proteinuria by targeting PPARα to inhibit fatty acid oxidation
  2276. Novel dual PPARα/γ agonists protect against liver steatosis and improve insulin sensitivity while avoiding side effects
  2277. Discovery of novel modulators for the PPARα (peroxisome proliferator activated receptor α): Potential therapies for nonalcoholic fatty liver disease
  2278. Klf4-Sirt3/PPARα-Lcad pathway contributes to high phosphate-induced lipid degradation
  2279. Oleic acid-induced perilipin 5 expression and lipid droplets formation are regulated by the PI3K/PPARα pathway in HepG2 cells
  2280. Long Noncoding RNA ZFAS1 Protects HK-2 Cells against Sepsis‐Induced Injury through Targeting the miR3723p/PPARα Axis
  2281. PPARα polymorphisms association with total cholesterol and LDL-C levels in a Mexican population.
  2282. Preventive effects of total flavonoid C-glycosides from Abrus mollis on nonalcoholic fatty liver disease through activating the PPARα signaling pathway
  2283. Design, synthesis, and biological evaluation of deuterated indolepropionic acid derivatives as novel long-acting pan PPARα/γ/δ agonists
  2284. ACACA reduces lipid accumulation through dual regulation of lipid metabolism and mitochondrial function via AMPK-PPARα-CPT1A axis
  2285. Huoxue Huatan Decoction Ameliorates Myocardial Ischemia/Reperfusion Injury in Hyperlipidemic Rats via PGC-1α–PPARα and PGC-1α–NRF1–mtTFA …
  2286. Soyasapogenol C from Fermented Soybean (Glycine Max) Acting as a Novel AMPK/PPARα Dual Activator Ameliorates Hepatic Steatosis: A Novel SANDA …
  2287. Stevia and Stevioside Attenuate Liver Steatosis through PPARα-Mediated Lipophagy in db/db Mice Hepatocytes
  2288. … pericarp extract, suppresses tumor proliferation and angiogenesis in a mouse model of melanoma: possible involvement of PPARα and PPARγ pathways
  2289. Overexpression of microRNA-21 mediates Ang II-induced renal fibrosis by activating the TGF-β1/Smad3 pathway via suppressing PPARα
  2290. Metformin mitigates renal dysfunction in obese insulin-resistant rats via activation of the AMPK/PPARα pathway
  2291. Discovery of 4-benzyloxy and 4-(2-phenylethoxy) chalcone fibrate hybrids as novel PPARα agonists with anti-hyperlipidemic and antioxidant activities: Design …
  2292. LncRNA HOTAIR regulates the proliferation and apoptosis of vascular smooth muscle cells through targeting miRNA-130b-3p/PPARα axis.
  2293. HypERlnc attenuates angiotensin II‐induced cardiomyocyte hypertrophy via promoting SIRT1 SUMOylation‐mediated activation of PGC‐1α/PPARα pathway in AC16 …
  2294. When Activator and Inhibitor of PPARα Do the Same: Consequence for Differentiation of Human Intestinal Cells
  2295. Osteocalcin activates lipophagy via the ADPN-AMPK/PPARα-mTOR signaling pathway in chicken embryonic hepatocyte
  2296. The PPARα agonist fenofibrate reduces the cytokine imbalance in a maternal immune activation model of schizophrenia
  2297. The role of Huidouba in regulating skeletal muscle metabolic disorders in prediabetic mice through AMPK/PGC-1α/PPARα pathway
  2298. Fenofibrate ameliorates letrozole-induced polycystic ovary in rats via modulation of PPARα and TNFα/CD95 pathway
  2299. The PPARα/CYP4A14 bile acid pathway is associated with lipid metabolism disorders caused by low birth weight with high-fat diet
  2300. MicroRNA-483-5p inhibits hepatocellular carcinoma cell proliferation, cell steatosis, and fibrosis by targeting PPARα and TIMP2
  2301. Different Coactivator Recruitment to Human PPARα/δ/γ Ligand-Binding Domains by Eight PPAR Agonists to Treat Nonalcoholic Fatty Liver Disease
  2302. FMO1 Promotes Nonalcoholic Fatty Liver Disease Progression by Regulating PPARα Activation and Inducing Ferroptosis.
  2303. Basal Autophagy Is Necessary for A Pharmacologic PPARα Transactivation
  2304. PPARα plays an important role in the migration activity, and the expression of CYP2S1 and CYP1B1 in chrysin-treated HCT116 cells
  2305. Hypoxic preconditioning accelerates the healing of ischemic intestinal injury by activating HIF-1α/PPARα pathway-mediated fatty acid oxidation
  2306. N-Palmitoylethanolamide exerts antidepressant-like effects in rats: involvement of PPARα pathway in the hippocampus
  2307. Virtual identification of novel PPARα/γ dual agonists by 3D-QSAR, molecule docking and molecular dynamics studies
  2308. Tripartite motif-containing 46 promotes viability and inhibits apoptosis of osteosarcoma cells by activating NF-κB signaling through ubiquitination of PPARα
  2309. Pemafibrate, a novel selective PPARα modulator, attenuates tamoxifen-induced fatty liver disease
  2310. ZNF300 stimulates fatty acid oxidation and alleviates hepatosteatosis through regulating PPARα
  2311. Oleoylethanolamide ameliorates motor dysfunction through PPARα‐mediates oligodendrocyte differentiation and white matter integrity after ischemic stroke
  2312. Sodium butyrate alleviates free fatty acid-induced steatosis in primary chicken hepatocytes via the AMPK/PPARα pathway
  2313. Chaetomorpha linum polysaccharides alleviate NAFLD in mice by enhancing the PPARα/CPT-1/MCAD signaling
  2314. Molecular modelling, synthesis, and biological evaluations of a 3, 5-disubstituted isoxazole fatty acid analogue as a PPARα-selective agonist
  2315. Basal PPARα inhibits bile acid metabolism adaptation in chronic cholestatic model induced by α-naphthylisothiocyanate
  2316. Simvastatin affects the PPARα signaling pathway and causes oxidative stress and embryonic development interference in Mugilogobius abei
  2317. Synthesis of benzopyran derivatives as PPARα and/or PPARγ activators
  2318. Preparation of co-crystals of human PPARα-LBD and ligand for high-resolution X-ray crystallography
  2319. Structural Basis for PPARs Activation by The Dual PPARα/γ Agonist Sanguinarine: A Unique Mode of Ligand Recognition
  2320. HFD-induced TRAF6 upregulation promotes liver cholesterol accumulation and fatty liver development via EZH2-mediated miR-429/PPARα axis
  2321. Uncoupling protein 1 knockout aggravates isoproterenol-induced acute myocardial ischemia via AMPK/mTOR/PPARα pathways in rats
  2322. The natural compounds, Magnolol or Honokiol, promote adipose tissue browning and resist obesity through modulating PPARα/γ activity
  2323. … mechanisms underlying endoplasmic reticulum stress involvement in the development of gestational diabetes mellitus entail the CHOP-PPARα–NF–κB pathway
  2324. Exenatide reduces cardiomyocyte apoptosis by stimulating adiponectin secretion and activating APPL1-AMPK-PPARα axis
  2325. … upregulates fatty acid 2-hydroxylase (FA2H) via PPARα induction: A possible evidence for the cancellation of PPARβ/δ-mediated inhibition of PPARα in MDA-MB-231 …
  2326. Chaihu Guizhi Ganjiang Decoction attenuates nonalcoholic steatohepatitis by enhancing intestinal barrier integrity and ameliorating PPARα mediated lipotoxicity
  2327. Endocannabinoids and endocannabinoid-like compounds modulate hypoxia-induced permeability in CaCo-2 cells via CB1, TRPV1, and PPARα
  2328. Fenofibrate alleviates NAFLD by enhancing the PPARα/PGC-1α signaling pathway coupling mitochondrial function
  2329. Lupeol alleviates autoimmune myocarditis by suppressing macrophage pyroptosis and polarization via PPARα/LACC1/NF-κB signaling pathway
  2330. Inhibition of PPARα target genes during cyclosporine A-induced nephrotoxicity and hepatotoxicity
  2331. WY14643 improves left ventricular myocardial mitochondrial and systolic functions in obese rats under chronic persistent hypoxia via the PPARα pathway
  2332. Comparative study of the effect of 17 parabens on PXR-, CAR-and PPARα-mediated transcriptional activation
  2333. Accumulation of lipid droplets in a novel Bietti crystalline dystrophy zebrafish model with impaired PPARα pathway
  2334. Shen-Shuai-II-Recipe inhibits tubular inflammation by PPARα-mediated fatty acid oxidation to attenuate fibroblast activation in fibrotic kidneys
  2335. Active Ingredient Paeonol of Jijiu Huiyang Decoction Alleviates Isoproterenol-Induced Chronic Heart Failure via the GSK3A/PPARα Pathway
  2336. Engineered Fenofibrate as Oxidation-Sensitive Nanoparticles with ROS Scavenging and PPARα-Activating Bioactivity to Ameliorate Nonalcoholic Fatty Liver Disease
  2337. Alkaloids from the rhizomes of Acorus calamus and their PPARα, PPARγ, and glucokinase-activating activities
  2338. Gardenia fruit and Eucommia leaves combination improves hyperlipidemia and hyperglycemia via pancreatic lipase and AMPK-PPARα and Keap-1-Nrf2-HO …
  2339. The mRNA levels of PPARα, HIF-1α, and VEGF in the liver tissues of rats with alcoholic liver disease
  2340. Dietary supplementation of vitamin E and citric acid could significantly promote the relative expression of PPARα and aconitase genes, concentration of …
  2341. Phthalate Exposure, PPARα Variants, and Neurocognitive Development of Children at Two Years
  2342. Icariside II exerts anti-type 2 diabetic effect by targeting PPARα/γ: Involvement of ROS/NF-κB/IRS1 signaling pathway
  2343. Identification of phytochemicals as putative ligands for the targeted modulation of peroxisome proliferator‐activated receptor α (PPARα) in animals
  2344. Therapeutic Potential of Ginsenoside Rb1-PLGA Nanoparticles for Heart Failure Treatment via the ROS/PPARα/PGC1α Pathway
  2345. PPARα-Mediated positive-feedback loop contributes to cold exposure memory
  2346. Therapeutic role of Artemether in the prevention of hepatic steatosis through miR‐34a‐5p/PPARα pathway
  2347. Exosomes derived from human dermal fibroblasts (HDFn‐Ex) alleviate DNCB‐induced atopic dermatitis (AD) via PPARα
  2348. Salidroside inhibits insulin resistance and hepatic steatosis by downregulating miR-21 and subsequent activation of AMPK and upregulation of PPARα in the liver and …
  2349. The IL-6/STAT signaling pathway and PPARα are involved in mediating the dose-dependent cardioprotective effects of fenofibrate in 5-fluorouracil-induced …
  2350. Lonicerae Japonicae Flos extract and chlorogenic acid attenuates high-fat-diet-induced prediabetes via CTRPs-AdipoRs-AMPK/PPARα axes
  2351. Bromide alleviates fatty acid‐induced lipid accumulation in mouse primary hepatocytes through the activation of PPARα signals
  2352. Gastrodin attenuates lithium-pilocarpine-induced epilepsy by activating AMPK-mediated PPARα in a juvenile rat model
  2353. Dihydromyricetin ameliorates hepatic steatosis and insulin resistance via AMPK/PGC-1α and PPARα-mediated autophagy pathway
  2354. Adiponectin stimulates apolipoprotein a-1 gene expression in Hepg2 cells Via ampk, PPARα, and lxrs signaling mechanisms
  2355. Suppression of Hepatic PPARα in Primary Biliary Cholangitis Is Modulated by MiR-155
  2356. … myocardial damage induced by lipopolysaccharide via the toll-like receptor 4 (TLR4)/Nuclear factor kappa B (NF-κB)/Proliferator-Activated receptor α (PPARα …
  2357. Genistein and Sex Hormone Supplementation Modulated Hepatic PPARα, δ, and γ Subtypes and STAT1 Expressions in a NASH Rat Model with Bilateral …
  2358. Fructose-1, 6-bisphosphatase 1 suppresses PPARα-mediated gene transcription and non-small-cell lung cancer progression
  2359. Research progress of active components of traditional Chinese medicine in treatment of hyperlipidemia by activating PPARα pathway
  2360. Potential natural dual agonist PPARα/γ-induced antidiabetic and antidyslipidemic properties of safrole-free nutmeg seed (Myristica fragrans Houtt) extract
  2361. PrPC promotes endometriosis progression by reprogramming cholesterol metabolism and estrogen biosynthesis of endometrial stromal cells through PPARα …
  2362. … alleviated cognitive impairment and blood‒brain barrier damage in sepsis-associated encephalopathy by regulating ABC efflux transporters in a PPARα …
  2363. Autophagy-dependent increased ADAM10 mature protein induced by TFEB overexpression is mediated through PPARα
  2364. Cholecystokinin Octapeptide Promotes ANP Secretion through Activation of NOX4–PGC-1α–PPARα/PPARγ Signaling in Isolated Beating Rat Atria
  2365. Structural Basis for PPARα Activation by 1H-pyrazolo-[3, 4-b] pyridine Derivatives
  2366. Molecular cloning and structural characterization of PPARα gene from turbot (Scophthalmus maximus) and functional exploration of lipid metabolism in response to …
  2367. … (PEA) reduces postoperative adhesions after experimental strabismus surgery in rabbits by suppressing canonical and non-canonical TGFβ signaling through PPARα
  2368. Transcriptional profiling of drug-induced liver injury biomarkers: Association of hepatic Srebf1/PPARα signaling and crosstalk of thrombin, alcohol dehydrogenase …
  2369. PPARα and PPARγ activation is associated with pleural mesothelioma invasion but therapeutic inhibition is ineffective
  2370. PPARα/γ, adiponectin, and GLUT4 overexpression induced by moronic acid methyl ester influenced glucose and triglyceride levels of experimental diabetic mice
  2371. Telmisartan is the most effective ARB to increase adiponectin via PPARα in adipocytes
  2372. Effect of fenofibrate and selective PPARα modulator (SPPARMα), pemafibrate on KATP channel activity and insulin secretion
  2373. In silico identification of microRNAs targeting the PPARα/γ: promising therapeutics for SARS-CoV‑2 infection
  2374. Evolution of a 4-benzyloxy-benzylamino chemotype to provide efficacious, potent, and isoform selective PPARα agonists as leads for retinal disorders
  2375. Cyanidin Increases the Expression of Mg2+ Transport Carriers Mediated by the Activation of PPARα in Colonic Epithelial MCE301 Cells
  2376. Crataegus aronia prevents high‐fat diet‐induced hepatic steatosis in rats by activating AMPK‐induced suppression of SREBP1 and activation of PPARα
  2377. Osthole inhibits oleic acid/lipopolysaccharide-induced lipid accumulation and inflammatory response through activating PPARα signaling pathway in cultured …
  2378. Garcinia biflavonoid 1 improves lipid metabolism in HepG2 cells via regulating PPARα
  2379. Musclin Mitigates the Attachment of HUVECs to THP-1 Monocytes in Hyperlipidemic Conditions through PPARα/HO-1-Mediated Attenuation of Inflammation
  2380. Functional analysis of Epinephelus coioides peroxisome proliferative–activated receptor α (PPARα): Involvement in response to viral infection
  2381. Hydroxychloroquine Potentiates Apoptosis Induced by PPARα Antagonist in 786-O Clear Cell Renal Cell Carcinoma Cells Associated with Inhibiting …
  2382. Fenofibrate-promoted hepatomegaly and liver regeneration are PPARα-dependent and partially related to the YAP pathway
  2383. MicroRNA-21 Contributes to Acute Liver Injury in LPS-Induced Sepsis Mice by Inhibiting PPARα Expression
  2384. Nitric oxide synthesis stimulated by arachidonic acid accumulation via PPARα in acetylcholine‐stimulated gastric mucous cells
  2385. The 5-lipoxygenase inhibitor zileuton protects pressure overload-induced cardiac remodeling via activating PPARα
  2386. Effects of a selective PPARα modulator, sodium-glucose cotransporter 2 inhibitor, and statin on the myocardial morphology of medaka nonalcoholic fatty liver disease …
  2387. Effects of benzotriazole ultraviolet stabilizers on rat PXR, CAR and PPARα transcriptional activities
  2388. 3, 3′, 5-triiodo-l-thyronine inhibits drug-induced liver injury through activation of PPARα as revealed by network pharmacology and biological experimental …
  2389. Amoxicillin modulates ApoA-I transcription and secretion, predominantly via PPARα transactivation inhibition
  2390. Amelioration of oxidative stress and neuroinflammation by Saroglitazar, a dual PPARα/γ agonist in MES induced epileptic rats
  2391. Mulberry fruit repairs alcoholic liver injury by modulating lipid metabolism and the expression of miR-155 and PPARα in rats
  2392. Selective activation of PPARα maintains thermogenic capacity of beige adipocytes
  2393. Rutaecarpin reduces lipids by DGKθ‐dependent activation of PPARα
  2394. Macrophage angiotensin-converting enzyme (ACE) reduces atherosclerosis by increasing PPARα and fundamentally changing lipid metabolism
  2395. Study on the Mechanism of Estrogen Regulating Endometrial Fibrosis After Mechanical Injury Via MIR-21-5P/PPARα/FAO Axis
  2396. Adverse Outcome Pathway on antagonist binding to PPARα leading to body-weight loss
  2397. The key molecular mechanisms of sini decoction plus ginseng soup to rescue acute liver failure: Regulating PPARα to reduce hepatocyte necroptosis?
  2398. Alcoholic fatty liver is blunted by rFGF21 administration in mice lacking adipose FGFR1: The role of FGF21 in PPARα-mediated regulation of adipose tissue mass
  2399. FABP regulates fatty acid metabolism and oxidative response via PPARα/RXR signaling in Litopenaeus vannamei following environmental exposure of clofibric acid
  2400. Docosahexaenoic acid inhibits TNFα-induced ICAM-1 expression by activating PPARα and autophagy in human endothelial cells
  2401. MicroRNA-144-3p Inhibits Host Lipid Catabolism and Autophagy by Targeting PPARα and ABCA1 During Mycobacterium Tuberculosis Infection
  2402. Peripheral sgp130-mediated trans-signaling blockade induces obesity and insulin resistance in mice via PPARα suppression
  2403. Synthesis of DHA (omega-3 fatty acid): FADS2 gene polymorphisms and regulation by PPARα
  2404. Exploring dual agonists for PPARα/γ receptors using pharmacophore modeling, docking analysis and molecule dynamics simulation
  2405. Synthesis of 2-Prenylated Alkoxylated Benzopyrans by Horner–Wadsworth–Emmons Olefination with PPARα/γ Agonist Activity
  2406. Molecular characterization and tissue distribution of SREBP-1 and PPARα in Onychostoma macrolepis and their mRNA expressions in response to thermal exposure
  2407. Experimental study on the role and mechanism of Allicin in ventricular remodeling through PPARα and PPARγ signaling pathways
  2408. Perilipin 2 Impacts Acute Kidney Injury via Regulation of PPARα
  2409. PDE9 inhibition activates PPARα to stimulate mitochondrial fat metabolism and reduce cardiometabolic syndrome
  2410. C3aR Antagonist Alleviates C3a Induced Tubular Profibrotic Phenotype Transition via Restoring PPARα/CPT-1α Mediated Mitochondrial Fatty Acid Oxidation …
  2411. Studies on novel regulators of the fibroblast growth factor 23 (FGF23) synthesis in bone cells: the impact of p38MAPK, PPARα, and myostatin [kumulative Dissertation]
  2412. Tilianin alleviates lipid deposition and fibrosis in mice with nonalcoholic steatohepatitis by activating the PPARα/Nnat axis
  2413. Triclosan administration to humanized UDP-glucuronosyltransferase 1 neonatal mice induces UGT1A1 through a dependence on PPARα and ATF4
  2414. Downregulation of CPT1A exerts a protective effect in dextran sulfate sodium‐induced ulcerative colitis partially by inhibiting PPARα signaling pathway
  2415. Cheonggukjang-specific component 1, 3-diphenyl-2-propanone as a novel PPARα/γ dual agonist: An in vitro and in silico study
  2416. Identification of a novel regulatory pathway for PPARα by RNA-seq characterization of the endothelial cell lipid peroxidative injury transcriptome
  2417. Effects of a novel selective PPARα modulator, statin, sodium-glucose cotransporter 2 inhibitor, and combinatorial therapy on the liver and vasculature of medaka …
  2418. … -47 induces metabolic dysfunction-associated steatotic liver disease (MASLD) through CD36-mediated increased fatty acid uptake and PPARα-induced abnormal fatty …
  2419. Antiretroviral drug-induced endothelial dysfunction is improved by dual PPARα/γ stimulation in obesity
  2420. Recombinant Humanized IgG1 Antibody Promotes Reverse Cholesterol Transport through FcRn-ERK1/2-PPARα Pathway in Hepatocytes
  2421. Propane-2-sulfonic acid octadec-9-enyl-amide, a novel PPARα/γ dual agonist, attenuates molecular pathological alterations in learning memory in AD mice
  2422. FNDC5 Attenuates Atherosclerotic Plaque Formation and Regulates PPARα/HO-1 in ApoE−/− Mice
  2423. Effects of Individual Amino Acids on PPARα Transactivation, mTORC1 Activation, ApoA-I Transcription and pro-ApoA-I Secretion
  2424. Periostin Acts as a Bridge between Gestational Diabetes Mellitus (GDM) and Chronic Inflammation to Modulate Insulin Resistance by Modulating PPARα/NF-κB/TNF-α …
  2425. Loss of PPARα function promotes epigenetic dysregulation of lipid homeostasis driving ferroptosis and pyroptosis lipotoxicity in metabolic dysfunction associated …
  2426. The hsa-miR-214-3p/ATGL axis regulates aberrant lipolysis to promote acute myeloid leukemia progression via PPARα in vitro
  2427. Gemfibrozil reduces lipid accumulation in SMMC‑7721 cells via the involvement of PPARα and SREBP1
  2428. Association of placental PPARα/γ and miR-27b expression with macrosomia in healthy pregnancy
  2429. Two faces of PPARα/NFκB signaling pathway in inflammatory responses to adipocytes lipolysis in grass carp Ctenopharyngodon idella
  2430. Chrysin attenuates estradiol-induced endometrial hyperplasia in rats via enhancing PPARα activity
  2431. PPARα agonist WY-14,643 induces adipose atrophy and fails to blunt chronic ethanol-induced hepatic fat accumulation in mice lacking adipose FGFR1
  2432. Association of POR and PPARα polymorphisms with risk of anti-tuberculosis drug-induced liver injury in Western Chinese Han population
  2433. Effects of aerobic exercise on PPARα signaling in diabetes rats and its association with PPARγ
  2434. Activation or inhibition of PPARα-mediated fatty acid β-oxidation does not active cardiomyocyte proliferation in normal or infarcted adult mice
  2435. Lipid Messenger Phosphatidylinositol-4, 5-Bisphosphate Is Increased by Both PPARα Activators and Inhibitors: Relevance for Intestinal Cell Differentiation
  2436. Structural development of 1H-pyrazolo-[3, 4-b] pyridine-4-carboxylic acid derivatives as human peroxisome proliferator-activated receptor alpha (PPARα)-selective …
  2437. Cucurbita ficifolia Bouché Regulates the Metabolism of Carbohydrates and Lipids in Liver by Activation of PPARα without Affectation on PPARγ in Vivo and in …
  2438. Combining fecal 16 S rRNA sequencing and spinal cord metabolomics analysis to explain the modulatory effect of PPARα on neuropathic pain
  2439. The mechanism behind BAF60c in myocardial metabolism in rats with heart failure is through the PGC1α-PPARα-mTOR signaling pathway
  2440. Moderate aerobic exercise-induced cytokines changes are disturbed in PPARα knockout mice
  2441. Ror1 promotes PPARα‐mediated fatty acid metabolism in astrocytes
  2442. Atractylenolide II-ameliorated hyperlipidemia in mice by regulating AMPK/PPARα/SREBP-1C signaling pathway
  2443. Dietary lipid supplementation could significantly affect the growth, fatty acid profiles, and expression of PPARα, leptin, and adiponectin genes in juvenile genetically …
  2444. Upregulation of tripeptidyl-peptidase 1 by 3-hydroxy-(2, 2)-dimethyl butyrate, a brain endogenous ligand of PPARα: Implications for late-infantile Batten disease …
  2445. Aspirin up‐regulates suppressor of cytokine signaling 3 in glial cells via PPARα
  2446. Sphingosine 1‐phosphate combining with S1PR4 promotes regulatory T cell differentiation related to FAO through Nrf2/PPARα
  2447. Fasudil mediates neuroprotection in ischemia/reperfusion by modulating the ROCK-PPARα-NOX axis
  2448. Enantioselective Synthesis of 7(S)-Hydroxydocosahexaenoic Acid, a Possible Endogenous Ligand for PPARα
  2449. First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors
  2450. A novel microRNA boosts hyper-β-oxidation of fatty acids in liver by impeding CEP350-mediated sequestration of PPARα and thus restricts chronic hepatitis C
  2451. The role of synthetic ligand of PPARα in regulation of transcription of genes related to mitochondria biogenesis and dynamic in an animal model of Alzheimer’s …
  2452. Electroacupuncture improves glucose and lipid metabolism by regulating APN/AMPK/PPARα signaling of skeletal muscle in Zucker diabetic obese rats
  2453. Identification of 3H-benzo[b] [1,4] diazepine derivatives as PPARα agonists by in silico studies and biochemical evaluation
  2454. PFOA/PFOS Facilitated Intestinal Fatty Acid Absorption by Activating the PPARα Pathway: Insights from Organoids Model
  2455. Gut microbial sodium butyrate alleviates renal ischemia-reperfusion injury by regulating HES1/PPARα
  2456. PPARα, δ and FOXO1 Gene Silencing Overturns Palmitate-Induced Inhibition of Pyruvate Oxidation Differentially in C2C12 Myotubes
  2457. Effect of Buyang Huanwu Tang on myocardial mitochondrial energy metabolism and AMPK/PPARα signaling pathway in rats with diastolic heart failure
  2458. Effects of sodium arsenite on the expression of lipid metabolism related genes SREBP-1c, PPARα and FAS in L-02 cells
  2459. Molecular Docking of Anthocyanin Compound as Anti-Hyperlipidemia Against PPARα, HMG-CoA Reductase and ACAT Proteins
  2460. Dibutylstannanediyl (2Z, 2′ Z)-bis (4-(benzylamino)-4-oxobut-2-enoate inhibits prostate cancer progression by activating p38 MAPK/PPARα/SMAD4 signaling
  2461. PPARα agonist fenofibrate prevents postoperative cognitive dysfunction by enhancing fatty acid oxidation in mice
  2462. Tanshinone IIA Alleviates Atherosclerosis Through Inhibition of NF-κB and PPARα/ABCA1 Signaling Pathways
  2463. WY14643 Increases Herpesvirus Replication Independently of PPARα Expression and Inhibits IFNβ Production
  2464. Silencing of PPARαBb mRNA in brown trout primary hepatocytes: Effects on molecular and morphological targets under the influence of an estrogen and a PPARα …
  2465. 2, 4-Dihydroxyphenyl-benzo [d] thiazole (MHY553), a synthetic PPARα agonist, decreases age-associated inflammatory responses through PPARα activation and RS …
  2466. Commentary: Dapagliflozin Mediates Plin5/PPARα Signaling Axis to Attenuate Cardiac Hypertrophy
  2467. The Effect of Turmeric and Mangosteen Peel Extract on PPARα Gene Expression in the Retina of HFD-Induced Rat Model
  2468. Rutin forestalls dysregulated cardiac bioenergetics in bisphenol A and dibutyl phthalate-exposed rats through PPARα and AMPK modulation
  2469. Selective PPARα agonist pemafibrate inhibits TNF-α-induced S100A7 upregulation in keratinocytes
  2470. Peroxisome proliferator-activated receptor alpha (PPARα) rs4253778 polymorphism in a Turkish soccer player cohort
  2471. PPARα Gene Is Involved in Body Composition Variation in Response to an Aerobic Training Program in Overweight/Obese
  2472. Roles of PPARα and PPARγ As Regulator of Free Fatty Acids in Nonalcoholic Steatohepatitis
  2473. PPARα ablation suppresses T cell responses and anti-tumor immunity by compromising the antigen-presenting properties of tumor-associated Macrophages
  2474. WY-14643 attenuates lipid deposition via activation of the PPARα/CPT1A axis by targeting Gly335 to inhibit cell proliferation and migration in ccRCC
  2475. Lithocholic acid decreases mRNA stability of nuclear receptor PPARα by upregulating miR-21 expression in hepatoma HepG2 cells
  2476. Potential Role of PPARα in Ameliorating Neuropathic Pain by Gut Microbiota Alteration
  2477. Effect of Bezafibrate, a PPARα Activator, on Acute and Subacute Inflammation in Male Wistar Rats
  2478. Selective Activation of PPARα Mitigates Peritoneal Inflammation and Fibrosis through NLRP3 Inflammasome Suppression and Inflammation Modulation
  2479. Oleuropein Promotes Neural Plasticity and Neuroprotection via PPARα-Dependent and Independent Pathways
  2480. Energy metabolism in cellular regenerative processes: focus on PPARα
  2481. The PPARα Agonist Fenofibrate Reduces the Levels of Proinflammatory Cytokines in a Maternal Immune Activation Model of Schizophrenia
  2482. Scintillation Proximity Assay (SPA)-Based Radioligand Binding for PPARα, PPARγ, and PPARδ Receptors
  2483. Targeting PPARα in low ambient temperature exposure-induced cardiac dysfunction and remodeling
  2484. Adiponectin improves endometrial receptivity in rats with polycystic ovary syndrome by upregulating the PPARα/HOXA10 pathway
  2485. Immunohistochemistry of PPARα, PPARγ and IFNγ in kidney tissues of african catfish (clarias gariepinus) at different seasons
  2486. PPARα suppresses low-intensity-noise-induced body weight gain in mice: the aggravation of fatty liver is covered up
  2487. Daidzein protects endothelial cells against high glucose-induced injury through the dual-activation of PPARα and PPARγ.
  2488. The mechanism of BAF60c in myocardial metabolism through the PGC1α/PPARα/mTOR signaling pathway in rats with heart failure
  2489. PPARα-Ligand Binding Modes Revealed by X-ray Crystallography
  2490. Hydroxycitric acid inhibits oxalate nephropathies formation through crystallization regulation and activation of the PPARα pathway
  2491. Keratocytes promote corneal neovascularization through MMP13 induced by PPARα-inhibition
  2492. WY14643, a agonist of PPARα, attenuates HFD-induced AIH by regulating hepatocyte lipid metabolism, necrosis and apoptosis via inhibiting JNK signaling pathway
  2493. 17-OR: efficacy and safety of chiglitazar, a novel PPARα/γ/d pan-agonist, in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 …
  2494. PPARα agonist exerts protective effects in podocyte injury via inhibition of the ANGPTL3 pathway
  2495. The contribution of the AGT, GNB3, MTHFR, MTRR, ApoE, and PPARα polymorphisms to the development of masked arterial hypertension in patients with low …
  2496. … with early-stage diabetic nephropathy evaluated by the MR mDixon-Quant technique: association with the expression of SREBP-1 and PPARα in renal tissue
  2497. The Effect of Curcuma and Garcinia Peel on Rat PPARα Gene Expression Induced by High-Fat Diet
  2498. Construction of a PPARα reporter assay system with drug-metabolizing capability
  2499. Formononetin improves heart failure with preserved ejection fraction in mice by activating the PPARα/PGC-1 pathway
  2500. Oleoylethanolamide facilitates PPARα and TFEB signaling and attenuates Aβ pathology in a mouse model of Alzheimer’s
  2501. Computer‐Assisted Selective Optimization of Side‐Activities—from Cinalukast to a PPARα Modulator
  2502. Corrigendum: Effects of Poria cocos extract on metabolic dysfunction-associated fatty liver disease via the FXR/PPARα-SREBPs pathway
  2503. Blockade of the PPARα metabolic checkpoint with TPST-1120 suppresses tumor growth and stimulates anti-tumor immunity
  2504. Genetic variation characteristics and tissue expression analysis of PPARα gene in Tibetan sheep.
  2505. Study of the effect of CHOP signaling molecule in PPARα activation and inhibition with response to inflammation in mice with acute liver failure
  2506. Author Correction: Wogonin suppresses osteopontin expression in adipocytes by activating PPARα
  2507. Mori Folium Improves Glucose and Lipid Metabolism Disorders in Rats with Type 2 Diabetes Mellitus by Regulating PI3K/Akt/PPARα/CPT-1 Pathway
  2508. PPARα and fatty acid oxidation coordinate hepatic transcriptional architecture
  2509. Roles of PPARα in Liver Health and Diseases
  2510. Effects of PPARα pathway on hepatic lipid metabolism in non-alcoholic fatty liver disease rat model
  2511. … of eight weeks of high-intensity intermittent training (HIIT) and low-intensity endurance training (LIET) with a high-fat diet on the expression of PPARα and PLIN5 of …
  2512. Aerobic exercise improves hepatic steatosis by modulating miR-34a-mediated PPARα/SIRT1-AMPK signaling pathway
  2513. In vivo brain levels of acetylcholine and 5‐hydroxytryptamine after oleoylethanolamide or palmitoylethanolamide administrations are mediated by PPARα engagement
  2514. Branched-chain amino acids regulate hyaluronan synthesis and PPARα expression in the skin
  2515. The loss of hepatic PPARα prompts fatty liver disease-induced hypertension and cardiovascular disease
  2516. The anti-inflammatory and anti-apoptotic role of crocin against expression of MMp-9, TIMP-1, MCP-1, caspase-3, PPARα in heart tissue, and metamorphoses of …
  2517. Functional Bioassays Lithograph Ligand Reflections in the PPARα Sphere
  2518. Effect of Fenofibrate as PPARα Agonist in Suppressing the Development of Oxaliplatin-Induced Peripheral Neuropathy via TRPA1 Modulation.
  2519. The Role of Endothelial PPARα and TBK1 in Vascular Inflammation and Atherogenesis
  2520. Restoring cellular NAD (P) H levels by PPARα and LXRα stimulation to improve mitochondrial complex I deficiency
  2521. Research progress on the biological characteristics of PPARα and its role in cerebral infarction
  2522. PPARγ Pro12Ala and C161T polymorphisms, but not PPARα L162V, are associated with osteoporosis risk in Turkish postmenopausal women
  2523. … of Secondary Metabolites in Flower-Petal Annona muricata as Agonists for Peroxisome Proliferator-Activated Receptor-Alpha (PPARα) for Liver Function
  2524. Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Cofactor Recruitment Assay for PPARα and PPARγ
  2525. Berberine attenuates angiotensin Ⅳ-induced cardiomyocyte hypertrophy via activation of PPARα/NO signaling pathway
  2526. Phase 1/1b multicenter trial of TPST-1120, a peroxisome proliferator-activated receptor alpha (PPARα) antagonist as a single agent (SA) or in combination in patients …
  2527. Ketogenic diet improves low temperature tolerance in mice by up-regulating PPARα in the liver and brown adipose tissue
  2528. The new epigenetic driver role of PPARα and mitochondria in metabolic dysfunction associated liver disease (MASLD), paving the way towards new therapeutics and …
  2529. The Effect Of Intense Periodic Training And Consumption Of Black Grape Seed Extract On PPARα And PparΓ Gene Expression In Pancreatic Tissue Of Male Rats With …
  2530. PPARα‐targeted mitochondrial bioenergetics mediate repair of intestinal barriers at the host‐microbe intersection during SIV infection
  2531. MiR-455-3p mediates PPARα through UBN2 to promote apoptosis and autophagy in acute myeloid leukemia cells
  2532. Carnitine Status and Fatty Acid Oxidation in the Small Intestines of Nursing Piglets under PPARα Activation
  2533. PPARα regulates the development and inflammation of vein graft lesions
  2534. Arid1a protects against hepatic steatosis and insulin resistance via PPARα-mediated fatty acid oxidation
  2535. Effects of combined FGF15 overexpression and PPARα activation on mash development in mice
  2536. Gualou Xiebai Banxia Decoction treats type 2 diabetes mellitus combined with acute myocardial infarction via chemerin/CMKLR1/PPARα signaling pathway
  2537. Mechanisms of tanshinone Ⅱ_A in reducing 4-HNE-induced hepatocyte damage by activating PPARα
  2538. Evaluation of the Relationship between Peroxisome Proliferator Receptors (PPARα, PPARγ, and PPARδ) Expression and Carcinoembryonic Antigen (CEA) in …
  2539. The exogenous natural phospholipids, EPA-PC and EPA-PE, contributes to ameliorate lipid accumulation and inflammation via activation of PPARα/γ
  2540. AI-guided use of balanced PPARα/γ dual agonist finetunes macrophage responses in inflammatory bowel disease
  2541. PPARα and δ Ligand Design: Honing the Traditional Empirical Method with a More Holistic Overview
  2542. Eight Weeks of Swimming Training and CBD Oil Consumption Downregulates the Expression of MAPK and PPARα Genes in the Heart Tissue of Myocardial …
  2543. Propane-2-sulfonic acid octadec-9-enyl-amide, a novel PPARα/γ dual agonist, reverses neuroinflammation in lipopolysaccharide-induced mice
  2544. Structure-based virtual screening of plant-derived natural compounds as potential PPARα agonists for the treatment of dyslipidemia
  2545. The Role of PPARα in Liver Progenitor Cell-Mediated Liver Regeneration
  2546. Function of PPARα signaling in the retinal microvasculature.
  2547. Effect of Modified Gegen Qinliantang on FXR/SHP/PPARα Signaling Pathway in Type 2 Diabetic db/db Mice
  2548. Contribution of Polymorphism in PPARα Untranslated Region to The Development of Axial Spondyloarthritis
  2549. Abstract 1514 FK506-Binding Protein 51 (FKBP51), a New Regulator of Insulin Receptor Alternative Splicing and PPARα Activation That May Control Metabolic …
  2550. Discovery of (E)-4-styrylphenoxy-propanamide: A dual PPARα/γ partial agonist that regulates high-density lipoprotein-cholesterol levels, modulates adipogenesis, and …
  2551. Peroxisome Proliferator-Activated Receptor-α (PPARα) Regulates Mitochondrial Metabolism and Wound Healing in the Cornea
  2552. PPARα in Ocular Neuronal Degeneration
  2553. Probing the role of the PPARα regulated gene TMED5
  2554. Effects of PPARα on metabolic syndrome and its mechanism in mice.
  2555. PPARα regulates monocyte activation through interaction with the cGAS-STING pathway
  2556. Bilirubin is a Metabolic Hormone that Reshapes the PPARα Coregulator Profile in Adipocytes
  2557. Curcumin promotes progression of AApoAII amyloidosis and peroxisome proliferation in mice by activating the PPARα signaling pathway
  2558. IL6/STAT Signaling Pathway and PPARα are Involved in Mediating the dose Dependent Cardioprotective Effect of Fenofibrate in 5-fluorouracil induced Cardiotoxicity
  2559. PPARα loss-of-function-induced microglial polarization contributes to diabetic retinal neurodegeneration and neurovascular dysfunction
  2560. 180-OR: Tissue-Specific Functions of PPARα Overexpression in Liver, Adipose, and Pancreatic ß Cells
  2561. HEK293A Cells Memorize a Brief Cold Exposure via a PPARα-Mediated Positive-Feedback Mechanism
  2562. Differential effects of individual amino acids on PPARα transactivation, ApoA-I transcription and (pro)-ApoA-I secretion
  2563. The Effects of Sodium Butyrate Supplementation on the Expression Levels of PGC-1α, PPARα, and UCP-1 Genes, Serum Level of GLP-1, Metabolic Parameters, and …
  2564. PPARα Selective Antagonist GW6471 Inhibits Cell Growth in Breast Cancer Stem Cells Inducing Energy Imbalance and Metabolic Stress. Biomedicines 2021, 9 …
  2565. Targeting PPARα/γ by icariside Ⅱ to rescue acute liver injury via coactivating SIRT6
  2566. Study on mechanism of protective effect in nonalcoholic fatty liver rats by TiaoganQuzhi Formula based on miR-34a/SIRT1/PPARα signaling pathway
  2567. Hepatic JNK-mediated bile acid homeostasis regulates liver cancer through PPARα
  2568. QSAR rationales for the PPARα/γ agonistic activity of 4, 4-Dimethyl-1, 2, 3, 4-tetrahydroquinoline derivatives
  2569. Pueraria Flos Alleviates Alcoholic Liver Injury Via Regulation of PPARα and MAOA: Deciphering the Effective Forms and Potential Mechanism Based on a …
  2570. FABP3 deficiency exacerbates metabolic derangement in cardiac hypertrophy via PPARα pathway
  2571. Persistent Emerging Contaminants at Trace Levels Dysregulates Biomolecules in Different Organs in Mice: Role of PPARα
  2572. Abstract MP25: Differential Expression Of PPARα In Peripheral Arterial Segments Of Patients With Advanced Atherosclerosis
  2573. Activation of PPARα stimulates hippocampal neurogenesis
  2574. The Protective Role of PPAR𝛼 in Cardiac Metabolism Under Metabolic Stress
  2575. High-intensity interval training (HIIT) induces hepatic ketone body production possibly through altering expression of mTORC1, PPARα and FGF21 in mice
  2576. In silico screening of Solanum lycopersicum carotenoids from Carotenoids Database for candidates PPARα agonists
  2577. PPARα inhibition impairs the reconsolidation of fear memories in mice
  2578. Effects of Metformin on Attenuating Renal Dysfunction Through the Modulation of AMPK/PPARα Dependent Pathways in Obese Rats
  2579. The Loss of PPARα in Adipocytes Induces Lipogenesis via the PASK‐SREBP1 Signaling Axis
  2580. Upregulation of BDNF and hippocampal functions by a hippocampal ligand of PPARα Dhruv Patel, Avik Roy, Sumita Raha, Madhuchhanda Kundu, Frank J …
  2581. USP7/PGC1β/PPARα Axis Promotes Cardiometabolic Disorders and Mitochondrial Homeostasis Dysfunction in Diabetic Mice
  2582. microRNA-18a upregulates the regulatory immune function in patients with chronic hepatitis B through the PPARα/γ signaling pathway
  2583. Effects of sodium arsenite on the expression of lipid metabolism related genes SIZEBP-1c, PPARα and FAS in L-02 cells.
  2584. Diabetes-induced down-regulation of PPARα plays a key role in the deficiency of endothelial progenitor cells and mitochondrial function
  2585. Targeting Microglial PPARα Ameliorates the Outcome of Ischaemic Stroke by Enhancing Interaction with Infiltrating Peripheral Monocytes/Macrophages
  2586. Fenofibrate induced‐hepatomegaly and liver regeneration is PPARα dependent and partially related to the activation of YAP pathway
  2587. Liver and Biliary Tract Physiology/Pathophysiology: High-fat diet induces fibrosis in mice lacking CYP2A5 and PPARα: a new model for steatohepatitis …
  2588. Comparative Efficacy of Sweated and Non-Sweated Salvia Miltiorrhiza Bge. Extracts on Acute Myocardial Ischemia Via Regulating the PPARα/RXRα/NF-κB Signaling …
  2589. Novel Dual PPARα/δ Agonist F3SM Increased Oxidative Muscle Fiber and Ameliorated Metabolic Disorders in Non‐trained Mice
  2590. Involvement of AKT/FOXO Genes in the Interactions of PPARα and PHD in DOCA‐Induced Pathology
  2591. The nuclear receptor PPARα (peroxisome proliferator-activated receptor α) as a novel therapeutic target for schizophrenia
  2592. ADMET Prediction of Dual PPARα/γ Agonists for Identification of Potential Anti-diabetic Agents
  2593. Potential Natural Dual Agonist PPARα/γ-induced Antidiabetic and Anti-dyslipidemic Properties of Safrole-Free Nutmeg Seed (Myristica fragrans Houtt) Extract
  2594. [Retracted] Active Ingredient Paeonol of Jijiu Huiyang Decoction Alleviates Isoproterenol-Induced Chronic Heart Failure via the GSK3A/PPARα Pathway
  2595. Biomarkers of one-carbon metabolism and B-vitamin status: Targeted metabolomics in rats and humans exploring the effects of PPARα-activation and dietary …
  2596. Maternal Feeding of a Synthetic PPARα Agonist Alters Renal Development of Fatty Acid Metabolism in the Neonatal Piglet
  2597. The regulation of cGAS-STING signaling by PPARα-mediated autophagy in ischemic retinopathy
  2598. Icariside II, a Novel Dual PPARα/γ Agonist, Confers Protection Against D-GalN/LPS-Induced Acute Liver Injury: Involvement of SIRT6/NF-κB/Pyroptosis Axis
  2599. Effects of PPARα pathway on hepatic lipid metabolism in non-alcoholic fatty liver disease rat model
  2600. Expression of PPARα and PGC1α proteins in cardiac tissue of male rats with type 2 diabetes after high intensity interval training
  2601. Aspirin Modulates Hippocampal Plasticity and Protects Memory via PPARα
  2602. Dapagliflozin Attenuates Aorta Smooth Muscle Aging and Atherosclerosis via Inhibiting the PPARα Pathway
  2603. PPARα agonist suppresses inflammation after corneal alkali burn by suppressing proinflammatory cytokines, MCP-1, and nuclear translocation of NF-B
  2604. Prenatal PPARα Activation Moved Forward Transient Browning of WAT at Neonates and Increased HFD-Induced UCP1 Expression in WAT of Male Mice at Adulthood
  2605. Chlorogenic Acid Relieves Hfd-Induced Non-Alcoholic Fatty Liver Disease Via Microbiota and Enhancing Foxo1/PPARα Pathway
  2606. Cyclophilin D Sequesters PPARα in Mitochondria to Impair Fatty Acid Oxidation in Cisplatin‐induced Acute Kidney Injury
  2607. PPARα agonist and metformin co-treatment ameliorates NASH in mice induced by a choline-deficient, amino acid-defined diet with 45% fat.
  2608. Abstract C109: Tumor derived exosomal lipids-induced dendritic cell immunosuppression by PPARα
  2609. PPARα interacts with PHD proteins on Renal Fibrosis in a Mouse Unilateral Ureteral Obstruction Model of Chronic Kidney Disease
  2610. Oleuropein-induced acceleration of CYP-catalyzed drug metabolism: central role for nuclear receptor PPARα
  2611. Correlations of PPARα and PPARγ expressions with 1H-MRS quantified hepatic fat content in pups of rats that experienced intrauterine growth restriction
  2612. Erratum: In vitro and in vivo study of the pathogenic role of PPARα in experimental periodontitis
  2613. MiR-33a-5p Promotes M1 Macrophage Polarization and Inflammatory Accumulation in Long-Term Stored Blood Through Regulation of the PPARα/ACC2/AMPK/CPT …
  2614. Corrigendum to” Upregulation of tripeptidyl-peptidase 1 by 3-hydroxy-(2, 2)-dimethyl butyrate, a brain endogenous ligand of PPARα: Implications for late-infantile …
  2615. … well as a reduction in chocolate and caloric intake at post-weaning periods in the feeding tests. Their liver showed a decreased gene expression of Cnr1, PPARα
  2616. Retraction: Metabolomics reveals that PPARα activation protects against lithocholic acid-induced liver injury
  2617. PPARα-deficiency exacerbates ethanol-induced chronic injury of gastric mucosa in mice
  2618. PPARα and γ Activation Effects of New Nor-triterpenoidal Saponins from the Aerial Parts of Anabasis articulata
  2619. Expression of PPARα and PGC1α proteins in cardiac tissue of male Wistar rats with type 2 diabetes after 8 weeks of high intensity interval training
  2620. Deletion of Telomere‐Rap1 aggravates cardiac aging by impairing fatty acid oxidation via PPARα signaling
  2621. EARLY PPARα ACTIVATION PROTECT AGAINST HEPATIC MICROSTEATOSIS INDUCED BY POST-NATAL OVERFEEDING
  2622. Effects of PPARα on metabolic syndrome and its mechanism in mice.
  2623. Synthesis of PPARα Agonist GW641597X
  2624. GLP-1-mediated delivery of the PPAR𝛼/𝛾 dual-agonist Tesaglitazar improves obesity and glucose metabolism in mice
  2625. Loss of Repressor Activator Protein 1 Precipitates Cardiac Aging in Mice via p53/PPARα Signaling
  2626. PPARα in Osteocytes Regulates Marrow Fat
  2627. Correction to: Alternate-day fasting alleviates high fat diet induced non-alcoholic fatty liver disease through controlling PPARα/Fgf21 signaling
  2628. Limonin inhibits apoptosis, promotes autophagy and improves non-alcoholic fatty liver disease by promoting oxidative metabolism of fatty acids through PPARα
  2629. BDE-47 Promotes Non-Alcoholic Fatty Liver Disease Through CD36-Mediated Increased Fatty Acid Uptake and PPARα-Induced Abnormal Fatty Acid Oxidation
  2630. Carnitine Status and Fatty Acid Oxidation in the Intestines of Nursing Piglets under PPARα Activation
  2631. PPARα antagonists as cytotoxic agents in gliomas and pancreatic, colorectal, and renal cancer
  2632. PPARα-Mediated Positive-Feedback Loop Contributes to Cold Exposure Memory
  2633. Irisin/PPARα improves the ox-LDL-induced endothelial cell pyroptosis and inflammatory response
  2634. Research data supporting” PPARα-independent effects of nitrate supplementation on skeletal muscle metabolism in hypoxia”
  2635. … Analyses and Computational Modeling Reveal That Fatty Acid Transport Protein 2 (FATP2) Impacts the Transcriptional Activity of PPARα Thus Altering the …
  2636. PPARα Agonist Fenofibrate Attenuates Iron Induced Liver Injury in Mice by Modulating 1 the Sirt3 and β-catenin Signaling 2
  2637. Effects of methamphetamine on KI-67, PPARα, PPARγ and Bax genes on human SH-SY5Y cell proliferation, differentiation and apoptosis.
  2638. Phytanic acid activates PPARα to promote beige adipogenic differentiation of preadipocytes.
  2639. Attenuation of high-fat diet-induced fatty liver through PPARα activation by stevioside.
  2640. Expression of Concern on “Testosterone Replacement Modulates Cardiac Metabolic Remodeling after Myocardial Infarction by Upregulating PPARα”
  2641. Peripheral sgp130-mediated trans-signaling blockade induces obesity and insulin resistance in mice via PPARα suppression
  2642. Retracted: Possible Role of Interaction between PPARα and Cyclophilin D in Cardioprotection of AMPK against In Vivo Ischemia-Reperfusion in Rats
  2643. HM-chromanone Attenuates Hepatic Steatosis by Activating AMPK and PPARα Pathway in HepG2 Cells
  2644. Deficiency of circadian gene Per2 blocks luteolin-induced adipocyte browning in mice through weakening liver PPARα/RXRα/FGF21 pathway
  2645. Efficacy of Zhibai Dihuang Decoction on energy metabolism of spermatogenic cells in Ureaplasma urealyticum-infected rats: A study based on AMPK and PPARα …
  2646. Fine particles cause the abnormality of cardiac ATP levels via PPARα-mediated utilization of fatty acid and glucose using in vivo and in vitro models.
  2647. … -chain chlorinated paraffins (SCCPs) disrupt hepatic fatty acid metabolism in liver of male rat via interacting with peroxisome proliferator-activated receptor α (PPARα).
  2648. … -glutamyl carboxylated Gas6 mediates the beneficial effect of vitamin K on lowering hyperlipidemia via regulating the AMPK/SREBP1/PPARα signaling cascade of …
  2649. Preventive effects of total flavonoid C-glycosides from Abrus mollis on nonalcoholic fatty liver disease through activating the PPARα signaling pathway.
  2650. Pemafibrate, a selective PPARα modulator, and fenofibrate suppress microglial activation through distinct PPARα and SIRT1-dependent pathways
  2651. … of a phenolic-rich extract from Hypericum attenuatum Choisy in KK-Ay mice mediated through AMPK/PI3K/Akt/GSK3β signaling and GLUT4, PPARγ, and PPARα …
  2652. Synthesis of DHA (omega-3 fatty acid): FADS2 gene polymorphisms and regulation by PPARα
  2653. Anti-diabetic effect of a shihunine-rich extract of Dendrobium loddigesii on 3T3-L1 cells and db/db mice by up-regulating AMPK-GLUT4-PPARα.
  2654. NHR-49/PPARα regulates HLH-30/TFEB-mediated innate immune response via a flavincontaining monooxygenase in C. elegans
  2655. Transcription factors NHR-49/PPARα and HLH-30/TFEB promote host defense in C. elegans via a flavin-containing monooxygenase
  2656. 1894-P: HIF-2α Induced by Hypoxia Exacerbates Nonalcoholic Fatty Liver Disease Progression via Suppressing PPARα
  2657. Retraction Note: Estradiol Inhibits Cytokine-Induced Expression of VCAM-1 and ICAM-1 in Cultured Human Endothelial Cells Via AMPK/PPARα Activation
Related Posts

Reverses And Prevents Fatty Liver

Tryptophan Hydroxylase 2

Advanced Glycation End Products (Ages)

Mandatory FDA Disclaimer: Not intended to diagnose, treat, cure or prevent any disease.

Mandatory FDA Disclaimer: Not intended to diagnose, treat, cure or prevent any disease.

0
    0
    Your Cart
    Your cart is emptyReturn to Shop
    Continue Shopping